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SUMMARY 
 
Tyrosine kinase inhibitors (TKIs) have revolutionized the treatment of certain cancers. They 
are usually well-tolerated, but can cause adverse reaction including liver injury. Currently, 
mechanisms of hepatotoxicity associated with TKIs are only partially clarified. We therefore 
aimed at investigating the in vitro mechanisms of hepatotoxicity of 10 TKIs that have been 
reported to cause liver injury in patients in our first three papers. We treated HepG2 cells, 
HepaRG cells, and mouse liver mitochondria with TKIs (concentrations 0.5-100 µM) for 
different periods of time and assessed toxicity. 
 
In the first paper, we investigated erlotinib, imatinib, lapatinib, and sunitinib. In HepG2 cells, 
all TKIs showed a time- and concentration-dependent cytotoxicity and, except erlotinib, a 
drop in intracellular ATP. For imatinib, lapatinib, and sunitinib, cytotoxicity increased in 
HepaRG cells induced with rifampicin, suggesting formation of toxic metabolites. Imatinib, 
lapatinib, and sunitinib reduced the mitochondrial membrane potential in HepG2 cells and in 
mouse liver mitochondria. In HepG2 cells, these compounds increased reactive oxygen 
species (ROS) production, impaired glycolysis, and induced apoptosis. In addition, imatinib 
and sunitinib impaired oxygen consumption and activities of complex I and/or III of the 
electron transport chain, and reduced the cellular GSH pool. In conclusion, imatinib and 
sunitinib are mitochondrial toxicants after acute and long-term exposure and inhibit 
glycolysis. Lapatinib affects mitochondria only weakly and inhibits glycolysis, whereas the 
cytotoxicity of erlotinib could not be explained only by a mitochondrial mechanism. 
 
In the second paper, we investigated crizotinib, dasatinib, pazopanib, ponatinib, regorafenib, 
and sorafenib. Regorafenib and sorafenib strongly inhibited oxidative metabolism and 
glycolysis, decreased the mitochondrial membrane potential, and induced apoptosis and/or 
necrosis of HepG2 cells at concentrations similar to steady-state plasma concentrations in 
humans. In HepaRG cells, pretreatment with rifampicin decreased membrane toxicity and 
dissipation of ATP stores, indicating that toxicity was associated mainly with the parent 
drugs. Ponatinib strongly impaired oxidative metabolism but only weakly glycolysis, and 
induced apoptosis of HepG2 cells at concentrations higher than steady-state plasma 
concentrations in humans. Crizotinib and dasatinib did not significantly affect mitochondrial 
functions and inhibited glycolysis only weakly, but induced apoptosis of HepG2 cells. 
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Pazopanib was associated with a weak increase in mitochondrial ROS formation and 
inhibition of glycolysis without being cytotoxic. In conclusion, regorafenib and sorafenib are 
strong mitochondrial toxicants and inhibitors of glycolysis at clinically relevant 
concentrations. Ponatinib affects mitochondria and glycolysis at higher concentrations than 
reached in plasma (but possibly in liver), whereas crizotinib, dasatinib and pazopanib show no 
relevant toxicity.  
 
In the third paper, we wanted to better characterize the mechanisms underlying the 
mitochondrial impairment observed with the multikinase inhibitors ponatinib, regorafenib, 
and sorafenib in our second paper. The multikinase inhibitors impaired the activity of 
different complexes of the respiratory chain. As a consequence, they decreased the 
mitochondrial membrane potential concentration-dependently. They induced mitochondrial 
fission and mitophagy as well as mitochondrial release of cytochrome c associated with 
apoptosis and/or necrosis. In conclusion, ponatinib, regorafenib, and sorafenib impair the 
function of the respiratory chain, which is associated with increased ROS formation and a 
drop in the mitochondrial membrane potential. Despite mitochondrial fission and mitophagy, 
some cells are eliminated concentration-dependently by apoptosis or necrosis. Mitochondrial 
dysfunction may represent a toxicological mechanism of hepatotoxicity associated with 
certain kinase inhibitors. 
 
In the fourth paper, we switched to the in vivo situation and aimed to investigate the in vivo 
mechanisms of hepatotoxicity of sunitinib in mice. We treated mice with 7.5 mg/kg sunitinib 
for 14 days. Sunitinib did not affect nutrient intake or body weight, but was associated with a 
six-fold increase in plasma ALT. Enzyme activity of the mitochondrial electron transport 
chain was decreased in liver tissue and significantly for complex III in isolated liver 
mitochondria. The decreased complex activity was associated with mitochondrial ROS 
formation and increased SOD2 expression. In addition, the citrate synthase activity and 
protein expression of PGC-1α were reduced. Caspase 3 cleavage and TUNEL-positive 
hepatocytes were increased, compatible with hepatocyte apoptosis and increased plasma ALT. 
In conclusion, mice treated with 7.5 mg/kg sunitinib for 14 days had an impaired 
mitochondrial function leading to hepatocyte apoptosis with the key regulator of 
mitochondrial proliferation and function PGC-1α may an important mechanistic factor for 
these findings. 
 
  1 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
INTRODUCTION 
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1 LIVER AND DRUG-INDUCED LIVER INJURY 
 
The liver is a vital organ that is part of the digestive system found in all vertebrates. In 
humans, it is located in the upper-right quadrant of the abdomen, under the rib cage and below 
the diaphragm. The liver has different important functions such as detoxification of 
metabolites, protein synthesis, production of biochemicals that are important for digestion, 
regulation of glycogen storage, metabolism, decomposition of red blood cells, hormone 
production, and storage of vitamins A, D, E, K, and B12. 
The liver has two major blood sources: the portal vein and the hepatic artery. The portal vein 
is responsible for 75% of the liver blood supply and carries blood from the digestive system to 
the liver and has therefore nutrients from the digestive system. The hepatic artery supplies the 
liver with oxygen-rich blood from the heart. In addition, liver cells produce bile, a yellow-
green fluid important for fat digestion. The bile is transported to the liver through a series of 
ducts to the small intestine or to the gallbladder for storage. 
The liver is the most important organ for the metabolism of virtually every foreign substance. 
Most drugs and xenobiotics are lipophilic and thus enable crossing the membranes of 
intestinal cells. Due to biochemical processes in the hepatocytes, drugs become more 
hydrophilic and are excreted in urine or bile. The hepatic biotransformation includes oxidative 
pathways, primarily through the cytochrome P450 enzyme system (Xie et al. 2016). 
Afterwards, conjugation to a glucuronide, a sulfate or glutathione takes place and the 
hydrophilic product is exported into plasma or bile by transporters on the hepatocyte 
membrane and is excreted by the kidney or the gastrointestinal tract (Zamek-Gliszczynski et 
al. 2006).  
Because the liver is the responsible for drug absorption, metabolism and elimination, it is a 
preferential target organ for drug toxicity. Indeed, drug-related hepatotoxicity and, more 
specifically, idiosyncratic drug-induced liver injury is the most frequent reason for acute liver 
failure in the USA (Amacher 2012; Lee 2013). In addition, hepatotoxicity is the major cause 
of drug withdrawal from the market and non-approval by regulatory authorities in the past 
five decades (Regev 2014). Because drug induced hepatotoxicity occurs rarely, it often 
remains undetected during drug development, where only a few thousand subjects are treated. 
The following sections will describe the drug-induced liver injury in more detail focusing on 
the definition, types, risk factors, and targets of cell injury. 
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1.1 Definition of drug-induced liver injury 
 
Drug-induced liver injury (DILI) is defined as a liver injury that is caused by various 
medications, herbs, or other xenobiotics that leads to abnormalities in liver tests or liver 
dysfunction, with reasonable exclusion of other reasons (Suk and Kim 2012). DILI can 
present in several clinical forms, varying from asymptomatic and transient elevations in liver 
biochemical tests to jaundice and severe life threatening acute liver failure, but seldom ends in 
chronic liver disease (Devarbhavi 2012). DILI is clinically defined according to the DILI 
Expert Working Group as the occurrence of any one of the following: more than five-fold 
elevation above the upper limit of normal (ULN) for alanine aminotransferase (ALT), more 
than two-fold elevation above the ULN for alkaline phosphatase (ALP) or more than three-
fold elevation in ALT together with a bilirubin elevation of more than two-fold ULN (Aithal 
et al. 2011). Clinical presentations of DILI are hepatocellular, cholestatic or mixed forms and 
are defined by the ratio of ALT elevation to ALP elevation (see Table 1). Antimicrobials and 
drugs for the central nervous system are the most common causes of DILI (Suk and Kim 
2012). 
 
Table 1: Liver injury patterns according to (Weiler et al. 2015). 
Type of liver injury Cholestatic Mixed Hepatocellular 
 Injury to bile ducts or 
affecting bile flow 
Hepatocellular and 
cholestatic injury 
Injury predominantly 
to hepatocytes 
R value ≤2 >2 and <5 ≥5 R	value = ALT	level/ALT	ULNALP	level/ALP	ULN 
 
 
1.2 Types of drug reactions  
 
DILI can be classified into intrinsic (Type A) and idiosyncratic (Type B) reactions (see Table 
2). Intrinsic reactions are dose-dependent, predictable, and experimentally reproducible, 
having a high incidence. The pain medication acetaminophen (APAP) is the most prominent 
drug for intrinsic DILI and is responsible for almost half of the cases of acute liver failure in 
the USA (Gunawan and Kaplowitz 2007). APAP causes dose-related hepatotoxicity in 
humans and animals through the toxic metabolite N-acetyl-p-benzoquinone imine that 
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covalently binds to cellular constituents, which depletes the glutathione content and ultimately 
leads to mitochondrial dysfunction and hepatocellular necrosis (Roth and Ganey 2010). In 
contrast, idiosyncratic drug reactions occur at therapeutic doses in susceptible individuals at 
rates from 1 in every 1000 to 1 in every 100 000 patients, with a drug-consistent pattern 
(Devarbhavi 2012). Idiosyncratic drug reactions are unexpected, not strictly dose-dependent, 
occur rarely, and currently cannot be predicted by conventional clinical toxicology tests 
(Fontana 2014). The delay or latency period is between 5 to 90 days from the first ingestion of 
the drug and idiosyncratic reactions are frequently fatal if the drug is continued once the 
reaction has started (Hussaini and Farrington 2014). Because of the unpredictability of 
idiosyncratic toxicity in in vivo and in vitro models, idiosyncratic DILI remains the major 
issue for new drug entities (Regev 2014). 
 
Table 2: Intrinsic vs. idiosyncratic DILI (Roth and Ganey 2010). 
Characteristics Intrinsic Idiosyncratic 
Affected patients Affects all individuals at some 
dose 
Attacks only susceptible 
individuals 
Dose Clearly dose-related Obscure relation to dose 
Exposure Predictable latent period after 
exposure 
Variable onset relative to exposure 
Physiopathology Distinctive liver lesion Variable liver pathology 
Prediction Predictable using routine animal 
testing 
Not predictable using routine 
animal testing 
 
 
1.3 Risk factors for idiosyncratic DILI 
 
The traditional thinking is that idiosyncratic DILI is not dose-related. However, a recent study 
suggested that drugs with a daily dose higher than 50 mg can predispose for idiosyncratic 
DILI (Lammert et al. 2008). In addition, multifactorial mechanisms appear to underlie DILI, 
including drug-related risk factors (chemical features of the drug, dose, route, and duration), 
host-related risk factors (age, sex, genetics, and underlying diseases) and environmental risk 
factors (diet type, alcohol, coffee, smoking, multidrug therapy, immune state, and nutritional 
status) (Figure 1) (Licata 2016). Moreover, genetic factors have an important role concerning 
underlying mechanisms and susceptibility. Polymorphisms in genes involved in drug 
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metabolism may increase the drug plasma concentrations. Such genetic variations include 
CYP2E1, N-acetyltransferase 2, UDP-glucuronosyltransferase 2B7, and glutathione S-
transferase M1/T1 (Stephens et al. 2012). In addition, patients with genetic variations in the 
antioxidant enzymes mitochondrial superoxide dismutase 2 (SOD2) and glutathione 
peroxidase 1 (GPX1) are at higher risk to develop DILI (Lucena et al. 2010). An association 
between specific human leukocyte antigen (HLA) alleles and idiosyncratic DILI has been 
reported for several drugs (Kim and Naisbitt 2016). For example, the HLA-B*5701 allele 
increases the risk for flucloxacillin-induced DILI by 80-fold (Daly et al. 2009). Lapatinib is 
another example, where DQA1*02:01 and DRB1*07:01 alleles were found more often in 
patients with elevated transaminases than in patients with normal transaminases (Spraggs et 
al. 2011; Spraggs et al. 2012). 
 
 
Figure 1: DILI is multifactorial and depends on complex interplay of drug, host, and 
environmental factors (Licata 2016). 
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1.4 Targets of cell injury  
 
According to Lee (2003), at least six mechanisms are involved in the development of DILI 
(see Figure 2). Cytochrome P450 enzymes are lead to covalent binding of the drug to 
intracellular proteins, consequently producing intracellular dysfunction resulting in the loss of 
ionic gradient, reduced ATP levels, actin disruption, cell swelling, and cell rupture (Yun et al. 
1993) (Figure 2A). If drugs affect transporter proteins at the canalicular membrane, they can 
interrupt bile flow and cause cholestasis (Trauner et al. 1998) (Figure 2B). Normally, drugs 
are relatively small molecules and are unlikely to cause an immune response. Nevertheless, 
biotransformation of the drug can result in the formation of drug-enzyme-adducts. These 
adducts can be large enough to serve as immune targets, and if they migrate to the surface of 
the hepatocyte, they can induce the formation of antibodies (antibody-mediated cytotoxicity) 
or direct cytolytic T-cell response (Robin et al. 1997) (Figure 2C and D). The secondary 
cytokine response can potentially cause an inflammation and neutrophil-mediated 
hepatotoxicity (Jaeschke et al. 2002). Another mechanism of DILI is through programmed 
cell death (apoptosis) together with immune-mediated injury, destroying hepatocytes by 
tumor necrosis factor and the Fas pathways, including cell shrinkage and fragmentation of 
nuclear chromatin (Reed 2001) (Figure 2E). If the drug activates pro-apoptotic molecules, 
they will compete with protective anti-apoptotic survival pathways within the cell. This 
dynamic interaction may shift the balance to or against cell damage. The last possible DILI-
pathway is the damage of mitochondria, disrupting fatty-acid oxidation and energy production 
of the cell. Drugs can inhibit respiratory-chain enzymes or mitochondrial DNA, resulting in 
oxidative stress and subsequently anaerobic metabolism, lactic acidosis, and triglyceride 
accumulation (Pessayre et al. 2001) (Figure 2F). Clearly, more than one of the mentioned 
cellular pathways to liver injury is possible.  
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Figure 2: Six mechanisms of drug-induced liver injury. Injury to liver cells occurs in 
patterns specific to intracellular organelles affected. (A) Blebbing of cell membrane, rupture 
and cell lysis. (B) Interruption of bile flow and cholestasis. (C) High-energy reactions through 
the cytochrome P450 system. (D) Enzyme-drug adducts migrate to the cell surface and induce 
the formation of antibodies or direct cytolytic T-cell response. (E) Apoptosis together with 
immune-mediated injury. (F) Damage of mitochondria, disrupting fatty-acid oxidation and 
energy production of the cell. According to (Lee 2003).  
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1.5 In vitro models 
 
Cell-based screening models are important in early drug development stages to detect 
hepatotoxicity in vitro before testing the new compounds in vivo in animals or humans. In the 
following section, different cellular models and their advantages and disadvantages will be 
described. 
 
 
1.5.1 Human hepatocytes 
 
Human hepatocytes in monolayer culture are the gold standard in vitro model for testing 
toxicity and drug metabolism (Zeilinger et al. 2016). They preserve key hepatic-specific 
functions such as carbohydrate metabolism, plasma protein synthesis and secretion, lipid 
metabolism and transport, bile acid synthesis and uptake, and drug biotransformation by 
cytochrome P450 and conjugation enzymes that are still inducible (Gomez-Lechon et al. 
2014). In addition, intact cells are used and therefore the plasma membrane is conserved and 
uptake and excretion mechanisms remain active (Castell et al. 2006). However, limitations of 
human hepatocytes are their short viability, rapid changes in structure once they are in culture, 
large variability of different donors, and last but not least, their high costs (Gomez-Lechon et 
al. 2014). 
 
 
1.5.2 Isolated mitochondria 
 
Isolating mitochondria from different species such as mice or rat is another approach to 
estimate hepatotoxicity. After acute drug exposure, isolated mitochondria can be used to 
measure the activity of oxidative phosphorylation, mitochondrial membrane potential and 
other mitochondrial functions (Brand and Nicholls 2011; Felser et al. 2013). Nevertheless, 
isolated mitochondria have no contact to the plasma membrane, cytosol and other organelles 
and have no access to substrates and inhibitors coming from the cytoplasm and are therefore 
not in their physiological environment. 
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1.5.3 Hepatoma cell lines 
 
Human hepatic cell lines created from tumor tissue or by genetic engineering of primary 
human liver cells are widely used in vitro models due to their good availability and high 
proliferation capacity under standardized and reproducible conditions (Zeilinger et al. 2016). 
HepG2, HepaRG, Hep3b, and Huh7 cells have been used as hepatic cell lines to study 
hepatotoxicity in vitro. Hepatoma cell lines have several advantages versus human 
hepatocytes as they grow continuously with an almost unlimited lifespan, have a quite stable 
phenotype, are easily available and are simple to culture (Castell et al. 2006). Drawbacks are 
the limited biotransformation activities (Donato et al. 2013). HepG2 cells are the most often 
used human hepatoma cell line and in addition with another human hepatoma cell line, 
HepaRG, that expresses drug metabolism and transport abilities and retains the possibility to 
differentiate in vitro, they are the most relevant cell lines to study drug-induced 
hepatotoxicity. 
 
 
1.5.3.1 HepG2 cells 
 
HepG2 cells (Figure 3) are an excellent model to study mitochondrial toxicity because of their 
high content of organelles and mitochondrial DNA (Pinti et al. 2003). HepG2 cells have 
similar characteristics as normal hepatocytes but the major drawback is the lack of relevant 
liver cytochrome P450 enzymes (Castell et al. 2006). HepG2 cells are normally grown in 
media containing 25 mM glucose which is five-fold higher than in physiological conditions 
(Swiss and Will 2011). However, under these conditions, the cells derive almost all of their 
energy from glycolysis rather than via mitochondrial oxidative phosphorylation, the so-called 
Crabtree effect (Marroquin et al. 2007). Therefore, mitochondrial toxicants have little effect 
on cell growth, viability, or cell death. By replacing the glucose with galactose (10 mM), 
HepG2 cells are forced to rely on mitochondrial oxidative phosphorylation to generate 
sufficient ATP because the oxidation of galactose to pyruvate via glycolysis yields no net 
ATP (Marroquin et al. 2007). These HepG2 cells under galactose conditions will be more 
susceptible to mitochondrial toxicants. Nevertheless, interpretation of data has to be done 
carefully because continuously growing tumor cells differ from normal, resting, and non-
neoplastic cells in patients. 
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Figure 3: HepG2 cells under the microscope (Elshafie et al. 2017). The photographs were 
taken at a magnification x40. 
 
 
1.5.3.2 HepaRG cells 
 
The HepaRG cell line (Figure 4) is one of the most advanced hepatocyte cell culture models 
because it combines easy handling with physiological drug metabolism (Mueller et al. 2015). 
HepaRG cells were obtained from a liver tumor of a female patient suffering from 
hepatocarcinoma (Guillouzo et al. 2007). HepaRG cells can differentiate from a progenitor 
state to mature hepatocytes and primitive biliary cells which are stable over several weeks 
(Josse et al. 2008). HepaRG cells express between 81% and 92% of human hepatocyte genes 
including metabolizing enzymes (Mueller et al. 2015).  
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Figure 4: Light microscopy of differentiated HepaRG cells. (A) HepaRG cells treated with 
standard medium observed under phase-contrast microscopy, H: hepatocyte-like cells, EC: 
epithelial-like cells. (B) Staining of bile canaliculi. (C) Staining by Oil Red O for 14 days. 
Lipid droplet accumulation in hepatocyte-like cells. (D) HepaRG cells were treated with 
amiodarone for 24 h followed by Oil Red O staining. Unstained vesicles corresponding to 
lamellar bodies are visible in both hepatocyte-like and biliary epithelial-like cells. (Antherieu 
et al. 2012) 
 
 
1.5.3.3 3D cell culture 
 
The drawback of all the aforementioned in vitro models is the lack of 3D organization of 
hepatocytes. Several 3D liver culture strategies are available, one of which is the human 3D 
micro-tissue spheroid culture from InSphero. They use a gravity-enforced cellular assembly 
that enables the formation of cellular contacts (Messner et al. 2013). After formation of the 
microtissue, they can be cultured up to 5 weeks with stable function including cell-cell 
contacts and transporter activity. A recent study demonstrated that the 3D human liver 
microtissues outperformed human hepatocytes in identifying clinically relevant hepatotoxins 
(Proctor et al. 2017). 
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2 MITOCHONDRIA 
 
Mitochondria has been recognized as an important drug biosensor, being a key off-target of 
drugs inducing idiosyncratic DILI (Han et al. 2013). A lot of drugs causing metabolic failure 
are highly associated with impaired mitochondrial function (Chan et al. 2005; Hargreaves et 
al. 2016). Therefore, mitochondrial toxicity has become a major topic in drug development, 
being the reason for many drug candidate failures, black box warnings or drug withdrawal 
from the market (Wallace 2015). Mitochondria play a key role in the regulation of cellular 
function as they supply 90% of the overall cellular energy through oxidative phosphorylation. 
Consequently, damage at a specific or different mitochondrial targets leads to multi-tissue 
toxicity. Especially mitochondria-rich organs such as the heart, brain, muscle, and liver that 
are working under highly aerobic conditions and relying on the energy-producing metabolism 
of the mitochondria are more susceptible to mitochondrial toxicants. Mitochondrial 
dysfunction thus can be induced by xenobiotics or by drugs via a direct interaction of 
mitochondrial function, by an interference with mitochondrial transcription, mitochondrial 
translation, or by increased superoxide anion formation leading to oxidative stress. 
In the following chapter, basic principles of mitochondrial structure, bioenergetics, biogenesis 
and different mechanisms leading to an impairment of mitochondrial function will be 
described in more detail. 
 
 
2.1 Structure 
 
Mitochondria are highly specialized organelles that are organized in a dynamic complex 
network. Mitochondria (Figure 5) are organized by two membrane systems, the outer and the inner 
mitochondrial membranes, both formed of phospholipid bilayers. Mitochondria are differentiated into 
distinct compositional and functional regions, where diverse transporting and enzymatic proteins are 
integrated. The space between these two membranes is called intermembrane space, in which essential 
proteins (e.g. cytochrome c, creatine kinase) are housed, playing a major role in cell homeostasis and 
mitochondrial energetics. Moreover, in the inner mitochondrial membrane, multiple invaginations 
increasing the surface area are formed into the matrix compartment that houses assembled respiratory 
complexes, proteins for ATP synthesis, and transport. 
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Figure 5: Schematic representation of a mitochondrion. The outer mitochondrial 
membrane encloses the entire organelle to separate it from the cytosol. The intermembrane 
space is the space between the outer and the inner mitochondrial membrane. The inner 
mitochondrial membrane separates the mitochondrial matrix from the intermembrane space. 
The mitochondrial matrix is the space enclosed by the inner mitochondrial membrane. 
(Yusoff and Jaafar 2015) 
 
 
2.1.1 Outer membrane 
 
The outer mitochondrial membrane encloses the entire organelle to separate it from the 
cytosol. It contains a large number of integral membrane proteins, so called Voltage-
dependent anion channels (VDAC), to form pores that allow the transfer of small molecules 
up to 5000 Da. VDACs are diffusion pores for small hydrophilic molecules to facilitate the 
exchange of ions between mitochondria and cytosol. The VDACs play a key role in 
regulating energetic and metabolic flux across the outer mitochondrial membrane by 
transporting ions such as Ca2+, Na+, K+, Cl- or OH- and ATP, ADP, pyruvate, malate and 
other metabolites (Blachly-Dyson and Forte 2001). Mitochondrial pro-proteins are imported 
through specialized translocation complexes – translocases of the outer membrane (TOM). 
Short-chain fatty acids can simply diffuse through the outer mitochondrial membrane, but 
long-chain fatty acids transport involves the carnitine palmitoyltransferase 1 (CPT1). A 
disruption of the outer mitochondrial membrane permits proteins from the intermembrane 
space to leak into the cytosol, leading to cell death. 
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2.1.2 Intermembrane space 
 
The intermembrane space is the space between the outer and the inner mitochondrial 
membrane. Because the outer mitochondrial membrane is permeable to small molecules, the 
composition of the intermembrane space of ions and sugar is equal to the one of the cytosol. 
 
 
2.1.3 Inner membrane 
 
The inner mitochondrial membrane separates the mitochondrial matrix from the 
intermembrane space. The inner mitochondrial membrane is – contrary to the outer 
mitochondrial membrane – impermeable for small molecules. Only oxygen, water, and carbon 
dioxide can freely pass the inner mitochondrial membrane. Therefore, the inner mitochondrial 
membrane is a chemical barrier and an electrical isolator. Transporters of the inner membrane 
(translocase of the inner membrane, TIM) are needed to import proteins to the mitochondrial 
matrix. The TIM23 complex facilitates the transport of proteins across the inner 
mitochondrial membrane whereas the TIM22 complex integrates the proteins to the inner 
mitochondrial membrane. 
The inner mitochondrial membrane consists of 80% proteins and 20% lipids, in contrast to the 
outer mitochondrial membrane, which consist of 50% proteins and 50% lipids. This 
membrane is constituted by a highly specialised lipid bilayer, containing cardiolipin in high 
quantities (Ikon and Ryan 2017). The inner mitochondrial membrane folds extensively to the 
mitochondrial cristae, increasing the total membrane surface area. For typical liver 
mitochondria, the area of the inner mitochondria membrane is about five times that of the 
outer mitochondrial membrane. 
The mitochondrial electron transport chain (ETC) consists of five complexes that are located 
in the inner mitochondrial membrane and produces ATP via oxidative phosphorylation. The 
ETC will be explained in detail later. The ETC pumps protons from the matrix to the 
intermembrane space across the inner mitochondrial membrane to produce a proton gradient 
that is used by the ATP synthase to produce ATP. Uncoupling proteins (UCP) are regulated 
proton channels in the inner mitochondrial membrane that dissipate the proton gradient by 
pumping the protons back from the intermembrane space to the mitochondrial matrix and 
producing heat. UCPs play a role in the generation of reactive oxygen species (ROS). ADP 
and ATP cannot cross the inner mitochondrial membrane. Therefore, ADP/ATP translocases 
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enable the import of ADP into the mitochondria and the export of new-formed ATP out of the 
mitochondria. CPT2 together with a translocase transfer fatty acids inside the matrix, where 
the β-oxidation takes place. 
 
2.1.4 Matrix 
 
The mitochondrial matrix is the space enclosed by the inner mitochondrial membrane. The 
matrix contains the mitochondrial DNA, ribosomes, soluble enzymes, small organic 
molecules, nucleotide cofactors, and inorganic ions. The matrix contains enzymes for the 
tricarboxylic acid cycle (TCA), β-oxidation, and the urea cycle. 
 
 
2.1.5 mtDNA 
 
Mitochondria have their own independent circular DNA located in the matrix (see Figure 6). 
Each mitochondrion contains several copies of mitochondrial DNA (mtDNA), approximately 
100-10,000 per cell (Schon et al. 1997). In humans, the 16,569 base pairs of the mtDNA 
encode for only 37 genes: 13 are for polypeptides, 22 for transfer RNA and 2 for small and 
large subunits of ribosomal RNA (see table 3). All 13 polypeptides are used in the ETC. The 
remaining proteins of the ETC are encoded by the nuclear DNA. Mitochondria are lacking 
protective histones and have relatively lacking repair mechanisms (Meyer et al. 2013). In 
addition, mitochondria are in direct proximity to the ETC, where the majority of ROS is 
produced (Fruehauf and Meyskens 2007). Therefore, the mutation rate of the mtDNA is 5-10 
times higher than in the nuclear DNA (Tao et al. 2014). The high number of mtDNA is the 
only working buffering system against stressors. 
 The mtDNA is only inherited from the mother. Mitochondria are the only organelles that are 
under genetic control of both nuclear DNA and its own mitochondrial genome. 
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Figure 6: Human mtDNA. The human mitochondrial genome is a 16.6 kb double-stranded 
and circular DNA molecule. The displacement loop (D loop), a 1.1 kb non-coding region, is 
involved in the regulation of transcription and replication of mtDNA. The rest encodes 
37 genes: 13 are for polypeptides, 22 for transfer RNA and two for small and large subunits of 
ribosomal RNA. (Gorman et al. 2016) 
 
Table 3: Mitochondrial-encoded genes: 13 proteins, 2 ribosomal RNAs (rRNA) and 22 
transfer RNAs (TRNA). Adapted from (Schon et al. 2012). 
Proteins rRNAs tRNAs 
ATP synthase 6 12S rRNA tRNA-Ala tRNA-Met 
ATP synthase 8 16S rRNA tRNA-Arg tRNA-Phe 
COX I  tRNA-Asn tRNA-Pro 
COX II  tRNA-Asp tRNA-Ser1 
COX III  tRNA-Cys tRNA-Ser2 
Cytochrome b  tRNA-Gln tRNA-Thr 
ND1  tRNA-Glu tRNA-Trp 
ND2  tRNA-Gly tRNA-Tyr 
ND3  tRNA-His tRNA-Val 
ND4  tRNA-Ile  
ND4L  tRNA-Leu1  
ND5  tRNA-Leu2  
ND6  tRNA-Lys  
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2.2 Mitochondrial bioenergetics 
 
Mitochondria are the main organelles for energy production in the cell as they convert the 
energy produced by the oxidation of pyruvate and fatty acid and from the TCA cycle into 
ATP through oxidative phosphorylation. Glycolysis in the cytosol is the other pathway for 
ATP production. However, glycolysis produces only 2 molecules of ATP per glucose 
molecule whereas oxidative phosphorylation produces more than 30 molecules of ATP per 
glucose molecule. Mitochondria are also the main organelles involved in fat oxidation. The 
following sections explain the three main energy-producing pathways of mitochondria. 
 
 
2.2.1 Tricarboxylic acid cycle 
 
The tricarboxylic acid cycle is the key metabolic pathway that connects carbohydrate, fat, and 
protein metabolism and consists of a series of eight enzyme-catalyzed reactions taking place 
in the mitochondrial matrix. The TCA cycle oxidizes acetyl-CoA from carbohydrates, fats and 
proteins into CO2 and water and produces ATP, nicotinamide adenine dinucleotide (NADH), 
and flavin adenine dinucleotide (FADH2) as described in Figure 7. The intermediates of the 
TCA cycle are used by many essential energy consuming biosynthetic pathways such as 
amino acids, cholesterol, porphyrin, or nucleotide bases (Williamson and Cooper 1980).  
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Figure 7: The tricarboxylic acid cycle. The TCA cycle oxidize acetyl-CoA from 
carbohydrates, fats and proteins into CO2 and water and producing ATP, NADH, and FADH2. 
 
 
2.2.2 β-oxidation 
 
Mitochondria are the main organelle for the degradation of fatty acids as they carry out more 
than 90% of the cellular β-oxidation, the prime pathway for the degradation of fatty acids. 
The residual 10% are realized in the peroxisomal pathway. In order to enter mitochondria, 
long-chain fatty acyl-CoAs (C14-C18) require a carnitine shuttle, as the mitochondrial 
membranes are impermeable to these acyl-CoAs. In contrast, short-chain (C4-C6) and 
medium-chain (C6-C14) fatty acids are able to freely cross the inner and outer mitochondrial 
membranes. The first step of the carnitine shuttle is performed by CPT1 in the outer 
mitochondrial membrane that converts an acyl-CoA into an acylcarnitine. The carnitine 
acylcarnitine translocase (CACT) exchanges acylcarnitines for free carnitine molecules from 
the inside. After entering the mitochondria, CPT2 at the inner mitochondrial membrane 
reconverts the acylcarnitines into the CoA-esters, which can undergo β-oxidation (Houten and 
Wanders 2010). 
Mitochondrial β-oxidation is a cyclic four-enzyme reaction in the mitochondrial matrix where 
acyl-CoAs are shortened and two carboxy-terminal carbon atoms are released as acetyl-CoA 
unit each time a cycle is fully completed (see Figure 8). In the first step of the β-oxidation, an 
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acyl-CoA-ester is dehydrogenated to procedure a trans-2-enoyl-CoA. Afterwards, the double 
bond is hydrated to a L-3-hydroxy-acy-CoA and in the third step dehydrogenated to 3-keto-
acyl-CoA. Finally, this is thiolytic cleaved to a two-carbon chain-shortened acyl-CoA and an 
acetyl-CoA. The shortened acyl-CoA undergoes another cycle of β-oxidation. In addition to 
the acetyl-CoA, each cycle produces one NADH and one FADH2 that deliver electrons as 
electron carriers to the ETC. The produced acetyl-CoA enters the TCA cycle. 
As a result of inhibition of β-oxidation or fatty acid oxidation, free fatty acids and 
triglycerides are accumulating in the cytoplasm forming small vesicles and leading to 
microvesicular steatosis in patients (Jaeschke et al. 2002). 
 
 
Figure 8: β-oxidation in humans. Fatty acids get activated to acyl-CoAs after transport 
across the plasma membrane. CPT1 converts the acyl-CoA into an acylcarnitine which is 
transported across the mitochondrial membrane by CACT. CPT2 converts the acylcarnitine 
back into the acyl-CoA. Long chain acyl-CoAs are metabolized by membrane bound 
enzymes, the VLCAD (very long chain acyl-CoA dehydrogenase), MTP (mitochondrial 
trifunctional protein), LCHAD (long chain hydroxyacyl-CoA dehydrogenase) and thiolase 
activity. Short and medium chain fatty acids are metabolized in the mitochondrial matrix by 
MCAD (medium chain acyl-CoA dehydrogenase), SCAD (short chain acyl-CoA 
dehydrogenase), crotonasa, M/SCHAD (medium and short chain hydroxyacyl-CoA 
dehydrogenase), and MCKAT (medium chain 3-ketoacyl-CoA thiolase). (Houten and 
Wanders 2010) 
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2.2.3 Mitochondrial electron transfer chain and oxidative phosphorylation 
 
The ETC is located in the inner mitochondrial membrane and is composed of five complexes 
with multiple protein subunits (Figure 9). Briefly, electrons are transferred from NADH to 
complex I and from FADH2 to complex II. Both complexes transfer their electrons to 
coenzyme Q, which transports the electrons to complex III. Complex III delivers the electrons 
to cytochrome c, which will then transfer the electrons to complex IV to reduce oxygen to 
water. In addition, complexes I, III, and IV pump protons across the inner mitochondrial 
membrane and therefore producing an electrochemical proton gradient – the mitochondrial 
membrane potential. The membrane potential is used by the ATP synthase (Complex V) to 
phosphorylate ADP to ATP. This process is called oxidative phosphorylation (OXPHOS) and 
produces most of the ATP within the cell. The single complexes of the ETC will be described 
in the next sections in more detail. 
 
 
Figure 9: The mitochondrial electron transport chain (Bird et al. 2014). Electrons enter 
the ETC by oxidation of NADH at complex I and succinate at complex II. They are 
transferred by the mobile electron carrier coenzyme Q to complex III and afterwards via 
cytochrome c (cyt c) to complex IV, where they are used to reduce oxygen to form water. 
Complex V utilizes the electrochemical gradient to couple proton flow through the complex 
with ATP synthesis from ADP and phosphate (Pi). In addition, complexes I, III, and IV are 
pumping protons (H+) across the inner mitochondrial membrane into the intermembrane space 
to maintain the mitochondrial membrane potential. IMM: inner mitochondrial membrane; 
IMS: intermembrane space; ox: oxidized; red: reduced; Ψ: charge. 
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2.2.3.1 Complex I 
The complex I of the ETC is known as the NADH:ubiquinone oxidoreductase or 
NADH:dehydrogenase. Complex I is composed of 49 subunits, 42 encoded by the nucleus 
and 7 by the mtDNA (Wirth et al. 2016). Complex I contains 14 central subunits, 7 
hydrophilic and 7 hydrophobic polypeptides. The hydrophilic central subunits comprise all 
redox active prosthetic groups, namely one flavin mononucleotide (FMN) and eight iron-
sulfur clusters (Figure 10) (Wirth et al. 2016).  
 
 
Figure 10: Structure of complex I. Complex I is an L-shaped enzyme, with a large 
hydrophilic domain containing the flavin mononucleotide, iron-sulfur (FeS) clusters, and the 
binding site for the ubiquinone headgroup. (Roberts and Hirst 2012) 
 
Complex I catalyzes the transfer of two electrons from NADH to the lipid-soluble carrier 
ubiquinone (Q) reducing it to ubiquinol (QH2) and translocates four protons across the inner 
mitochondrial membrane. The reaction can be described as follow: 
NADH ↔ NAD+ + H+ + 2 e- 
NADH + Q + 5H+ ↔ NAD+ + QH2 + 4H+ 
 
Complex I is one of the main sites where premature electron leakage to oxygen occurs. 
Complex I can be inhibited by rotenone as it inhibits the transfer of electrons from iron-sulfur 
centers in complex I to ubiquinone by blocking the quinone-binding site of complex I. 
Therefore, complex I is unable to pass off its electrons to ubiquinone and is creating a back-
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up of electrons within the mitochondrial matrix (Brand 2010). Consequently, the rate of 
superoxide formation at complex I is increased several-fold through rotenone. 
 
 
2.2.3.2 Complex II 
The complex II is known as succinate:ubiquinone oxidoreductase or succinate dehydrogenase. 
It is composed of four nuclear encoded subunits. Complex II can be competitively inhibited 
by malonate by binding to the active site of the enzyme without reacting to it and therefore 
competing with succinate, the normal substrate of complex II. Complex II catalyzes the 
oxidation of succinate to fumarate with the reduction of ubiquinone to ubiquinol using two 
electrons and two protons. Complex II is a parallel electron transport to complex I, but unlike 
complex I, no protons are pumped across the inner mitochondrial membrane. The reaction can 
be described as follow: 
Succinate + Q ↔ Fumarate + QH2 
 
 
2.2.3.3 Complex III 
The complex III is known as ubiquinone-cytochrome c oxidoreductase or cytochrome c 
reductase. It is composed of 10 nuclear and 1 mtDNA encoded subunits. Three subunits have 
prosthetic groups – the cytochrome b subunit has two b-type hemes (bL and bH), the 
cytochrome c has one c-type heme (c1), and the Rieske Iron Sulfur Protein (ISP) subunit has 
an iron-sulfur cluster. The Q cycle mechanism postulates two separate quinone-binding sites – 
one for quinol oxidation (Qo site) and the other for quinone reduction (Qi site). One electron 
from the substrate quinol is transferred at the Qo site and further to the ISP, to cytochrome c1 
and the soluble electron acceptor cytochrome c. The second electron is transferred to heme bL 
and bH ending at the Qi site (Gao et al. 2003). The fully reduced quinone at the Qi site picks 
up two protons from the mitochondrial matrix and moves to the Qo site for reoxidation. 
Therefore, a complete Q cycle consumes two quinol-molecules at the Qo site, generates one 
quinol-molecule at the Qi site, and translocates four protons to the intermembrane space 
(Figure 11).  
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Figure 11: Structure of complex III including the binding site for quinol oxidation (Qo 
site), the binding site for quinone reduction (Qi site). A complete Q cycle consumes two 
quinol-molecules at the Qo site, generates one quinol-molecule at the Qi site, and translocates 
four protons to the intermembrane space. 
 
Overall, complex III catalyzes the transfer of two electrons from ubiquinol to two molecules 
of cytochrome c, a water-soluble electron carrier located within the intermembrane space. The 
reaction can be described as follow: 
QH2 + 2 cyt c3+ + 2 H+ ↔ Q + 2 cyt c2+ + 4 H+ 
 
Complex III can be inhibited by antimycin A by binding to the Qi site and therefore inhibiting 
the electron transfer from the heme bH to quinone. When the electron transfer is reduced, 
complex III also leaks electrons to molecular oxygen, resulting in ROS formation. 
 
 
2.2.3.4 Complex IV 
The complex IV is known as cytochrome c oxidase and is composed of 10 nuclear and 3 
mtDNA encoded subunits. Complex IV transfer four electrons from cytochrome c to the 
terminal electron acceptor – molecular oxygen producing two molecules of water. The 
reaction can be described as follow: 
4 cyt c2+ + 8 H+ + O2 ↔ 4 cyt c3+ + 4 H+ + 2 H2O 
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Complex IV translocates four protons across the inner mitochondrial membrane and can be 
inhibited by cyanide. Cyanide prevents the transport of electrons from cytochrome c to 
oxygen. 
 
 
2.2.3.5 Complex V 
The complex V is known as F1F0-ATPase or ATP synthase and is composed of 16 nuclear and 
2 mtDNA encoded subunits. Complex V uses the electrochemical proton gradient across the 
inner mitochondrial membrane created by complexes I, III, and IV to produce ATP. The 
reaction can be described as follow: 
ADP + Pi + H+ ↔ ATP + H2O + H+ 
 
The ATP synthase (Figure 12) consists of two main subunits, F0 and F1. F0 consists of mainly 
hydrophobic regions embedded in the inner mitochondrial membrane to allow the protons to 
translocate the inner mitochondrial membrane. The proton flow will be converted to a rotation 
of the F1 part. F1 consists of six hydrophilic subunits, three of them are binding ADP and the 
other three catalyze the ATP synthesis. 
 
 
Figure 12: The ATP synthase. The ATP synthase consists of the F0 and F1 subunits. F0 is 
mainly embedded in the inner mitochondrial membrane to allow the protons to translocate the 
inner mitochondrial membrane. The proton flow will be converted to F1-rotation. 
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2.3 Reactive oxygen species 
 
Oxygen exists in two different forms: as its molecular form (O2) and as a free radical. A free 
radical is an atom, molecule or ion that has unpaired valence electrons. These unpaired 
electrons make free radicals highly chemically reactive towards other molecules. Oxygen has 
two unpaired electrons in separate orbitals in the valence shell making it especially 
susceptible to radical formation. Sequential reduction of molecular oxygen leads to the 
formation of a group of reactive oxygen species: superoxide anion radical (O2-), hydrogen 
peroxide (H2O2) and hydroxyl radical (OH) (Figure 13). One electron reduction of oxygen 
generates the superoxide anion radical (O2-), which is not a very reactive species and its 
chemical reactivity depends on the site of generation in the cell and on the collision with 
suitable substrates. Further addition of one electron to superoxide will form hydrogen 
peroxide (H2O2), which is non-radical, but can diffuse long distances, cross membrane and 
can react with transition metals by a hemolytic cleavage yielding the highly reactive hydroxyl 
radical (OH). Hydrogen peroxide can also be formed by two electrons reduction of oxygen. 
Addition of one electron to hydrogen peroxide forms a hydroxyl anion and a hydroxyl radical 
(OH), the most reactive oxygen species because it reacts with almost all biological 
compounds. The hydroxyl radical will only mediate direct effects close to its site of 
generation and cannot diffuse long distances. The reactions can be described as follow: 
O2 + e- → O2- 
2 H+ + O2- + O2- → H2O2 + O2 
O2 + 2 e- → O22- 
H2O2 + e- → HO- + OH 
2 H2O2 → 2 H2O + O2 
 
Another type of ROS is singlet oxygen (1O2), which is produced from triplet oxygen (3O2) 
through energy input. Singlet oxygen is not a free radical but is highly reactive, especially 
with organic compounds that contain double bonds. The next sections will explain the 
biological role and cellular sources of ROS as well as the resulting oxidative stress and the 
antioxidant system. 
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Figure 13: Generation of different ROS by energy transfer or sequential univalent 
reduction of ground state triplet oxygen (Apel and Hirt 2004). 
 
 
2.3.1 Biological role of free radicals 
 
Oxygen radicals are not always bad. Indeed, they are produced in a number of essential 
reactions. ROS are involved in intra- and intercellular signaling and used by the immune 
system to attack and kill pathogens (Wilson et al. 2017b). Short-term oxidative stress is 
important in the prevention of aging by the induction of mitohormesis (Gems and Partridge 
2008). On the other hand, ROS can be harmful to cells because they are able to damage all 
macromolecules, including lipids, proteins and nucleic acids (Wilson et al. 2017a). 
 
 
2.3.2 Cellular sources of ROS 
 
ROS are produced intracellularly through multiple mechanisms: enzymatic reactions – such 
as NADPH oxidase, NADPH-cytochrome P450 reductase and xanthine oxidase; cellular 
sources – such as mitochondrial ETC, microsomal monooxygenase, leukocytes, and 
macrophages; and environmental factors – such as ultraviolet light, radiation, toxic chemicals, 
aromatic hydroxylamines and aromatic nitro compounds.  
NADPH oxidases contain cytosolic FAD- and NADPH-binding domains, six transmembrane 
domains, and two heme groups (Togliatto et al. 2017). The heme groups transfer the electrons 
from cytosolic NAD(P)H across the membrane to oxygen to produce superoxide anion 
outside the cell or in phagosomes to kill bacteria and fungi (Nguyen et al. 2017). The reaction 
can be described as follow: 
NADPH + 2 O2 → NADP+ + 2 O2- + H+ 
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NADPH-cytochrome P450 reductase is composed of multiple domains that transport electrons 
from NADPH to cytochrome P50 via flavin cofactors in the endoplasmic reticulum (Gray et 
al. 2010). NADPH-cytochrome P450 reductase has the ability to autooxidize and generate 
ROS (Mishin et al. 2010). 
Xanthine oxidases are enzymes that catalyze the oxidation of hypoxanthine to xanthine and 
the oxidation of xanthine to uric acid. Xanthine oxidase can reduce molecular oxygen with 
formation of superoxide radical anion and hydrogen peroxide (Bonini et al. 2004). 
Most of the electrons transferred to the ETC safely react with protons and oxygen to form 
water, but some electrons directly react with oxygen at complexes I and III and form 
superoxide anion radical that afterwards can generate other ROS (Ott et al. 2007). Therefore, 
mitochondria are the main endogenous source of ROS in the normal cell and produce around 
90% of cellular ROS (Balaban et al. 2005). Under normal conditions less thea 0.1% of 
electrons passing through the ETC leak and form superoxide (Brand 2010). Superoxide can be 
produced in complex I in two different situations. The first one is when electrons back up in 
the chain of iron-sulfur clusters. This is the case when NADH is present but the downstream 
ETC is blocked by rotenone (complex I), antimycin A (complex III), cyanide (complex IV) or 
other inhibitors. The second situation is the reverse electron transfer, when electrons flow 
back from complex II via ubiquinone to complex I leading to a reduction of complex I and 
ROS formation (Drose and Brandt 2012). Superoxide formation at complex III takes place at 
the Qo ubiquinone site releasing ROS to both sides of the inner mitochondrial membrane. The 
rate of ROS formation is strongly increased under oxidant-induced reduction conditions – in 
the presence of a Qi site inhibitor like antimycin A, sufficient amount of reducing equivalents 
and an oxidized downstream respiratory chain. In addition, a high mitochondrial membrane 
potential can increase the ROS formation at the Qo site. Inhibition of reducing ubiquinone at 
the Qi site and slowing it down by a high mitochondrial membrane potential result in a 
backup of electrons and an accumulation of semiquinone radical at the Qo site transferring the 
electrons to oxygen forming superoxide (Drose and Brandt 2012). 
 
MOLECULAR MECHANISMS OF TYROSINE KINASE                      INTRODUCTION 
INHIBITORS-ASSOCIATED HEPATOTOXICITY 
 28 
 
Figure 14: Main mechanisms for mitochondrial ROS generation. The main centers of 
mitochondrial superoxide formation are complex I and III, although small amounts can be 
formed at complex II and IV. In addition, the main routes of superoxide transformation are 
prepresented. SOD: superoxide dismutase, H2O2: hydrogen peroxide, ONOO-: peroxynitrite, 
NO*: nitric oxide, ΔΨm: mitochondrial potential, AS: ATP synthase. Only the inner 
mitochondria membrane is represented. (Camello-Almaraz et al. 2006) 
 
 
2.3.3 Oxidative stress 
 
Oxidative stress occurs with an over-formation of ROS or a decreased antioxidant system 
within the cell. Therefore, oxidative stress can be described as an imbalance between ROS 
formation and the ability to detoxify the ROS or to repair the resulting damage. Cells can 
tolerate mild to moderate oxidative stress leading to increased antioxidant defense. High 
oxidative stress will lead to damages within the cell including proteins, lipids and nucleic 
acids. One of the best known toxic effects of ROS is the damage of cellular membranes by 
lipid peroxidation of polyunsaturated fatty acids present in membrane phospholipids, 
particularly arachidonic and linoleic acid (Ademowo et al. 2017). As a consequence, the 
membrane fluidity, which is essential for proper function of membranes, decreases. Unless 
superoxide is quickly dismutated, it can react with nitric oxide (NO) to form DNA- and 
protein-damaging peroxynitrite (Pessayre et al. 2012). The DNA can be damaged by base 
damage or strand breaks, which can cause long-term effects when the damage is inside a 
coding region. mtDNA is 10 times more susceptible for DNA damage than nuclear DNA 
because 90% of ROS are produced within mitochondria and mitochondria are lacking 
protective histones and have an incomplete repair mechanisms (Meyer et al. 2013). Protein 
damage by ROS can lead to peptide chain breaks and the thereby modified protein length and 
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protein structure may induce a loss of catalytic function of the protein. Normally, any damage 
to cells is repaired rapidly but severe oxidative stress can cause cell death. Moderate oxidative 
stress triggers apoptosis while more intense oxidative stress causes ATP depletion, preventing 
controlled apoptotic death leading to necrosis. 
 
 
2.3.4 Antioxidant system 
 
Cells developed several antioxidant defense mechanisms to protect themselves against ROS. 
An antioxidant inhibits the oxidation of other molecules. The enzymatic scavenger system is 
composed of superoxide dismutase (SOD), catalase, glutathione peroxidase and 
peroxiredoxin. The antioxidant systems are described in more detail in this section. 
 
 
2.3.5 Superoxide dismutase 
 
SODs are a class of enzymes that catalyze the dismutation of the superoxide radical into 
oxygen and hydrogen peroxide: 
2 O2- + 2 H+ → H2O2 + O2 
 
As described before, superoxide is produced as a by-product of several reactions and by 
complex I and III of the ETC of mitochondria. If superoxide is not regulated, it can cause 
different types of cell damage (Hayyan et al. 2016). Hydrogen peroxide can also damage cells 
and is degraded by other enzymes such as catalase. Therefore, SOD is an important 
antioxidant defense in nearly all living cells exposed to oxygen. The importance of SODs is 
illustrated by several knock-out mice models. Mice lacking SOD2 survive only for a short 
time due to massive oxidative stress (Joe et al. 2015). Mice with a SOD1 knock-out develop a 
range of different pathologies such as hepatocellular carcinoma, acceleration of age-related 
muscle mass loss, earlier incidence of cataracts, and reduced lifespan (Elchuri et al. 2005; 
Muller et al. 2006). 
In humans, three forms of SODs (SOD1 to SOD3) are present. SOD1 is mainly located in the 
cytosol of cells and in the intermembrane space and contains a copper-zinc cofactor. SOD2 is 
located in the mitochondrial matrix and contains a manganese cofactor. SOD3 is extracellular 
and contains also a copper-zinc cofactor (Mates et al. 1999). 
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2.3.5.1 Catalase 
Catalase is concentrated in peroxisomes, whereas liver mitochondria contain no catalase. 
Catalase catalyzes the formation of water and oxygen out of hydrogen peroxide: 
2 H2O2 → 2 H2O + O2 
Catalase contains four iron-containing heme groups that allow reacting with hydrogen 
peroxide.  
 
 
2.3.5.2 Glutathione peroxidase 
Glutathione peroxidase (GPx) reduces hydrogen peroxide to water by transferring the energy 
of the reactive peroxides to a very small sulfur-containing protein called glutathione (GSH) to 
oxidized glutathione (GSSG): 
H2O2 + 2 GSH → GSSG + 2 H2O 
The sulfur of GSH acts as the reactive center, carrying reactive electrons from the peroxide to 
the glutathione. Five different forms of GPx exist in mammals. GPx1 and GPx4 are found in 
most tissues, whereas GPx2 and GPx3 can be found in the gastrointestinal tract and kidney, 
and GPx5 is specifically expressed in mouse epididymis. GPx1 and GPx2 are located in the 
cytosol, GPx 3 is extracellular and GPx4 is located in the cytosol and membrane fraction 
(Mates et al. 1999). As GPx consumes GSH, it is necessary to restore the GSH pool. The 
glutathione reductase converts GSSG back to GSH. 
 
 
2.3.5.3 Glutathione 
Glutathione (GSH) is an important antioxidant that is used in the reaction of glutathione 
peroxidase. GSH is a tripeptide with a glutamate, cysteine, and glycine amino acids where the 
thiol group of cysteine serves as reducing agent (Figure 15). The GSH-structure is unique as 
the peptide bond linking glutamate and cysteine is through the γ-carboxyl group of glutamate 
and not through the conventional α-carboxyl group. The only enzyme that can hydrolyze this 
unusual bond is γ-glutamyltranspeptidase, which is only present on external surfaces of 
certain cell types (Kunutsor and Laukkanen 2017). Therefore, GSH is resistant to intracellular 
degradation and is only metabolized extracellularly by cells that express γ-
glutamyltranspeptidase.  
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Figure 15: Structure of GSH (left) and GSSG (right). GSH is the tripeptide γ-L-glutamyl-
L-cysteinylglycine and GSSG is the oxidized form of GSH. 
 
GSH is present in all mammalian tissues at 1-10 mM with the highest concentration in the 
liver (Lu 2013). In addition to the antioxidant function by the GPx, GSH regulates the redox-
depending cell signaling by modifying the oxidative state of critical protein cysteine residues 
(Figure 16) (Forman et al. 2009). GSH can bind to the –SH generating glutathionylated 
proteins, which can either activate or inactivate the protein and protects sensitive thiols from 
irreversible oxidation (Dalle-Donne et al. 2009). 
 
 
Figure 16: Antioxidant function of GSH. Hydrogen peroxide (H2O2) can be metabolized by 
GSH peroxidase (GPx) in the cytosol and mitochondria and by catalase in the peroxisome. 
GSSG can be reduced back to GSH by glutathione reductase (GR) using NADPH and thereby 
forming a redox cycle. Organic peroxides (ROOH) can be reduced by either GPx or GSH S-
transferase (GST). In addition, GSH plays a role in protein redox signaling as it can react with 
oxidized proteins to sulfenic acid (Prot-SOH) during oxidative stress and forms protein mixed 
disulfides Prot-SSG which can be reduced back to the Prot-SH. Oxidative stress may leads to 
an accumulation of GSSG, therefore GSSG can either be actively transported out of the cell or 
react with Prot-SH to form a mixed disulfide Prot-SSG. (Lu 2013) 
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Once oxidized, GSSG can be reduced back to GSH by glutathione reductase using NADPH as 
an electron donor (Couto et al. 2013). In addition, the ratio of GSH to GSSG is often used as a 
marker for cellular oxidative stress (Lu 2013). Under normal conditions, the reduced GSH 
accounts for more than 98% of total GSH (Forman et al. 2009). Most of the cellular GSH is in 
the cytosol (80-85%), 10-15% is stored in mitochondria and a small percentage is in the 
endoplasmic reticulum (Lu 2013).  
The synthesis of GSH from its precursor amino acids involves two enzymatic steps with ATP 
consumption: formation of γ-glutamylcysteine from glutamate and cysteine by γ-
glutamylcysteine synthetase, the rate-limiting step, and formation of GSH from γ-
glutamylcysteine and glycine by GSH synthetase. 
 
 
2.3.5.4 Peroxiredoxins 
Peroxiredoxins also degrade hydrogen peroxide to water within mitochondria, cytosol and 
nucleus. 
 
 
2.4 Mitochondrial biogenesis 
 
Mitochondrial biogenesis can be described as growth and division of pre-existing 
mitochondria. Mitochondrial biogenesis is stimulated by environmental stress such as 
oxidative stress, caloric restriction, cold exposure, cell division, and exercise by activating the 
transcription cascade of mitochondrial biogenesis (Jornayvaz and Shulman 2010). Accurate 
mitochondrial biogenesis requires coordinated synthesis and import of 1000-1500 nuclear 
encoded proteins (Baker et al. 2007). The peroxisome proliferator-activated receptor-γ-
coactivator-1 (PGC-1) family stands at the beginning of the biosynthesis cascade with the 
members PGC-1α, PGC-1β, and PRC (PGC-1 related coactivator). PGC-1α is the master 
regulator of mitochondrial biogenesis (Lynch et al. 2017). It induces the nuclear respiratory 
factor 1 (NRF1) and NRF2, which together activate the mitochondrial transcription factor A 
(Tfam). Tfam transcribes mitochondrial-encoded proteins. PGC-1β is structurally similar to 
PGC-1α and is also involved in mitochondrial biogenesis but is not up-regulated in response 
to exercise. AMP-activated protein kinase (AMPK) acts as an energy sensor of the cell and 
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works as a key regulator of mitochondrial biogenesis by phosphorylating and activating PGC-
1α (Jornayvaz and Shulman 2010). 
The following sections will describe fission, fusion, and mitophagy that are important 
mechanisms for healthy mitochondria, in more detail. 
 
 
2.4.1 Fission and fusion 
 
Mitochondria are highly dynamic organelles undergoing fission and fusion, which are 
essential for maintaining healthy mitochondria. Fission is the event of a single mitochondrion 
breaking apart, whereas fusion is the event of two or more mitochondria joining to form a 
whole (Figure 17) (Mishra and Chan 2016). Increased fission creates fragmented 
mitochondria, which is helpful for the elimination of damaged mitochondria and for creating 
smaller mitochondria for transport (Youle and van der Bliek 2012). Therefore, balance 
between fusion and fission permits the cell to have the right mitochondrial network 
organization during biogenesis. 
Three large GTPases of the dynamin superfamily mediate mitochondrial fusion: Mitofusin 1 
(Mfn1), Mfn2 and optic atrophy 1 (Opa1) (Chan 2012). Mitochondrial fusion is a two-step 
process with outer-membrane fusion by Mfn1 and Mfn2 followed by inner-membrane fusion 
by Opa1. Complete loss of fusion through removal of bath mitofusin and Opa1 results in a 
dramatic decrease in mtDNA content, heterogeneous loss of mtDNA nucleoids and membrane 
potential and reduced respiratory chain function (Chen et al. 2005). Fusion is required for 
embryonic development and for cell survival at later development stages (Youle and van der 
Bliek 2012). In addition, Mfn2 maintains coenzyme Q levels (Mourier et al. 2015) and Opa1 
maintains mitochondrial cristae structure and is critical for respiratory chain supercomplex 
assembly (Cogliati et al. 2013). High OXPHOS activity correlates with mitochondrial fusion 
(Mishra et al. 2014). Oxidative stress can increase fusion due to elevated GSH levels 
promoting disulfide-mediated dimerization of mitofusin molecules (Shutt et al. 2012). 
Mitochondrial fission is mediated by Dynamin-related protein 1 (Drp1), a large cytosolic 
GTPase that is recruited to the outer mitochondrial membrane via collection of receptor 
protein and is forming a spiral around mitochondria to break the outer and the inner 
mitochondrial membrane. Fission has multiple functions such as facilitate mitochondrial 
transport, mitophagy and apoptosis (Mishra and Chan 2016). Inhibition of OXPHOS is 
associated with fission. 
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Figure 17: Fission and Fusion. The mitochondrial life cycle starts with growth and division 
of pre-existing mitochondria by biogenesis and ends with degradation of impaired 
mitochondria by mitophagy. In between, mitochondria undergo frequent cycles of fission and 
fusion that allow the cell to generate multiple heterogeneous mitochondria (fission) or 
interconnected mitochondrial networks (fusion) depending on the physiological conditions. 
(Westermann 2010) 
 
 
2.4.2 Mitophagy 
 
Autophagy is a well-established mechanism of degrading cellular components and protects 
cells from deleterious protein aggregates by encapsulating and degrading them (Youle and 
van der Bliek 2012). Autophagy is also required for maintaining a healthy mitochondrial 
network by eliminating old and damaged mitochondria and preventing an accumulation of 
dysfunctional mitochondria, which can lead to cellular degeneration. Mitophagy, the 
autophagic elimination of mitochondria, is also used for the adjustment of mitochondrial 
numbers to react to changing metabolic needs and during certain cellular development stages 
(Figure 18). A study showed that one out of five mitochondria are eliminated via mitophagy 
(Twig et al. 2008). Mitophagy is linked to mitochondrial fission and fusion – fission is 
required for mitophagy (Twig et al. 2008). Mitophagy is regulated by PINK1 and parkin, 
genes that are responsible for some familiar Parkinson’s disease cases (Youle and van der 
Bliek 2012). PINK1 is a mitochondrial-localized kinase that is imported and degraded under 
normal conditions. The import, like for all proteins, is dependent on the mitochondrial 
membrane potential. Therefore, a depolarization results in PINK1 accumulation in the outer 
mitochondrial membrane and phosphorylates other proteins including ubiquitin to recruit and 
activate the cytosolic parkin (Matsuda et al. 2010; Okatsu et al. 2015). Activated parkin 
results in ubiquitination of proteins of outer mitochondrial membrane proteins including Mfn1 
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and Mfn2, whose degradation is required for directing the mitochondrion to the autophagic 
membrane (Chan et al. 2011). Ubiquitination recruits the autophagy adaptor LC3 that is 
leading to mitophagy. Another mitophagy pathway is mitophagy receptors on the outer 
mitochondrial membrane such as NIX1, BNIP3 and FUNDC1. These receptors bind LC3 and 
therefore leading to mitochondria degradation. 
Mitophagy can be activated under certain cellular stress like energy stress, hypoxic conditions 
and metabolic conditions promoting increased mitochondrial function. 
 
 
Figure 18: Model of parkin-induced mitophagy. In healthy mitochondria, PINK1 is 
permanent degradated by the inner mitochondrial membrane protease. PINK1 is accumulated 
to the outer mitochondrial membrane is damaged mitochondria with depolarized membrane 
potential. Accumulated PINK1 is recruiting the E3 ligase parkin from the cytosol and 
resulting in ubiquitination of several outer membrane proteins and elimination of Mfn1 and 
Mfn2. Finally, parkin induces autophagic elimination of damaged mitochondria. (Youle and 
van der Bliek 2012) 
 
 
2.5 Apoptosis 
 
Mitochondria play a central role in most forms of cell death (Pessayre et al. 2010). An 
impairment of mitochondrial function by oxidative stress or other factors ultimately leads to 
cell death by apoptosis or necrosis. Two pathways can initiate apoptosis: the intrinsic pathway 
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is triggered by oxidative stress, cytosolic calcium overload, endoplasmic reticulum stress, and 
DNA stress and the extrinsic pathway is triggered by signals of other cells (Figure 19). The 
intrinsic apoptotic pathway leads to the opening of the MPTP (mitochondrial permeability 
transition pore), which spans the inner and outer mitochondrial membrane and releases the 
pro-apoptotic factor cytochrome c into the cytosol. Cytochrome c binds to Apaf-1 (Apoptotic 
protease activating factor-1) and pro-caspase-9 to form an apoptosome, which cleaves the 
pro-caspase-9 to its active form caspase-9 and subsequently activates caspase-3. The extrinsic 
pathway is activated through TNF (tumor necrosis factor) or Fas (First apoptosis signal) 
signaling, resulting in the formation of the DISC (death-inducing signaling complex) and 
activation of caspase-8, which activates caspase-3. Both pathways activate the effector 
caspase-3 that can activate other effector caspases and cleaves PARP (poly ADP-ribose 
polymerase) preventing further DNA repair (Los et al. 2002). Activation of effector caspases 
kills the cell by protein degradation and phagocytosis of the cell. The activation of caspases is 
an ATP-dependent process, where a certain functioning of the mitochondria is still required 
(Wang and Youle 2009). The cell goes to necrosis if ATP depletion occurred where the cell 
membrane integrity is lost and an uncontrolled release of cell products into the extracellular 
space occurs.  
 
 
Figure 19: Intrinsic and extrinsic apoptosis pathway. The release of cytochrome c from 
mitochondria results in the formation of the apoptosom and activation of caspase-9 in the 
intrinsic pathway. The DISC complex is formed in the extrinsic pathway upon ligand binding 
to specific receptors and caspase-8 is activated. Caspase-8 and caspase-9 activate downstream 
caspases such as caspase-3 resulting in cell death. (Favaloro et al. 2012) 
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2.6 Drug induced mitochondrial toxicity 
 
Proper mitochondrial function is dependent upon the impermeability of the inner 
mitochondrial membrane and the integrity of the respiratory complexes. In addition, 
mitochondrial replication requires the capacity to replicate and express mtDNA (Dykens and 
Will 2007). Several drugs are known to inhibit mitochondrial function. The following 
paragraph will discuss the possible targets of drug-induced mitochondrial toxicity (Figure 20). 
Some fibrates and thiazolidinediones acutely impair mitochondrial function by inhibition of 
the ETC or by uncoupling the electron transport from ATP production (Brunmair et al. 2004). 
Therefore, the mitochondrial membrane potential is decreased and ATP production reduced. 
Acetaminophen, doxorubicin, and ethanol produce oxidative stress via redox cycling or via 
glutathione depletion, CYP2E1-derived ROS generation, or reactive metabolite formation 
(Dykens and Will 2007). Some thiazolidinediones and statins induce mitochondrial 
permeability transition causing an irreversible collapse of the mitochondrial membrane 
potential and the release of pro-apoptotic factors (Bova et al. 2005; Kaufmann et al. 2006). 
Moreover, inhibition of metabolic pathways as fatty acid β-oxidation or Krebs cycle which 
deliver cofactors for the ETC will impair ATP production (Pessayre et al. 1999). In case of 
impairment of the fatty acid oxidation, the free fatty acids in the liver are insufficiently 
oxidized and are esterified into triglycerides that accumulate in the cytoplasm of hepatocytes 
as small vesicles or larger vacuoles. Acute impairment causes microvesicular steatosis with 
numerous tiny lipid vesicles. In contrast, in chronic impairment mixed forms of steatosis with 
tiny lipid vesicles and large fat vacuoles occur. Long-term chronic impairment results in 
macrovacuolar steatosis (Fromenty and Pessayre 1995). Inhibition of any of the mitochondrial 
membrane transporters that exchange metabolites across the impermeable inner mitochondrial 
membrane will also impair ATP production (Stewart and Steenkamp 2000).  
Nucleotide reverse transcriptase inhibitors prevent mitochondrial replication through 
inhibition of the mitochondrial polymerase. Therefore, they result in reduction of 
mitochondrial function in various tissues like muscle and liver (Lai et al. 1991). Certain 
aminoglycoside antibiotics result in long-term mitochondrial dysfunction to impaired protein 
synthesis, leading to ototoxicity and nephrotoxicity (Fischel-Ghodsian 2005). 
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Figure 20: Possible ways for the inhibition of mitochondrial function (Dykens and Will 
2007). 
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3 TYROSINE KINASE INHIBITORS 
 
3.1 Tyrosine kinases 
 
Kinases are enzymes that catalyze the transfer of a phosphate group from high-energy donor 
molecules, e.g. ATP, to specific substrates. Protein kinases phosphorylate proteins resulting in 
functional changes of the target protein. The human genome encodes for 518 protein kinases 
(Manning et al. 2002), 90 of them belong to the group of tyrosine kinases (TKs). Six other 
groups of protein kinases exist primarily phosphorylating serine and threonine residues. The 
TK group comprise approximately 30 families such as the vascular endothelial growth factor 
receptor (VEGFR) family and the fibroblast growth factor receptor (FGFR) family (Gotink 
and Verheul 2010). TKs can also be categorized into receptor and non-receptor (cytoplasmic) 
TKs. Receptor TKs are crucial in the transduction of extracellular signals into the cell while 
non-receptor TKs are essential in intracellular communication. A monomer of a receptor TK 
is composed of a N-terminal extracellular ligand-binding, a transmembrane, and a C-terminal 
intracellular domain with the TK activity. Ligand binding to the extracellular domain of the 
receptor TK stimulates receptor dimerization and a conformational change resulting in 
autophosphorylation of specific tyrosine residues of the intracellular kinase domain (Figure 
21) (Schlessinger 2000). Activation of signaling pathways leads to biological responses such 
as cell activation, proliferation, differentiation, migration, survival, and vascular permeability 
(Pawson 2004).  
 
 
Figure 21: Mechanism of action of tyrosine kinase. After Ligand binding, dimerization is 
leading to TK activation and tyrosine transphosphorylation, signal transduction, and down-
stream effects. Afterwards, receptor internalization and receptor degradation or re-expression 
occurs. (Paul and Mukhopadhyay 2004) 
Transcription 
Clathrin pit
Receptor
expression 
Ligand
binding 
Hetero/Homo
dimerization 
TK activation by
transphosphorylation 
Receptor
internalization
Degradation
or expression 
Down 
stream 
signaling
ligand
P
Receptor
internalization
P
P P
MOLECULAR MECHANISMS OF TYROSINE KINASE                      INTRODUCTION 
INHIBITORS-ASSOCIATED HEPATOTOXICITY 
 40 
3.2 Tyrosine kinase inhibitors 
 
Overexpression or mutation in TKs pathways can cause and exaggerate many types of cancer. 
Currently, there are two different classes of targeted treatments of deregulated TKs: 
therapeutic monoclonal antibodies such as cetuximab or necitumumab, or tyrosine kinase 
inhibitors (TKIs) such as imatinib or sunitinib (Figure 22). TKIs are a relatively new class of 
drugs with imatinib, initially for the treatment of patients with chronic myeloic leukemia, 
being the first on the market in 2001 (Mealing et al. 2013). The Food and Drug 
Administration (FDA) had approved a total of 31 small-molecule kinase inhibitors as of 
November 2016 (Zhang et al. 2017b). The TKIs can be classified according to the most 
important receptor, which they inhibit. Families of TKIs include Bcr-abl inhibitors (dasatinib, 
imatinib, nilotinib), ErbB inhibitors (erlotinib, gefitinib, lapatinib), VEGFR inhibitors 
(axitinib, pazopanib, sorafenib, sunitinib), and miscellaneous inhibitors (crizotinib, 
ruxolitinib, vemurafenib) (Josephs et al. 2013).  
TKIs can also be subdivided in three groups according to their mechanism of TK-inhibition: 
type I TKIs recognize the active conformation of the TK, type II TKIs recognize the inactive 
conformation of the TK and the covalent TKIs bind covalently to cysteines at specific sites of 
the TK (Gotink and Verheul 2010). Type I TKIs bind to the ATP-binding site of a TK by 
presenting one to three hydrogen bonds imitating the hydrogen bonds that are normally 
formed by ATP (Zhang et al. 2009). Sunitinib, inhibiting the VEGF pathway, is an example 
of a type I TKI. Type II TKIs indirectly compete with ATP by occupying the hydrophobic 
pocket that is in direct neighborhood to the ATP-binding site. Sorafenib, a type II TKI, uses a 
hydrophobic pocket to compete with ATP and therefore blocks the phosphorylation of 
VEGFR, platelet-derived growth factor receptor (PDGFR), Raf, and tyrosine-protein kinase 
(KIT) (Wan et al. 2004). A covalent TKI has an electrophilic group that reacts with the 
electron-rich sulfur in the cysteine residue and therefore irreversibly binds the inhibitor to the 
cysteine residue, blocking the ATP binding and TK activity (Kwak et al. 2005). Vandetanib is 
an example of a covalent TKI. The kinase domain and ATP-binding site of TKs have a high 
degree of similarity. Therefore, it is difficult to develop highly selective type I inhibitors 
because they occupy the ATP-binding site. Type II inhibitors can be more selective since 
kinases in the inactive conformation are more variable (Mol et al. 2004). Covalent inhibitors 
can be very selective because of their irreversible mechanism of binding to a cysteine residue 
of the TK.  
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Figure 22: Pathways blocked by tyrosine kinase inhibitors and monoclonal antibodies 
(Scagliotti and Govindan 2010). 
Abbreviations: EGF, endothelial growth factor; EGFR, endothelial growth factor receptor; 
GRB2, growth factor receptor-bound protein-2; MAPK, mitogen-activated protein kinase; 
MEK, MAPK/extracellular signal–related kinase kinase; PI3K, phos- phoinositide 3-kinase; 
PDGF, platelet-derived growth factor; PTEN, phosphatase and tensin homologue deleted on 
chromosome ten; SOS, son of sevenless; STAT, signal transducer and activator of 
transcription; VEGF, vascular endothelial growth factor; VEGFR, vascular endothelial 
growth factor receptor. 
 
TKIs are lipophilic low molecular drugs and can therefore, in contrast to monoclonal 
antibodies, enter the cell easily (Imai and Takaoka 2006). Once inside the cell, TKIs can 
interact with the intracellular receptor domain and intracellular signaling molecules resulting 
in a blockage of the activation of various signaling pathways (Gotink and Verheul 2010). 
TKIs can be taken orally once or twice daily at a fixed dose because the pharmacokinetics of 
TKIs is not significantly affected by weight (Houk et al. 2009). TKIs undergo intense hepatic 
metabolism with N-dealkylation mainly by CYP3A4 as the first metabolic step (Josephs et al. 
2013). TKIs as targeted treatments offer big advantages compared to traditional anti-cancer 
therapies because they are more specific, and therefore expected to have less side effects.  
However, they still have a narrow therapeutic window with dose-limiting adverse reactions, 
including in particular skin, intestinal, liver, and cardiovascular toxicity (Amitay-Laish et al. 
2011; Breccia and Alimena 2013; Yang and Papoian 2012), whereas bone marrow toxicity is 
rare. The reason for this is that many TKIs are multi-targeted kinase inhibitors, targeting a 
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number of different TKs which are involved in different signaling pathways. Inhibition of 
multiple kinases results in a broader efficacy than single-targeted inhibitor. On the other hand, 
inhibitors should be highly selective to minimize treatment-induced toxicities.  
 
 
3.3 Investigated TKIs 
 
This PhD project will take a deeper look at the 10 following TKIs and their unexpected liver 
toxicity.  
 
 
3.3.1 Crizotinib 
 
Crizotinib (Xalkori, Pfizer, Figure 23) acts as an anaplastic lymphoma kinase (ALK) and c-
ros oncogene 1 (ROS1) inhibitor. It was approved in August 2011 by the FDA for the 
treatment of locally advanced or metastatic non-small cell lung cancer that expresses the 
abnormal ALK gene. In March 2016, crizotinib was also approved for ROS1-positive non-
small cell lung cancer. About 5% of patients suffering from non-small cell lung cancer have a 
chromosomal rearrangement that generates a fusion gene between ALK and echinoderm 
microtubule-associated protein-like 4 (EML4) resulting in constant kinase activity and 
carcinogenesis (Gerber and Minna 2010). Crizotinib inhibits the kinase activity of the fusion 
protein by competitive binding within the ATP-binding pocket. 
The bioavailability of crizotinib is 32-66% after administration of a single 250 mg dose with 
Cmax after 4-6 hours. The volume of distribution of crizotinib is 25 L/kg and 90% are bound to 
plasma proteins (Josephs et al. 2013). Crizotinib is primarily metabolized by CYP3A4 and 
CYP3A5 to O-desalkymetabolites and eliminated in feces (63%) and urine (22%). The most 
common adverse events associated with crizotinib are visual disorders, nausea, vomiting, 
constipation, and diarrhea (Josephs et al. 2013). The trough plasma concentration in patients 
is on average 1.1 µM and maximal 1.9 µM (Kurata et al. 2015). 
Crizotinib was associated with elevated serum aminotransferase levels in up to 57% of treated 
patients in clinical trials with 6% of these patients having more than five times the ULN (Shah 
et al. 2013). In a phase 3 clinical trail, 16% of patients reported an ALT/AST elevation of 
grade 3-4 (Shaw et al. 2013). Serum aminotransferase elevation begins after 4-12 weeks of 
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treatment with minimal or non-symptomatic liver injury. However, fatal cases of liver injury 
with crizotinib treatment have been reported (van Geel et al. 2016). Therefore, the FDA 
labeled crizotinib for hepatotoxicity and routine liver monitoring during therapy is 
recommended. Crizotinib suppresses state 3 respiration driven by succinate and induces 
mitochondrial swelling at 100-fold Cmax, releases cytochrome c at 50-fold Cmax and inhibits 
complex I and increases ROS formation at 20-fold Cmax in isolated rat liver mitochondria 
(Zhang et al. 2017b). 
 
 
Figure 23: Chemical structure of crizotinib. 
 
 
3.3.2 Dasatinib 
 
Dasatinib (Sprycel, Bristol-Myers Squibb, Figure 24) was approved in June 2006 by the FDA 
for people with chronic myelogenous leukemia (CML) that is resistant or intolerant to 
imatinib and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) 
(Brave et al. 2008). The Philadelphia chromosome is a defective and short chromosome due 
to translocation of the Abelson murine leukemia viral oncogene homolog 1 (ABL1) gene on 
chromosome 9 and the breakpoint cluster region (BCR) gene on chromosome 22 giving the 
fusion gene BCR-ABL1. BCR-ABL1 codes for a hybrid protein – a TK that is always on and 
therefore causing the cell to divide uncontrollably. Dasatinib binds the active and inactive 
conformation of the ABL1 kinase domain and is 325 fold more potent than imatinib (Aguilera 
and Tsimberidou 2009). Dasatinib is a multi-target TKI with the main targets BCR-ABL1, 
Src, c-KIT, ephrin receptors and several other TKs. Dasatinib suppresses progenitor growth 
through inhibition of proliferation and a modest increase in apoptosis in dividing progenitors 
(Konig et al. 2008). 
Dasatinib is absorbed rapidly with Cmax after 0.5-3 hours. The volume of distribution of 
dasatinib is 30-40 L/kg and 92-97% are bound to plasma proteins (Josephs et al. 2013). 
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Dasatinib is primarily metabolized by CYP3A4 to active metabolites and eliminated mainly 
via feces. The most common adverse events associated with dasatinib are myelosuppresion, 
edema, nausea, rash, fatigue, and headache (Josephs et al. 2013). In October 2011, the FDA 
announced that dasatinib might increase the risk of pulmonary hypertension. The Cmax plasma 
concentration in patients is 0.6 µM (Haura et al. 2010). 
In clinical trials, 50% of dasatinib-treated patients showed elevated serum aminotransferase 
levels and 1-9% showed elevations above five times the ULN but cases were usually mild and 
self-limited (Shah et al. 2013). No cases of acute liver injury due to dasatinib therapy have 
occurred. Dasatinib does not cause mitochondrial toxicity in isolated rat liver mitochondria 
(Zhang et al. 2017b). In another study in rat hepatocytes, dasatinib was found to induce 
oxidative stress with ROS formation, GSH depletion, decreased mitochondrial membrane 
potential, and decreased superoxide dismutase (SOD) activity and induction of apoptosis (Xue 
et al. 2012). Another study conducted on primary human hepatocytes has shown that dasatinib 
induced autophagy in the liver which through the p38 signaling was protective against 
hepatotoxicity (Yang et al. 2015). 
 
 
Figure 24: Chemical structure of dasatinib. 
 
 
3.3.3 Erlotinib 
 
Erlotinib (Tarceva, Genentech, Figure 25) was approved by the FDA in November 2004 for 
the treatment of locally advanced or metastatic non-small cell lung cancer after the failure of 
more than one or two previous chemotherapeutics (Smith 2005). In November 2005, erlotinib 
was also approved for the treatment of pancreatic cancer in combination with gemcitabine. 
Erlotinib is a receptor TKI acting on the epidermal growth factor receptor (EGFR) by binding 
reversibly to the ATP-binding site of the receptor (Raymond et al. 2000).  
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The bioavailability of erlotinib is 69-76% with Cmax after 4 hours. It is highly bound to plasma 
proteins (92-95%) and has a volume of distribution of 3 L/kg (Josephs et al. 2013). Erlotinib 
undergoes extensive metabolism by CYP3A4, but also CYP3A5, CYP2D6 and CYP1A1 with 
O-desmethylerlotinib as the main metabolite (Li et al. 2007). Erlotinib is eliminated mainly 
via feces. The most common adverse events associated with erlotinib are skin toxicity and 
diarrhea. The Cmax plasma concentration in patients is 7.6 µM (Haura et al. 2010). 
Elevations in serum aminotransferase levels are common during erlotinib treatment (35-45%) 
and levels above five time ULN occur in up to 10% of the patients (Shah et al. 2013). The 
abnormalities are usually asymptomatic but there have been reports of clinically apparent 
liver injury. However, several fatal cases are reported with erlotinib treatment (Huang et al. 
2009; Liu et al. 2007; Pellegrinotti et al. 2009; Schacher-Kaufmann and Pless 2010). 
Therefore, routine liver monitoring during therapy is recommended. Erlotinib inhibits 
complex V at 10-fold Cmax in isolated rat liver mitochondria (Zhang et al. 2017b).  
 
 
Figure 25: Chemical structure of erlotinib. 
 
 
3.3.4 Imatinib 
 
Imatinib (Gleevec, Novartis, Figure 26) was the first TKI on the market, approved by the 
FDA in 2001. Imatinib is used for the treatment of patients with CML, Ph+ ALL, and certain 
types of gastrointestinal stromal tumors (GIST), systemic mastocytosis, and myelodysplastic 
syndrome. Imatinib binds and stabilizes the inactive form of BCR-ABL1, therefore inhibiting 
autophosphorylation and inducing apoptosis of BCR-ABL1-positive cells (Gambacorti-
Passerini et al. 1997). Imatinib is quite selective for BCR-ABL1 but also inhibits c-kit and 
PDGFR. Some patients develop a resistance to imatinib through point mutations in the kinase 
domain of BCR-ABL1 that impair imatinib binding but do not change the kinase activity 
(Shah and Sawyers 2003), by alteration of the equilibrium of ABL kinase favoring the active 
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state instead of the inactive state where imatinib is binding (Cowan-Jacob et al. 2004) or by 
overexpressing the BCR-ABL1 gene (Hochhaus et al. 2002). 
The bioavailability of imatinib is 98% with a volume of distribution of 2-4 L/kg and 95% 
plasma protein binding (Josephs et al. 2013). Imatinib is mainly metabolized through 
CYP3A4, CYP3A5, and CYP2C8 to the active N-desmethylimatinib and is eliminated via 
feces (68%) and urine (13%). The most common adverse events associated with imatinib are 
myelosuppression, edema, nausea, diarrhea, musculoskeletal symptoms, fatigue, and 
headache. The concentration of imatinib in patients is 3.2 µM (Bolton et al. 2004). 
Imatinib treatment is associated with elevated serum aminotransferase levels but levels above 
five times ULN occurred in just 2-4% of the patients (Shah et al. 2013). However, imatinib 
treatment is linked to rare cases of acute liver injury with jaundice after treatment for 6 days 
to several years. Imatinib is associated with three forms of acute liver injury: transient and 
usually asymptomatic elevations of serum transaminases, clinically apparent acute hepatitis 
and reactivation of an underlying chronic hepatitis B. The liver injury can be fatal (Ridruejo et 
al. 2007). Imatinib-associated liver injury shows immune features and responses to 
prednisone therapy suggest that the liver injury is possibly immunologically mediated. 
Imatinib suppresses state 3 respiration driven by glutamate/malate at 30-fold Cmax, releases 
cytochrome c at 50-fold Cmax and inhibits complex I at 100-fold Cmax in isolated rat liver 
mitochondria (Zhang et al. 2017b).  
 
 
Figure 26: Chemical structure of imatinib. 
 
 
3.3.5 Lapatinib 
 
Lapatinib (Tykerb, GlaxoSmithKline, Figure 27) was approved in March 2007 by the FDA 
for combination therapy with capecitabine (Xeloda) for the treatment of breast cancer (Higa 
and Abraham 2007). In January 2010, lapatinib was also approved for the treatment of 
postmenopausal women with hormone receptor positive metastatic breast cancer that 
overexpresses the human epidermal growth factor receptor 2 (HER2). Lapatinib inhibits the 
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activity of HER2 and EGFR by binding to the ATP-binding pocket of the kinase domain, 
preventing autophosphorylation and activation of signal mechanism (Wood et al. 2004). 
The bioavailability of lapatinib is variable and increased with food intake. The volume of 
distribution of lapatinib is 31 L/kg and more than 99% plasma protein binding (Josephs et al. 
2013). Lapatinib is mainly metabolized through CYP3A4 and to a lesser degree by CYP3A5, 
CYP2C19, and CYP2C8 and is eliminated via feces. Most common adverse events associated 
with lapatinib are diarrhea, fatigue, nausea, and rash (Burris et al. 2005). The Cmax plasma 
concentration in patients is 4.8 µM (Midgley et al. 2007). 
Elevated serum aminotransferase levels are common during lapatinib treatment (37-53%) 
with values greater than five times the ULN being rare (Shah et al. 2013). But lapatinib has 
been linked to several cases of clinically relevant liver injury starting after one to three 
months of lapatinib treatment. Therefore, the FDA labeled lapatinib for hepatotoxicity and 
routine liver monitoring during therapy is recommended. A study suggested an HLA-
associated mechanism because DQA1*02:01 and DRB1*07:01 were found more often in 
patients with elevated transaminases than in patients with normal transaminases suggesting an 
immune-mediated mechanism (Spraggs et al. 2011; Spraggs et al. 2012). Lapatinib releases 
cytochrome c at 10-fold Cmax on isolated rat liver mitochondria (Zhang et al. 2017b). A 
study in rats demonstrated that lapatinib triggers hepatic toxicity mainly as sinusoidal injury 
with transaminase level elevations (Demirci et al. 2012). Involvement of CYP3A4 induction 
in the hepatotoxicity induced by lapatinib via increasing reactive metabolite formation was 
suggested by a study in HepaRG cells (Hardy et al. 2014) and in a study in HepG2 cells 
where the metabolite is inducing oxidative stress, reduced oxygen consumption and decreased 
GSH levels (Eno et al. 2016). 
 
 
Figure 27: Chemical structure of lapatinib. 
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3.3.6 Pazopanib 
 
Pazopanib (Votrient, GlaxoSmithKline, Figure 28) was approved in October 2009 by the 
FDA for the treatment of advanced renal cell carcinoma. In 2012, pazopanib was also 
approved for patients with soft tissue sarcoma who had received chemotherapy. Pazopanib 
binds to the ATP-binding site of VEGRF, PDGFR, and c-kit kinases resulting in pathway 
deactivation essential for cell survival, migration, cell permeability, and proliferation (Keisner 
and Shah 2011). 
The bioavailability of pazopanib is low (14-39%) with Cmax after 2-8 hours. The volume of 
distribution of lapatinib is 0.1-0.2 L/kg and more than 99% plasma protein binding (Josephs 
et al. 2013). Pazopanib is mainly metabolized through CYP3A4 and to a lesser degree by 
CYP1A2 and CYP2C8 and is eliminated via feces. The most common adverse events 
associated with pazopanib are nausea, vomiting, diarrhea, hypertension, and change in hair 
color. The average plasma concentration of pazopanib in patients is 93 µM (Herbrink et al. 
2016). 
Pazopanib was associated with elevated serum aminotransferase levels in up to 53% of treated 
patients and elevated total serum bilirubin in one-third of treated patients in clinical trials 
(Shah et al. 2013). Transaminases higher than five times the ULN occurred in 8% of patients 
and the combination of ALT and bilirubin elevations in 1-2% of patients. However, fatal 
cases of liver injury with pazopanib treatment have been reported (Klempner et al. 2012). 
Therefore, the FDA labeled pazopanib for hepatotoxicity and routine liver monitoring during 
therapy is recommended. Several possible mechanism of pazopanib-hepatotoxicity have been 
hypothesized such as immune mediated toxicity, UGT1A1 inhibition or on-target toxicity on 
VEGFR (Kapadia et al. 2013). Another study found an elevated risk for ALT elevations in 
pazopanib-treated patients with HLA-B*57:01 providing further evidence for the involvement 
of immune-mediated mechanism is pazopanib-associated hepatotoxicity (Xu et al. 2016). In 
addition, Pazopanib affects oxygen consumption and inhibits complex I at Cmax 
concentrations in isolated rat liver mitochondria (Zhang et al. 2017b). Another study with 
patient-specific hepatocyte-like cells showed that pazopanib induces oxidative stress and 
disruption of iron metabolism (Choudhury et al. 2017). 
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Figure 28: Chemical structure of pazopanib. 
 
 
3.3.7 Ponatinib 
 
Ponatinib (Iclusig, ARIAD Pharmaceuticals, Figure 29) was approved by the FDA in 
December 2012 but temporarily suspended from October to December 2013 because blood 
clots were observed in patients. Pazopanib was reintroduced into the market after additional 
warning labels and postmarket investigation was performed (Prasad and Mailankody 2014). 
Ponatinib is used for the treatment of chronic, accelerated or blast phase CML and Ph+ ALL. 
Ponatinib inhibits the BCR-ABL1 fusion protein even with the T315I mutation that is 
responsible for therapy resistance with imatinib, nilotinib, and dasatinib. The T315I mutation 
blocks the access of the drug to the ATP-binding site and confers a high degree of resistance 
to all currently approved TKIs (O'Hare et al. 2007). Ponatinib contains a novel triple-bond 
linkage that avoids the steric hindrance caused by the T315I mutation (Cortes et al. 2012). 
Ponatinib reaches the Cmax after 6 hours and is more than 99% bound to plasma proteins 
(Price et al. 2013). Ponatinib is mainly metabolized through CYP3A4 and minor by CYP2C8, 
CYP2D6, and CYP3A5 and is eliminated via feces. The main adverse events associated with 
ponatinib are hypertension, rash, fatigue, and headache. The mean peak concentration at 
steady state in patients is 1.4 µM (Price et al. 2013). 
In clinical trials, 56% of ponatinib-treated patients showed elevated serum aminotransferase 
levels and 8% showed elevations above five times the ULN, but these were usually reversible 
(Shah et al. 2013). However, fatal cases of liver injury with ponatinib treatment have been 
reported (Price et al. 2013). Therefore, the FDA labeled pazopanib for hepatotoxicity and 
routine liver monitoring during therapy is recommended. Ponatinib does not cause 
mitochondrial toxicity in isolated rat liver mitochondria (Zhang et al. 2017b). 
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Figure 29: Chemical structure of ponatinib. 
 
 
3.3.8 Regorafenib 
 
Regorafenib (Stivarga, Bayer, Figure 30) was approved by the FDA in September 2012 for 
the treatment of metastatic colorectal cancer. The approval was expanded for patients with 
advanced GIST in February 2013 (Waddell and Cunningham 2013). Regorafenib is a multi-
kinase inhibitor with anti-angiogenic activity due to inhibition of VEGFR, PDGFR, FGFR, 
RAF, c-kit, and other TKs. 
Regorafenib reaches the Cmax after 1-6 hours (Mross et al. 2012). Regorafenib is mainly 
metabolized by CYP3A4 and UGT1A9 (Teo et al. 2015). The main adverse effects associated 
with regorafenib are fatigue, loss of appetite, hand-food skin reaction, diarrhea, and high 
blood pressure. The average patient plasma concentration is 6.2 µM (Strumberg et al. 2012). 
Elevations in serum aminotransferase levels are common during regorafenib treatment (45-
65%) and levels above five time the ULN occur in 3-6% of the patients (Shah et al. 2013). 
Regorafenib-treatment is associated with fatal liver injury (Raissouni et al. 2015; Sacre et al. 
2016). For this reason, the FDA labeled pazopanib for hepatotoxicity and routine liver 
monitoring during therapy is recommended. In rat hepatocytes, regorafenib uncouples the 
oxidative phosphorylation, disrupts the mitochondrial membrane potential and induces 
necrosis and autophagy (Weng et al. 2015). In addition, regorafenib affects oxygen 
consumption, reduces the mitochondrial membrane potential, induces mitochondrial swelling 
and cytochrome c release at Cmax concentrations and inhibits complex II at 10-fold Cmax in 
isolated rat liver mitochondria (Zhang et al. 2017b). 
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Figure 30: Chemical structure of regorafenib. 
 
 
3.3.9 Sorafenib 
 
Sorafenib (Nexavar, Bayer and Onyx Pharmaceuticals, Figure 31) was approved in December 
2005 by the FDA for the treatment of renal cell carcinoma. Later, the approval was extended 
for patients with advanced hepatocellular carcinoma and locally recurrent or metastatic, 
progressive differentiated thyroid carcinoma refractory to radioactive iodine treatment (Llovet  
et al. 2008). Sorafenib is a multi-kinase inhibitor acting on Raf-1 and B-Raf serine-threonine 
kinases playing a major role in proliferation and differentiation of the cell and is often 
deregulated in tumors (Strumberg et al. 2007) and on the receptor TKs VEGFR, PDGFR 
(Wilhelm et al. 2008). Inhibition of tumor cell proliferation and of angiogenesis is considered 
to contribute to the antitumor effect of sorafenib (Josephs et al. 2013). 
The bioavailability of sorafenib is less than 50% with Cmax after 2-14 hours. The volume of 
distribution of sorafenib is 3-6 L/kg and more than 99% are bound to plasma proteins 
(Josephs et al. 2013). Sorafenib undergoes oxidative metabolism by CYP3A4 and is 
glucoronidated by UTG1A9 and is eliminated mainly via feces (77%). The most common 
adverse events associated with sorafenib are diarrhea, rash, nausea, vomiting, hand-foot 
syndrome, and fatigue. The concentration of sorafenib in patients is up to 21 µM (Strumberg 
et al. 2007). 
In clinical trials, 21-25% of sorafenib-treated patients showed elevated serum 
aminotransferase levels and 2% showed elevations above five times the ULN but were 
usually reversible (Shah et al. 2013). However, fatal cases of acute liver injury with sorafenib 
treatment have been reported (Fairfax et al. 2012). For sorafenib, it is known that it can 
induce ROS accumulation and GSH depletion in HepG2 cells (Chiou et al. 2009). Sorafenib 
affects oxygen consumption and reduces the mitochondrial membrane potential at Cmax 
concentrations, induces mitochondrial swelling at 2.5-fold Cmax and induces cytochrome c 
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release and inhibits complex V at 5-fold Cmax in isolated rat liver mitochondria (Zhang et al. 
2017b). In another study, sorafenib inhibits complex II, III, and V, activates Parkin and 
apoptosis (Zhang et al. 2017a).  
 
 
Figure 31: Chemical structure of sorafenib. 
 
 
3.3.10 Sunitinib 
 
Sunitinib (Sutent, Pfizer, Figure 32) was approved in January 2006 by the FDA for the 
treatment of renal cell carcinoma and imatinib-resistant gastrointestinal stromal tumor. 
Sunitinib inhibits various receptor tyrosine kinases such as the VEGFR 1-3 (Mendel et al. 
2003), PDGRF α and β (Roskoski 2007), foetal liver tyrosine kinase receptor 3 (FLT3) 
(O'Farrell et al. 2003), stem cell factor receptor (c-kit) (Abrams et al. 2003), and colony 
stimulating factor 1 receptor (CSF1R) (Murray et al. 2003). Accordingly, Sunitinib inhibits 
angiogenesis, tumor growth, and metastasis (Faivre et al. 2006).  
Sunitinib is well absorbed with Cmax of 6-12 hours. The volume of distribution of sorafenib is 
around 30 L/kg and 95% are bound to plasma proteins (Josephs et al. 2013). Sunitinib is 
mainly metabolized by CYP3A4 to the active metabolite N-desethylsunitinib and is mainly 
eliminated via feces. The main adverse events associated with sunitinib are fatigue, diarrhea, 
nausea, hypertension, hand-foot syndrome, and stomatitis. The average plasma concentration 
of patients treated with sunitinib is between 0.1 µM and 0.3 µM (Di Gion et al. 2011). 
Elevated serum aminotransferase levels are common during sunitinib treatment (40-60%) 
with values greater than five times the ULN occurring in 2-3% of the patients, but the 
elevations are normally asymptomatic (Shah et al. 2013). Rare reports of clinically apparent 
liver injury and even fatalities have been reported under sunitinib therapy (Weise et al. 2009). 
In addition, sunitinib has also been reported to cause hyperammonemia and encephalopathy 
(Lee et al. 2011). Sunitinib induces loss in mitochondrial membrane potential and inhibition 
MOLECULAR MECHANISMS OF TYROSINE KINASE                      INTRODUCTION 
INHIBITORS-ASSOCIATED HEPATOTOXICITY 
 53 
of complex II in mouse liver mitochondria (Porceddu et al. 2012). Another study in isolated 
rat liver mitochondria showed no mitochondrial toxicity due to sunitinib (Zhang et al. 2017b). 
 
 
Figure 32: Chemical structure of sunitinib. 
 
 
3.4 TKIs and hepatotoxicity 
 
Present clinical evidence suggests that TKIs are associated with idiosyncratic hepatotoxicity. 
A meta-analysis demonstrated that patients receiving TKIs were four-times more likely to 
experience high-grade hepatic adverse events than patients receiving placebo (Teo et al. 
2013). Several hypotheses about the mechanisms of TKI-induced hepatotoxicity have been 
proposed. A large percentage of drugs that induce idiosyncratic hepatotoxicity are capable of 
forming reactive metabolites (RM) (Leung et al. 2012; Walgren et al. 2005). In general, RMs 
are highly reactive and can therefore interfere with cellular molecules via covalent 
interactions and thus affect critical cell function and promote cell death. Hence, several 
scientist have postulated that hepatotoxicity due to TKIs is responsible for the formation of 
RM (Li et al. 2009; Li et al. 2010; Teng et al. 2010). This RM formation is probably enhanced 
due to changes in drug metabolism, either due to genetic polymorphisms in drug metabolizing 
enzymes or due to drug-drug-interaction (Teo et al. 2015). For lapatinib, it was demonstrated 
that metabolites induced oxidative stress, reduced oxygen consumption, and decreased GSH 
levels (Eno et al. 2016; Hardy et al. 2014). Other hypotheses include immune-mediated 
mechanisms (Spraggs et al. 2011). In addition, mitochondrial mechanisms of TKI-induced 
hepatotoxicity have been postulated mainly for dasatinb (Xue et al. 2012), pazopanib 
(Choudhury et al. 2017; Zhang et al. 2017b), regorafenib (Weng et al. 2015; Zhang et al. 
2017b), sorafenib (Chiou et al. 2009; Zhang et al. 2017a; Zhang et al. 2017b), and sunitinib 
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(Porceddu et al. 2012). Mitochondrial toxicity was mostly due to oxidative stress, inhibition 
of oxidative phosphorylation, and reduction of the mitochondrial membrane potential.  
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4 GOAL OF THE THESIS 
 
The goal of this thesis was to contribute to an increased and comprehensive understanding of 
the mechanisms of TKI-induced hepatotoxicity. The project focused on mitochondrial toxicity 
in human hepatocyte cell lines and isolated mitochondria in vitro and on sunitinib-induced 
hepatotoxicity in mice in vivo. We aimed to find out susceptibility factors for the idiosyncratic 
hepatotoxicity of TKIs. 
 
The purpose of the first study was to investigate the mechanisms of hepatotoxicity for 
erlotinib, imatinib, lapatinib, and sunitinib in vitro in more detail. We wanted to consider the 
question whether mitochondrial toxicity contributed to the hepatotoxicity seen in patients 
treated with these TKIs. Therefore we focused on energy metabolism, oxidative stress, and 
mechanism of cell death in HepG2 cells, HepaRG cells, and mouse liver mitochondria. 
 
In a second study, we investigated six more TKIs that are associated with hepatotoxicity in 
patients – crizotinib, dasatinib, pazopanib, ponatinib, regorafenib, and sorafenib. We wanted 
to answer the question if the mechanisms of hepatotoxicity of these TKIs are similar to the 
mechanisms of the previous four TKIs or not. Therefore, we used similar conditions and end 
points as in the first study.  
 
In the third project, we focused on the three most hepatotoxic TKIs of the second study – 
ponatinib, regorafenib, and sorafenib. We wanted to investigate the question what is the exact 
mechanism behind the demonstrated mitochondrial toxicity with decreased mitochondrial 
membrane potential, inhibited mitochondrial oxidative metabolism, and induction of 
apoptosis and/or necrosis. Therefore, we focused on single complexes of the mitochondrial 
electron transport chain and on events in fission, fusion, mitophagy, and apoptosis.  
 
The goal of the last study was to investigate the sunitinib-induced hepatotoxicity in vivo 
because so far the effects of sunitinib on liver mitochondria has been investigated in isolated 
rat liver mitochondria ex vivo and not in vivo. We wanted to consider the question whether the 
mechanisms of sunitinib-induced hepatotoxicity in vitro and in vivo are the same or whether 
there are specific effects in different species. Therefore, we investigated liver morphology and 
function as well as the function of the respiratory chain and mechanism of death in liver 
mitochondria in mice. 
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1 PAPER 1 
 
 
HEPATOCELLULAR TOXICITY ASSOCIATED WITH TYROSINE 
KINASE INHIBITORS: MITOCHONDRIAL DAMAGE AND 
INHIBITION OF GLYCOLYSIS 
 
 
Within this article, we will investigate the mechanisms of hepatotoxicity for erlotinib, 
imatinib, lapatinib and sunitinib in vitro. 
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Tyrosine kinase inhibitors (TKIs) are anticancer drugs with a lesser toxicity than
classical chemotherapeutic agents but still with a narrow therapeutic window. While
hepatotoxicity is known for most TKIs, underlying mechanisms remain mostly unclear.
We therefore aimed at investigating mechanisms of hepatotoxicity for imatinib, sunitinib,
lapatinib and erlotinib in vitro. We treated HepG2 cells, HepaRG cells and mouse liver
mitochondria with TKIs (concentrations 1–100 µM) for different periods of time and
assessed toxicity. In HepG2 cells maintained with glucose (favoring glycolysis), all TKIs
showed a time- and concentration-dependent cytotoxicity and, except erlotinib, a drop
in intracellular ATP. In the presence of galactose (favoring mitochondrial metabolism),
imatinib, sunitinib and erlotinib showed a similar toxicity profile as for glucose whereas
lapatinib was less toxic. For imatinib, lapatinib and sunitinib, cytotoxicity increased in
HepaRG cells induced with rifampicin, suggesting formation of toxic metabolites. In
contrast, erlotinib was more toxic in HepaRG cells under basal than CYP-induced
conditions. Imatinib, sunitinib and lapatinib reduced the mitochondrial membrane
potential in HepG2 cells and in mouse liver mitochondria. In HepG2 cells, these
compounds increased reactive oxygen species production, impaired glycolysis, and
induced apoptosis. In addition, imatinib and sunitinib impaired oxygen consumption
and activities of complex I and III (only imatinib), and reduced the cellular GSH pool.
In conclusion, imatinib and sunitinib are mitochondrial toxicants after acute and long-
term exposure and inhibit glycolysis. Lapatinib affected mitochondria only weakly and
inhibited glycolysis, whereas the cytotoxicity of erlotinib could not be explained by a
mitochondrial mechanism.
Keywords: tyrosine kinase inhibitor, hepatotoxicity, mitochondrial toxicity, glycolysis, ROS, apoptosis
Abbreviations: 1%m, mitochondrial membrane potential; AK, adenylate kinase; BSO, buthionine sulfoximine; CCCP,
carbonyl cyanide-chlorophenyl hydrazone; DMSO, dimethyl sulfoxide; DPBS, Dulbecco’s phosphate bu ered saline; FCCP,
carbonyl cyanide-4-(trifluoromethoxy)phenylhydrazone; GSH, glutathione (reduced form); OCR, oxygen consumption rate;
PBS, phosphate bu ered saline; ROS, reactive oxygen species; SOD1, superoxide dismutase 1; SOD2, superoxide dismutase
2; TK, tyrosine kinase; TKI, tyrosine kinase inhibitor; TMRM, tetramethylrhodamine methyl ester.
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INTRODUCTION
Tyrosine kinases (TK) are important enzymes that phosphorylate
target proteins, leading to activation of signal transduction
pathways. TK play a critical role in a variety of biological
processes, including cell proliferation and cell death (Josephs
et al., 2013). Mutations or structural alterations of TK can lead to
uncontrolled activation of TK, possibly favoring the development
of cancer (Krause and Van Etten, 2005). The critical role of TK in
the regulation of cell proliferation has led to the development of
a new generation of anticancer agents, the TKIs. Imatinib was the
first TKI entering the market and was approved initially for the
treatment of patients with chronic myeloid leukemia (Mealing
et al., 2013). Many other TKIs have since then been approved
inhibiting di erent kinases and for di erent indications, and
many more are under development.
Compared to classical chemotherapeutic agents, TKIs are
generally less toxic. Nevertheless, they still have a narrow
therapeutic window, with adverse e ects mainly a ecting the
skin, gastrointestinal tract, pancreas, lungs, the cardiovascular
system including the heart, skeletal muscle and the liver
(Breccia and Alimena, 2013; Bauer et al., 2016). Grade 3 to
4 toxicity, which is potentially dose- or treatment-limiting,
has been described for most of the above-mentioned organs,
and, with di erent frequencies, for all TKIs currently used
(Caldemeyer et al., 2016). Hepatotoxicity has been reported for
several TKIs, including crizotinib, erlotinib, gefitinib, imatinib,
lapatinib, nilotinib, pazopanib, ponatinib, regorafenib, sunitinib,
and vemurafenib (Josephs et al., 2013; Shah et al., 2013; Spraggs
et al., 2013). The frequency of liver injury varies from 11%
for gefitinib (Liu and Kurzrock, 2014) to more than 50% of
patients treated with pazopanib (Shah et al., 2013). Severe liver
injury has been reported to a ect approximately 5% of the
patients (Iacovelli et al., 2014) and liver failure 0.8% of patients
treated with sunitinib, sorafenib, pazopanib, axitinib, vandetanib,
cabozantinib, ponatinib, or regorafenib (Ghatalia et al., 2014).
Fatalities are rare, but were reported for crizotinib (Sato et al.,
2014), erlotinib (Huang et al., 2009), imatinib (Ridruejo et al.,
2007), lapatinib, pazopanib (Klempner et al., 2012), ponatinib
(Price et al., 2013), regorafenib, and sunitinib (Gore et al., 2009).
Liver injury was hepatocellular in most cases, but also cholestasis
has been reported (Shah et al., 2013). In most cases, liver
injury develops 2–8 weeks after initiating therapy and features of
hypersensitivity are usually absent (Teng et al., 2010; Shah et al.,
2013).
Studies regarding the mechanism for hepatotoxicity of TKIs
are rare. Since the spectrum of the kinases inhibited varies
between the di erent compounds, a class e ect is unlikely.
For lapatinib, a study suggested a HLA-associated mechanism
(Spraggs et al., 2012). The DQA1⇤02:01 allele was found in 71%
of patients with elevated but only in 21% of patients with normal
transaminases (Spraggs et al., 2011), suggesting an immune-
mediated mechanism. For CP-724,714, a TKI whose clinical
development was stopped because of hepatotoxicity, proposed
mechanisms were mitochondrial toxicity and inhibition of
canalicular and basolateral transport proteins (Feng et al.,
2009). Recent publications suggested mitochondrial toxicity for
dasatinib (Xue et al., 2012) and regorafenib (Weng et al.,
2015). Another theory for TKI induced hepatotoxicity is the
formation of reactive metabolites that can interfere with critical
cell functions (Teo et al., 2015), since most TKIs undergo intense
hepatic metabolism by CYP3A4 (Josephs et al., 2013).
Since the exact mechanisms underlying hepatotoxicity of TKIs
are currently unclear, we decided to investigate the e ects of
di erent TKIs in human hepatocyte cell lines and in isolated
mouse liver mitochondria in more detail. We focused on
energy metabolism, since ATP is essential for cell survival and
mitochondrial toxicity is one of the main mechanisms of non-
immunologic drug-associated liver injury (Lee, 2003).
MATERIALS AND METHODS
Chemicals
Erlotinib mesylate, imatinib mesylate, lapatinib, and sunitinib
were purchased from Sequoia research products (Pangbourne,
United Kingdom). We prepared stock solutions in DMSO and
stored them at  20 C. All other chemicals were supplied by
Sigma–Aldrich (Buchs, Switzerland), except where indicated.
Cell Culture
The human hepatocellular carcinoma cell line HepG2 was
provided by American type culture collection (ATCC, Manassas,
VA, United States). HepG2 cells were cultured under two
di erent conditions – low glucose and galactose.
HepG2 cells under low glucose conditions were cultured in
Dulbecco’s Modified Eagle Medium (DMEM containing 1 g/l
[5.55 mM] glucose, 4 mM L-glutamine, and 1 mM pyruvate from
Invitrogen, Basel, Switzerland) supplemented with 10% (v/v)
heat-inactivated fetal bovine serum, 2 mM GlutaMax, 10 mM
HEPES bu er, 10 mM non-essential amino acids, 100 units/ml
penicillin, and 100 µg/ml streptomycin.
HepG2 cells under galactose conditions were cultured in
Dulbecco’s Modified Eagle Medium (DMEM, containing no
glucose but 4 mM L-glutamine) from Invitrogen (Basel,
Switzerland) supplemented with 10% (v/v) heat-inactivated
fetal bovine serum, 10 mM galactose, 10 mM HEPES bu er,
1 mM sodium pyruvate, 100 units/ml penicillin, and 100 µg/ml
streptomycin.
The HepaRG cell line was provided by Biopredic International
(Saint-Gregoire, France). Cells were cultured and di erentiated
as described earlier (Gripon et al., 2002). Induction of CYP3A4
was achieved by preincubation of di erentiated HepaRG cells
with 20 µM rifampicin for 72 h, with medium change every 24 h.
All cells were kept at 37 C in a humidified 5% CO2 cell
culture incubator and passaged using trypsin. The cell number
was determined using a Neubauer hemacytometer and viability
was checked using the trypan blue exclusion method.
Isolation of Mouse Liver Mitochondria
The experiments were performed in accordance with the
institutional guidelines for the care and use of laboratory animals.
Male C57BL/6 mice (n = 12, age 7–10 weeks) were purchased
from Charles River Laboratories (Sulzfeld, Germany) and housed
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in a standard facility with 12 h light–dark cycles and controlled
temperature (21–22 C). Themice were fed a standard pellet chow
and water ad libitum. The mice did not receive any treatment and
were sacrificed by cervical dislocation.
Liver mitochondria were isolated by di erential centrifugation
as described before (Hoppel et al., 1979). The mitochondrial
protein content was determined using the Pierce BCA protein
assay kit fromMerck (Zug, Switzerland).
Cytotoxicity and Cellular ATP Content
Cytotoxicity, a marker for plasma membrane integrity, was
assessed by using the ToxiLight assay from Lonza (Basel,
Switzerland) as described previously (Felser et al., 2013). The
intracellular ATP content, a marker for metabolic cell activity
and cell viability, was determined using a CellTiter Glo kit from
Promega (Wallisellen, Switzerland) as described before (Felser
et al., 2013).
Incubations with culture medium containing 0.1% DMSO
were used as negative and incubations containing 0.5% Triton X
as positive controls.
Glycolysis
The glycolytic flux was determined via the conversion of [3H]-
glucose to 3H2O as described before (Vander Heiden et al., 2001).
HepG2 cells were seeded in 6-well plates (500,000 cells/well)
and treated with drugs for 48 h. The positive control was
20 mM 2-deoxy-D-glucose. After treatment, HepG2 cells were
resuspended in 1 ml Krebs bu er (115 mM sodium chloride,
2 mM potassium chloride, 25 mM sodium bicarbonate, 1 mM
magnesium chloride, 2 mM calcium chloride, 0.25% FBS, pH 7.4)
and incubated for 30min at 37 C. After centrifugation, cell pellets
were resuspended in 0.5 ml Krebs bu er containing 10 mM
glucose and 0.5 µl D-3H(U) glucose (60 Ci/mmol, 0.5 µCi/assay,
Perkin Elmer, Schwerzenbach, Switzerland) and incubated for 1 h
at 37 C. After centrifugation, 50 µl supernatant were transferred
to tubes containing 50 µl 0.2 N HCl. Tubes were transferred
to scintillation vials containing 0.5 ml water and sealed. 3H2O
was allowed to evaporate from the tube and to condense in the
0.5 ml water for 1 week. Afterward, the tube was removed and
the radioactivity of the water was measured using a Packard 1900
TR liquid scintillation analyzer. The data were normalized to the
protein content.
Mitochondrial Membrane Potential in
Isolated Mouse Liver Mitochondria
The 1%m in freshly isolated mouse-liver mitochondria was
determined using the [phenyl-3H]-tetra-phenylphosphonium
bromide uptake assay as described previously (Felser et al., 2013).
Mitochondria were treated with test compounds for 15 min
at 37 C. The radioactivity of the samples was measured on a
Packard 1900 TR liquid scintillation analyzer.
Mitochondrial Membrane Potential in
HepG2 Cells
Mitochondrial membrane potential in HepG2 cells was
determined using TMRM (Invitrogen, Basel, Switzerland).
In brief, HepG2 cells were seeded in 24-well plates
(200,000 cells/well) and treated with drugs for 48 h. Cells
were washed with DPBS and suspended in PBS with 100 nM
TMRM. After 15 min incubation in the dark, cells were
centrifuged and resuspended in PBS for analyzing them with
flow cytometry using a FACSCalibur (BD Bioscience, Allschwil,
Switzerland). Data were analyzed using CellQuest Pro 6.0
software (BD Bioscience, Allschwil, Switzerland).
Cellular Oxygen Consumption
Cellular respiration in intact cells was measured with a Seahorse
XF24 analyzer (Seahorse Biosciences, North Billerica, MA,
United States) as described before (Felser et al., 2013). Cellular
respiration in intact cells was measured with a Seahorse XF24
analyzer (Seahorse Biosciences, North Billerica, MA, United
States). HepG2 cells were seeded in Seahorse XF 24-well culture
plates at 100,000 cells/well in DMEM growth medium and
allow to adhere overnight. Cells were treated for 48 h with
drugs. Before assessing the cellular respiration, the medium was
replaced with 750 µl unbu ered DMEM medium (4 mM L-
glutamate, 1 mM pyruvate, 1 g/l glucose, 63.3 mM sodium
chloride, pH 7.4) and equilibrated at 37 C in a CO2-free
incubator for at least 30 min. Afterward, plates were transferred
to the XF24 analyzer. Basal OCR was determined in the
presence of glutamate/pyruvate (4 and 1 mM, respectively).
The oxidative leak (a marker for uncoupling) was determined
after inhibition of the mitochondrial phosphorylation by adding
1 µM oligomycin. The mitochondrial electron transport chain
was stimulated maximally by the addition of 2 µM FCCP.
Finally, the extramitochondrial respiration was determined
after the addition of complex I inhibitor rotenone (1 µM).
For the determination of the basal respiration, the oxidative
leak, and the maximum respiration, the extramitochondrial
respiration was subtracted. Respiration was expressed as OCR per
minute.
Activity of Specific Enzyme Complexes
of the Mitochondrial Electron Transport
Chain
The activity of specific enzyme complexes of the respiratory
chain was analyzed using an Oxygraph-2k high-resolution
respirometer equipped with DataLab software (Oroboros
instruments, Innsbruck, Austria). HepG2 cells were treated
for 48 h with drugs. Afterward, they were suspended
in MiR05 (mitochondrial respiration medium containing
0.5 mM EGTA, 3 mM magnesium chloride, 20 mM taurine,
10 mM potassium dihydrogen phosphate, 20 mM HEPES,
110 mM sucrose, 1 g/l fatty-acid free bovine serum albumin,
and 60 mM lactobionic acid, pH 7.1) and transferred to
the pre-calibrated Oxygraph chamber (Pesta and Gnaiger,
2012).
Respiratory capacities through complexes I, II, III, and IV
were assessed in HepG2 cells permeabilized with digitonin
(10 µg/1 million cells). Complexes I and III were analyzed
using L-glutamate/malate (10 and 2 mM, respectively) as
substrates followed by the addition of adenosine-diphosphate
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(ADP; 2.5 mM) and rotenone (0.5 µM) as inhibitor of complex
I. Afterward, duroquinol (500 µM) was added to investigate
complex III activity.
Complexes II and IV were analyzed using succinate/rotenone
(10 mM and 0.5 µM, respectively) as substrates followed
by the addition of ADP (2.5 mM) and the complex III
inhibitor antimycin A (2.5 µM). N,N,N0,N0-tetramethyl-1,4-
phenylendiamine/ascorbate (0.5 and 2 mM, respectively) were
added to investigate complex IV.
The integrity of the outer mitochondrial membrane was
confirmed by the absence of a stimulatory e ect of exogenous
cytochrome c (10 µM) on respiration. Respiration was expressed
as oxygen consumption per mg protein. Protein concentrations
were determined using the Pierce BCA protein assay kit from
Merck (Zug, Switzerland).
Freshly isolated mouse liver mitochondria were suspended
in MiR06 (mitochondrial respiration medium containing
0.5 mM EGTA, 3 mM magnesium chloride, 20 mM taurine,
10 mM potassium dihydrogen phosphate, 20 mM HEPES,
110 mM sucrose, 1 g/l fatty-acid free bovine serum albumin,
60 mM lactobionic acid, and 280 units/ml catalase, pH
7.1) and 250 µg mitochondria were transferred to the
pre-calibrated Oxygraph chamber and treated for 15 min
with drugs. Respiratory capacities through complexes I,
II, III, and IV were assessed with the same protocol as
for HepG2 cells, except the permeabilization step in the
beginning.
Mitochondrial b-Oxidation
Metabolism of [1-14C] palmitic acid (60 mCi/mmol,
PerkinElmer, Schwerzenbach, Switzerland) was assessed
via the formation of 14C-acid-soluble b-oxidation products
(Felser et al., 2013). HepG2 cells were seeded in 6-well plates
(500,000 cells/well) and treated with drugs for 48 h. The positive
control was 5 µM etomoxir. After treatment, HepG2 cells
were permeabilized with digitonin (10 µg/1 million cells) in
225 µl assay bu er (70 mM sucrose, 43 mM potassium chloride,
3.6 mM magnesium chloride, 7.2 mM potassium dihydrogen
phosphate, 36 mM TRIS, 0.2 mM ATP, 50 µM L-carnitine,
15 µM coenzyme A, 5 mM acetoacetate, pH 7.4) and incubated
for 10 min at 37 C. Afterward, 25 µl [1-14C] palmitic acid
(200 µM final concentration, 10 µCi/assay) was added to each
sample and incubated at 37 C. The reaction was stopped after
15 min by adding 250 µl 6% perchloric acid. The samples were
precipitated for 5 min on ice before centrifugation. Radioactivity
was measured in the supernatant using a Packard 1900 TR liquid
scintillation analyzer.
Cellular Accumulation of Reactive
Oxygen Species
Generation of ROS was assessed using the ROS-Glo H2O2 Assay
(Promega, Wallisellen, Switzerland). Briefly, cells were grown in
96-well plates and exposed to a range of TKIs for 48 h. The
assay was performed according to manufacturer’s manual and
the luminescence was measured using a Tecan M200 Pro Infinity
plate reader (Männedorf, Switzerland).
Mitochondrial Accumulation of
Superoxide
Generation of mitochondrial ROS was assessed using MitoSOX
Red (Invitrogen, Basel, Switzerland). HepG2 cells were seeded
into black costar 96-well plates and exposed to a range of TKIs.
The positive control was 100 µM amiodarone. After 48 h, cell
culture medium was removed and 2.5 µM MitoSOX dissolved
in 100 µl DPBS was added. After incubation for 10 min at
37 C in the dark, fluorescence was measured (excitation 510 nm,
emission 580 nm) using a Tecan M200 Pro Infinity plate reader
(Männedorf, Switzerland).
Glutathione (GSH) Content
The reduced form of glutathione (GSH) content was determined
using the luminescent GSH-Glo Glutathione assay (Promega,
Wallisellen, Switzerland). In brief, cells were grown in 96-well
plates and exposed to a range of TKIs for 48 h. The positive
control was 100 µM BSO. The assay was performed according to
manufacturer’s manual and the luminescence was measured after
15 min in the dark using a Tecan M200 Pro Infinity plate reader
(Männedorf, Switzerland).
mRNA Expression
HepG2 cells were treated with TKIs for 48 h. The mRNA
expression of SOD1 and SOD2 were assessed as described
previously (Felser et al., 2013). Briefly, the mRNA expression
was assessed using real-time PCR. RNA was extracted and
purified using the Qiagen RNeasy mini extraction kit (Qiagen,
Hombrechtikon, Switzerland). The quantity and purity of
RNA were measured with NanoDrop 2000 (Thermo Scientific,
Wohlen, Switzerland). cDNA was synthesized from 10 µg
RNA using the Qiagen omniscript system. The real-time
PCR was performed using SYBR Green (Roche Diagnostics,
Rotkreuz, Switzerland). We used primers for SOD1 (forward: 50-
TGGCCGATGTGTCTATTGAA-30, reverse: 50-ACCTTTGCC
CAAGTCATCTG-30) and SOD2 (forward: 50-GGTTGTTC
ACGTAGGCCG-30, reverse:50-CAGCAGGCAGCTGGCT-30)
and calculated relative quantities of specifically amplified cDNA
with the comparative-threshold cycle method. GAPDH was used
as endogenous reference (forward: 50-CATGGCCTTCCGTG
TTCCTA-30; reverse: 50-CCT- GCTTCACCACCTTCTTGA-30).
Quantification of Cytochrome c in
Cytoplasm and Mitochondria
For the quantification of cytochrome c, cytoplasm and
mitochondria were separated using a Mitochondrial/Cytosol
Fractionation Kit (ab65320, Abcam, Cambridge, United
Kingdom). Afterward, the cytochrome c content in the
mitochondrial and cytosolic fraction was quantified by western
blotting using Anti-cytochrome C antibody (ab133504, Abcam,
Cambridge, United Kingdom). The purity of the fractions
was checked by the determination of TOMM20 (a protein of
the outer mitochondrial membrane) and a-tubulin (a major
constituent of microtubules in the cytoplasm) by western blotting
(Supplementary Figure S1). The antibodies used for western
blotting were ab78547 (Abcam, Cambridge, United Kingdom) for
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TOMM20 and ab76290 (Abcam, Cambridge, United Kingdom)
for alpha-tubulin. Western blots were performed as described in
the following section.
Western Blotting
After treatment for 48 h, HepG2 cells were lysed with RIPA bu er
containing complete Mini protease inhibitor cocktail (Roche
Diagnostics, Mannheim, Germany). After centrifugation, the
supernatant was collected and stored at  80 C. Proteins were
resolved by SDS–PAGE using commercially available 4–12%
NuPAGE Bis-Tris gels (Invitrogen, Basel, Switzerland) and
transferred using the Trans-Blot Turbo Blotting System (Bio-
Rad, Cressier, Switzerland). The membranes were incubated with
PARP (46D11) rabbit mAb (Cell Signaling Technology, Danvers,
MA, United States), Anti-active Caspase-3 antibody (ab32042,
Abcam, Cambridge, United Kingdom), Anti-pro Caspase 3
antibody (ab32150, Abcam, Cambridge, United Kingdom),
Anti-SOD1 (ab20926, Abcam, Cambridge, United Kingdom) or
Anti-SOD2 (ab16956, Abcam, Cambridge, United Kingdom)
antibodies. After washing, membranes were exposed to
secondary antibodies (Santa Cruz Biotechnology, Dallas, TX,
United States). Immunoblots were developed using enhanced
chemiluminescence (GE Healthcare, Little Chalfont, United
Kingdom). Band intensities of the scanned images were
quantified using the National Institutes of Health Image J
program, version 1.48.
Caspase 3/7 Activity
Caspase 3/7 activity was determined using the luminescent
Caspase-Glo 3/7 assay (Promega, Wallisellen, Switzerland). Cells
were grown in 96-well plates and exposed to a range of TKIs for
48 h. The luminescence was measured using a Tecan M200 Pro
Infinity plate reader (Männedorf, Switzerland).
Statistical Analysis
Data are given as the mean ± SEM of at least three independent
experiments. Statistical analyses including calculation of EC50
values were performed using the GraphPad Prism 6 (GraphPad
Software, La Jolla, CA, United States). For the comparison of
more than two groups, one-way ANOVA was used, followed by
Dunnett’s post-test procedure. Di erences between experiments
with multiple conditions were compared using two-way ANOVA
followed by Bonferroni’s post hoc test. ⇤P-values < 0.05, ⇤⇤P-
values< 0.01, or ⇤⇤⇤P-values< 0.001 were considered significant.
RESULTS
Cytotoxicity and ATP Content in HepG2
Cells
Release of AK was determined as a marker of cytotoxicity, and
the cellular ATP content as a measure for mitochondrial function
and cellular integrity. As shown in Figures 1A–C, erlotinib
(investigated up to 20 µM) and imatinib were only slightly toxic
in HepG2 cells at the highest concentrations and after 24 to 48 h
of incubation. While erlotinib did not a ect the cellular ATP
content (Figures 1D–F), imatinib decreased the ATP content
in a time- and concentration-dependent fashion (starting at
5 µM after 24 h of incubation). In comparison, lapatinib was
cytotoxic starting at 10–20 µM depending on the incubation
time (Figures 1A–C). Lapatinib also decreased the cellular
ATP content, starting at similar concentrations as cytotoxicity
(Figures 1D–F). Sunitinib was cytotoxic starting at 5–10µMafter
24–48 h of incubation (Figures 1A–C) and decreased the cellular
ATP content starting at 5 µM after 24 or 48 h of incubation
(Figures 1D–F). The corresponding EC50 values are shown in
Table 1. For imatinib, sunitinib and erlotinib, similar results
were obtained in cells cultured with galactose instead of glucose
(Supplementary Figure S2), whereas as lapatinib was less toxic
under these conditions.
Cytotoxicity and ATP Content in HepaRG
Cells
Cytotoxicity and ATP content were also investigated in
HepaRG cells (Figures 2A–H). HepaRG cells contain inducible
cytochrome P450 enzymes (CYPs) (Berger et al., 2016), allowing
to test the possible contribution of metabolites for toxicity. After
48 h of treatment, erlotinib started to be cytotoxic at 5 µM
and to decrease the intracellular ATP at 10 µM (Figures 2A,E).
CYP induction was associated with less toxicity, suggesting
that the parent compound is more toxic than the metabolites.
For imatinib, cytotoxicity and reduction of intracellular ATP
started at 50 µM (Figures 2B,F). Since cytotoxicity was
significantly more accentuated after CYP induction, metabolites
may have played a role. Lapatinib started to be cytotoxic at
20 µM, but caused no significant decrease of intracellular ATP
(Figures 2C,G). At the highest concentration studied (50 µM),
cytotoxicity was increased by CYP induction. Sunitinib started
to be toxic at 10 µM and to decrease the ATP content starting
at 50 µM (Figures 2D,H). Similar to imatinib and lapatinib,
cytotoxicity was increased by CYP induction at the highest
concentration studied (50 µM). The corresponding EC50 values
are shown in Table 1.
CYP induction slightly increased cytotoxicity at high
concentrations of imatinib, lapatinib and sunitinib. Since the
parent compounds were also toxic themselves, we decided to
continue our investigations with the parent compounds using
HepG2 cells and isolated liver mitochondria.
Glycolysis and Mitochondrial Membrane
Potential in HepG2 Cells and Isolated
Mouse Liver Mitochondria
To investigate possible reasons for the observed decrease in
the cellular ATP content, we determined the e ect of the TKIs
investigated on glycolysis and on the1%m in HepG2 cells and in
mouse liver mitochondria.
We determined the glycolytic flux by quantifying the
conversion of [3H]glucose to 3H2O. As shown in Figure 3A,
imatinib, lapatinib, and sunitinib reduced the glycolytic flux in
HepG2 cells starting at 50, 20, and 20 µM, respectively. Erlotinib
did not impair glycolysis. The corresponding EC50 values are
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FIGURE 1 | Cytotoxicity and effect on the intracellular ATP content in HepG2 cells. Cytotoxicity was assessed by the release of AK. (A–C): Cytotoxicity after drug
exposure for 6, 24, and 48 h, respectively. (D–F): Cellular ATP content after drug exposure for 6, 24, and 48 h, respectively. Data are expressed as % AK release in
the presence of 0.5% Triton X (set at 100%) or as % ATP content in the presence of 0.1% DMSO (set at 100%). Data represent the mean ± SEM of at least three
independent experiments. ⇤p < 0.05, ⇤⇤p < 0.01 or ⇤⇤⇤p < 0.001 versus DMSO control.
given in Table 1. The positive control 2-deoxy-D-glucose reduced
glycolysis by 75%.
Next, we quantified the e ect on 1%m in HepG2 cells
treated for 48 h with the TKIs (Figure 3B). Imatinib, lapatinib
and sunitinib dissipated 1%m starting at 50, 20, and 1 µM,
respectively. In contrast, erlotinib did not decrease 1%m up to
20 µM. The uncoupler CCCP (50 µM) reduced 1%m by 62%
(data not shown).
As shown in Figure 3C, imatinib and sunitinib reduced
1%m of isolated mouse liver mitochondria after exposure for
15 min starting at 50 and 10 µM, respectively, while erlotinib
and lapatinib had no significant e ect. Non-radioactive tetra-
phenylphosphonium (positive control) apparently reduced1%m
by 38% (data not shown). The corresponding EC50 values are
given in Table 1.
Effect on Oxidative Metabolism
The observed decrease in intracellular ATP and mitochondrial
membrane potential could be caused by impairment of the
function and/or uncoupling of the respiratory chain (Kaufmann
et al., 2005). We therefore assessed the e ect of TKIs on oxygen
consumption by HepG2 cells using a XF24 analyzer. Cellular
oxygen consumption mainly reflects mitochondrial metabolism
(Felser et al., 2013). As shown in Figures 4A–C, exposure with
erlotinib, imatinib, and lapatinib between 1 and 20 µM for 48 h
did not significantly change the cellular oxygen consumption by
HepG2 cells. Sunitinib decreased the maximal respiration rate
(after addition of FCCP) in a concentration-dependent fashion,
reaching 28% at 10 µM. Sunitinib (1–10 µM) did not increase
the leak respiration after addition of oligomycin, excluding an
uncoupling e ect (Figure 4D).
In order to find out the mechanism of decreased
maximal respiration, the respiratory capacities through the
complexes of the electron transport chain were analyzed
using a high-resolution respirometry system. Irrespective
of the culture medium (low glucose or galactose), sunitinib
impaired the activity of complex I in HepG2 cells exposed
for 48 h in a concentration-dependent fashion, reaching
significance at 10 µM for galactose (Figure 5A and
Supplementary Figure S3). Imatinib inhibited complex III
TABLE 1 | Effect of tyrosine kinase inhibitors on different markers of toxicity.
HepG2 (AK release) HepG2 (ATP content) HepaRG (AK release) HepaRG (ATP content) Glycolysis (HepG2 cells) MMP (HepG2 cells)
6 h 24 h 48 h 6 h 24 h 48 h Induced Non-induced Induced Non-induced
Erlotinib >20 >20 >20 >20 >20 >20 >20 >20 >20 >20 >20 >20
Imatinib >100 >100 >100 >100 44.0 39.4 >100 >100 62.8 58.7 61.4 59.8
Lapatinib >50 46.7 33.2 >50 34.4 24.1 >50 >50 >50 >50 >50 27.5
Sunitinib >50 43.6 14.0 39.4 23.5 20.1 45.3 48.0 37.3 37.5 34.4 16.3
EC50 values were calculated using GraphPad Prism 6 as described in Methods based on the data provided in the corresponding figures. Incubation times in HepG2
cells for AK release and ATP content were as indicated and 48 h for HepaRG cells, glycolysis and the MMP. Units are µM. AK, Adenylate kinase; MMP, mitochondrial
membrane potential.
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FIGURE 2 | Effect of pretreatment with rifampicin on cytotoxicity and intracellular ATP content in HepaRG cells. HepaRG cells were pretreated for 72 h with
rifampicin and then exposed to drugs for 48 h. Cytotoxicity was assessed by the release of AK. (A–D) Cytotoxicity of erlotinib, imatinib, lapatinib, and sunitinib,
respectively. (E–H) Intracellular ATP content of erlotinib, imatinib, lapatinib, and sunitinib, respectively. Data are expressed as % AK release in the presence of 0.5%
Triton X (set at 100%) or as % ATP content in the presence of 0.1% DMSO (set at 100%). Data represent the mean ± SEM of at least three independent
experiments. ⇤p < 0.05, ⇤⇤p < 0.01 or ⇤⇤⇤p < 0.001 versus DMSO control. †p < 0.05, ††p < 0.01 or †††p < 0.001 rifampicin versus respective DMSO pretreatment.
FIGURE 3 | Effect on glycolysis and on the 1%m. (A) Glycolysis was determined using D-3H(U) glucose as a substrate as described in Methods. The rate of
glycolysis for the control incubations was 37.5 ± 2.6 nmoles/h/mg protein (mean ± SEM, n = 35 control incubations). (B) The 1%m was assessed in HepG2 cells by
TMRM fluorescent staining after drug exposure for 48 h. (C) Isolated mouse liver mitochondria were labeled with [3H]-tetraphenylphosphonium bromide and
mitochondrial accumulation of radioactivity was determined. All data are expressed as percentage of control incubations containing 0.1% DMSO. Data represent the
mean ± SEM of at least three independent experiments. ⇤p < 0.05, ⇤⇤p < 0.01 or ⇤⇤⇤p < 0.001 versus DMSO control.
in a concentration-dependent fashion, reaching significance
at 50 µM (low glucose, Supplementary Figure S3) or 10 µM
(galactose, Figure 5B).
In isolated mouse liver mitochondria exposed for 15 min,
sunitinib and imatinib were less toxic. Under these conditions,
100 µM sunitinib and 100 and 200 µM imatinib significantly
decreased the respiratory capacity through complex I
(Figure 5C).
Effect on Mitochondrial b-Oxidation
As shown in Supplementary Figure S4, erlotinib and lapatinib
did not a ect palmitate metabolism in HepG2 cells up to
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FIGURE 4 | Function of the respiratory chain in HepG2 cells. Oxygen consumption rate after exposure to (A) erlotinib, (B) imatinib, (C) lapatinib or (D) sunitinib for
48 h. Data represent the mean ± SEM of at least three independent experiments.
20 and 50 µM, respectively. Sunitinib and imatinib decreased
palmitate oxidation starting at 50 and 100 µM, respectively.
Since b-oxidation was inhibited at higher concentrations than
glycolysis and the function of the electron transport chain, we did
not assess the mechanism of this inhibition.
Effect on ROS Production, Cellular GSH
and SOD Expression
Toxicants inhibiting complex I and III can stimulate superoxide
production in mitochondria (Drose and Brandt, 2012).
Accordingly, specific mitochondrial superoxide accumulation
in HepG2 cells exposed for 48 h started at 50 µM for imatinib
and 20 µM for lapatinib, but not for erlotinib up to 20 µM
(Figure 6A). Sunitinib could not be investigated due to
self-fluorescence interacting with the assay.
We therefore determined also cellular production of H2O2
by HepG2 cells exposed to TKIs for 48 h (Figure 6B). All TKIs
investigated started to increase the cellular production of H2O2
at the lowest concentration investigated (2 µM for sunitinib and
5 µM for imatinib, lapatinib and erlotinib). For sunitinib and
imatinib, there was a sharp increase in H2O2 production at 20
and 50µM, respectively. The positive control 50µMamiodarone
increased the H2O2 accumulation 11-fold (data not shown).
Superoxide dismutases (SOD) are important for ROS defense
and are located in the mitochondrial matrix (SOD2) or in the
cytoplasm (SOD1) (Bresciani et al., 2015). InHepG2 cells exposed
for 48 h to imatinib, mRNA expression of SOD1 and SOD2
was increased at 50 µM, reaching statistical significance for
SOD1 (Figure 6C). Lapatinib suppressed mRNA expression of
SOD2, but did not a ect SOD1, whereas sunitinib increased
SOD1 expression without a ecting SOD2. With the exception
of erlotinib, TCIs generally increased the protein expression of
SOD1 and SOD2 in a concentration-dependent fashion, reaching
statistical significance for sunitinib (Figure 6D).
Accumulating ROS can be degraded by the glutathione
antioxidant system, which is an e ective scavenger of free radicals
(Schafer and Buettner, 2001; Fernandez-Checa and Kaplowitz,
2005). In HepG2 cells exposed for 48 h, imatinib started
to decrease the GSH content at 10 µM, reaching statistical
significance at 50 µM (Figure 6E). In cells exposed to sunitinib,
the cellular GSH content was not a ected at 10 µM but not
di erent from zero at 20 µM. Cytotoxicity, which was in a range
of 30% for 20 µM sunitinib, has likely contributed to this finding.
For erlotinib and lapatinib, no significant decrease in GSH was
found. 100 µM BSO, which served as positive control, decreased
the GSH content by more than 90% (data not shown).
Mechanisms of Cell Death in HepG2
Cells
Mitochondrial toxicity associated with imatinib and sunitinib
suggested involvement of mitochondria in cell death. Release
of cytochrome c from mitochondria into the cytoplasm is an
initial trigger for apoptosis (Green and Reed, 1998). As shown in
Figure 7A, all TKIs investigated were associated with an increase
of cytochrome c in the cytoplasm. This was associated with
a concentration-dependent increase in the activity of caspases
3/7 for imatinib, lapatinib, and sunitinib starting at 50, 20, and
20 µM, respectively, but not for erlotinib (Figure 7B). The
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FIGURE 5 | Effect on respiratory capacities through complexes I, II, III, and IV measured on the Oxygraph-2k-high-resolution respirometer. (A,B) Effect on HepG2
cells cultured with galactose after sunitinib and imatinib exposure for 48 h. (C) Effect on isolated mouse liver mitochondria after exposure for 15 min. Data represent
the mean ± SEM of at least three independent experiments. ⇤p < 0.05, ⇤⇤p < 0.01 or ⇤⇤⇤p < 0.001 versus DMSO control.
positive control 200 nM staurosporine increased the caspases 3/7
activity sixfold (data not shown).
As shown in Figure 7C, the ratio of active-to-pro caspase
3 protein level was increased significantly for lapatinib and
sunitinib starting at 50 and 20 µM, respectively. For imatinib
there was also a threefold increase at 50 µMbut without reaching
statistical significance, whereas erlotinib did not a ect the ratio of
active-to-pro caspase 3 protein levels (Figure 7C). Accordingly,
the protein expression of the full-length PARP was reduced for
imatinib and sunitinib starting for both at 10 µM, but not for
erlotinib and lapatinib (Figure 7D).
DISCUSSION
Our investigations demonstrated that imatinib, lapatinib, and
sunitinib reduce the 1%m, are associated with ROS production,
impair glycolysis, and induce apoptosis in HepG2 cells.
Furthermore, exposure to imatinib and sunitinib was associated
with impaired cellular oxygen consumption and reduced cellular
GSH levels. In HepaRG cells, CYP induction by rifampicin
increased cytotoxicity of these compounds, suggesting the
formation of toxic metabolites. Erlotinib, which could be
investigated only up to 20 µM due to solubility problems,
was slightly toxic in HepG2 and HepaRG cells. CYP induction
decreased the toxicity of erlotinib, suggesting the formation of
non-toxic metabolites.
The EC50 values in Table 1 and the data in Figures 1, 2
indicate that the toxicity associated with the TKIs investigated
was concentration- and time-dependent and that glycolysis was
inhibited at similar concentrations than ATP production. Our
data are compatible with the assumption that the mechanisms
causing hepatocellular toxicity of imatinib, lapatinib and
sunitinib can be explained by inhibition of certain mitochondrial
functions and of glycolysis.
Indeed, imatinib inhibited complex I and III and sunitinib
complex I of the electron transport chain. Inhibition of complex
I and complex III is associated with increased mitochondrial
ROS production (Drose and Brandt, 2012), which can reduce
the cellular GSH stores and induce mitochondrial membrane
permeability transition (Green and Reed, 1998; Kaufmann et al.,
2005). Inhibition of complex I was shown in both HepG2 cells
exposed for 48 h and in isolated mouse liver mitochondria
after acute exposure. In contrast, inhibition of complex III by
imatinib could only be observed in HepG2 cells. This can reflect
a di erence between species (humans and mice) or indicate that
mitochondrial damage depends on the duration of exposure, as
suggested also by the increase in the impairment of the cellular
ATP pool by TKIs with time (Table 1).
Mitochondrial membrane permeability transition is associated
with mitochondrial swelling, rupture of the outer mitochondrial
membrane and release of cytochrome c into the cytoplasm,
which induces cell death through apoptosis and/or necrosis
(Antico Arciuch et al., 2012). ROS production and release of
cytochrome c into the cytoplasm (suggesting mitochondrial
swelling and rupture of the outer mitochondrial membrane) was
demonstrated for both imatinib and sunitinib. As a consequence,
sunitinib and imatinib were associated with cleavage and
activation of caspase 3 and activation of caspase 7, which causes
degradation of PARP and initiation of apoptosis.
For lapatinib, the mechanism of hepatotoxicity partially
involved mitochondria and, possibly to a larger extent,
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FIGURE 6 | Cellular and mitochondrial ROS production, cellular GSH content and SOD expression. (A) Mitochondrial ROS production by HepG2 cells after drug
exposure for 48 h. (B) Production of H2O2 by HepG2 cells after drug exposure for 48 h. (C) mRNA expression of SOD1 and SOD2 in HepG2 cells after drug
exposure for 48 h. (D) Protein expression of SOD1 and SOD2 in HepG2 cells after drug exposure for 48 h. (E) GSH content in HepG2 cells after drug exposure for
48 h. Basel GSH concentration of control incubations (0.1% DMSO) was 24.4 ± 6.0 µM. All data are expressed as fold change to control incubations containing
0.1% DMSO. Data represent the mean ± SEM of at least three independent experiments. ⇤p < 0.05, ⇤⇤p < 0.01 or ⇤⇤⇤p < 0.001 versus DMSO control.
inhibition of glycolysis. In support of this assumption, lapatinib
showed a more pronounced cytotoxicity and reduction in
cellular ATP levels in the presence of glucose (favoring
glycolysis) compared to galactose (favoring mitochondrial
ATP generation) (Figure 1 and Supplementary Figure S2).
Lapatinib decreased the 1%m in mouse liver mitochondria
and increased mitochondrial ROS production, but did not
impair oxidative metabolism of HepG2 cells. Nevertheless,
also lapatinib was associated with release of cytochrome c
into the cytoplasm and induction of apoptosis. Interestingly,
a recently published study suggested that mitochondrial
toxicity of lapatinib is associated with the O-dealkylated
metabolite of lapatinib, which can form a quinone imine after
oxidation (Eno et al., 2016). These results are in agreement
with the finding in the current study that CYP induction of
HepaRG cells by rifampicin increased the toxicity of lapatinib
(Figure 2).
Erlotinib was cytotoxic in HepG2 and HepaRG cells and
decreased the ATP content in HepaRG but not in HepG2
cells. In agreement with these findings, erlotinib did not
a ect oxidative metabolism or the 1%m in HepG2 cells,
excluding a mitochondrial mechanism. Based in the EC50
values shown in Table 1, HepaRG cells appear to be slightly
more resistant than HepG2 cells to the toxicity associated
with imatinib, lapatinib and sunitinib, but not for erlotinib.
In comparison to HepG2 cells, HepaRG cells are more
di erentiated, as evidenced by a higher expression of CYPs
in the basal state and after treatment with rifampicin (Berger
et al., 2016). This may also be true for the mitochondrial
antioxidative defense system, which could protect HepaRG
cells from insults associated with mitochondrial generation
of ROS.
Our finding that certain TKIs damage mitochondria is
compatible with previous reports concerning regorafenib (Weng
et al., 2015) and dasatinib (Xue et al., 2012). Regorafenib is
an uncoupler of oxidative phosphorylation, and disrupts the
1%m and decreases the cellular ATP content (Weng et al.,
2015). Dasatinib increases mitochondrial ROS levels, reduces the
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FIGURE 7 | Assessment of apoptosis. (A) Western blot analysis of the ratio of expression of cytochrome c in the cytosolic to mitochondrial fraction. (B) Caspase 3/7
activity in HepG2 cells after drug exposure for 48 h. (C) Western blot analysis of the expression of active to pro caspase 3. (D) Western blot analysis of the
expression of full length PARP. All data are expressed as fold change to control incubations containing 0.1% DMSO. Data represent the mean ± SEM of at least
three independent experiments. ⇤p < 0.05, ⇤⇤p < 0.01 or ⇤⇤⇤p < 0.001 versus DMSO control.
cellular GSH content, decreases the1%m, and induces apoptosis
(Xue et al., 2012). Imatinib and sunitinib showed a similar
mechanism of hepatotoxicity with ROS production, impairment
of the1%m, GSH reduction, and apoptosis.
Considering the low incidence and occurrence at therapeutic
dosage, TKI-induced liver injury can be regarded as an
idiosyncratic (type B) adverse reaction, suggesting that a ected
patients have susceptibility factors (Tujios and Fontana, 2011).
However, as indicated by the current study and as observed
also in clinical practice, hepatotoxicity associated with TKIs
appears to be dose-related, favoring intrinsic (type A) toxicity
as a mechanism. At therapeutic dosages, imatinib, lapatinib,
and sunitinib typically reach plasma concentrations in the
range of 5, 4, and 0.3 µM, respectively (Huynh et al.,
2017). As shown by data in mice, the concentrations in
liver may be higher than in plasma by a factor of 2 for
imatinib (Tan et al., 2011) and by a factor of at least
10 for lapatinib (Spector et al., 2015) and sunitinib (Lau
et al., 2015), suggesting that toxic liver concentrations can
be reached in certain patients. The data of the current study
and clinical experience suggest that exposure is an important
risk factor for liver toxicity associated with TKIs. Hepatic
exposure is primarily dependent on the dose administered, but
may also be a ected by interacting drugs. Since most TKIs
are metabolized (mainly N-dealkylation for imatinib and for
sunitinib, and O-dealkylation for erlotinib and lapatinib) by
CYP3A4 (Josephs et al., 2013; Eno et al., 2016), concomitant
treatment with CYP3A4 inhibitors may increase toxicity. For
imatinib, lapatinib and sorafenib, also CYP3A4 inducers could
increase the risk for liver toxicity, since the metabolites formed
may be more toxic than the corresponding parent compounds.
Similar findings have been published for amiodarone, where
the N-dealkylated metabolites were also more hepatotoxic
than the parent compound (Zahno et al., 2011). Since
imatinib, lapatinib and sunitinib are mitochondrial toxicants,
mitochondrial dysfunction could be an additional susceptibility
factor. The critical role of mitochondrial function regarding
hepatotoxicity of mitochondrial toxicants has previously been
demonstrated for valproate (Krahenbuhl et al., 2000; Knapp
et al., 2008; Stewart et al., 2010) and for dronedarone
(Felser et al., 2014). Furthermore, the importance of an
intact hepatic mitochondrial antioxidative system has been
demonstrated in SOD2+/  mice exposed to nimesulide (Ong
et al., 2006).
The observed drop in the cellular ATP content by
mitochondrial dysfunction and inhibition of glycolysis can
lead to cell necrosis but can potentially damage cells also by
other mechanisms. In skeletal muscle, it has recently been shown
that staurosporine, a TKI which is not used as a drug, inhibits
ATP-dependent potassium channels (KATP channels) at low
cellular ATP levels probably by a direct interaction with the ATP
binding site (Mele et al., 2014). Since liver mitochondria contain
KATP channels which are important for maintaining the 1%m
(Mironova et al., 1997; Seino and Miki, 2003), inhibition of these
channels by TKIs may represent a mechanism of toxicity which
may be important also in other organs.
CONCLUSION
Our investigations demonstrate that imatinib, lapatinib, and
sunitinib were associated with mitochondrial dysfunction and
inhibition of glycolysis at concentrations that may be reached
in livers of a ected patients. CYP induction increased the
toxicity of these compounds, suggesting the formation of toxic
metabolites. Hepatocellular toxicity of these compounds was
concentration-dependent, corresponding with dose-dependent
toxicity in patients. Erlotinib showed a slight cytotoxicity in
both cell models investigated, which could not be explained by a
mitochondrial mechanism or impaired glycolysis. CYP induction
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reduced hepatocellular toxicity, suggesting that hepatocellular
toxicity is associated mainly with the parent compound.
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KINASE INHIBITORS IN HUMAN HEPATOCYTE CELL LINES 
 
 
Within this article, we will investigate the mechanisms of hepatotoxicity for crizotinib, 
dastinib, pazopanib, ponatinib, regorafenib, and sorafenib in vitro. 
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Abstract
Tyrosine kinase inhibitors have revolutionized the treatment of certain cancers. They are usually
well tolerated, but can cause adverse reactions including liver injury. Currently, mechanisms of
hepatotoxicity associated with tyrosine kinase inhibitors are only partially clarified. We therefore
aimed at investigating the toxicity of regorafenib, sorafenib, ponatinib, crizotinib, dasatinib and
pazopanib on HepG2 and partially on HepaRG cells. Regorafenib and sorafenib strongly inhibited
oxidative metabolism (measured by the Seahorse ‐XF24 analyzer) and glycolysis, decreased the
mitochondrial membrane potential and induced apoptosis and/or necrosis of HepG2 cells at con-
centrations similar to steady ‐state plasma concentrations in humans. In HepaRG cells, pretreat-
ment with rifampicin decreased membrane toxicity (measured as adenylate kinase release) and
dissipation of adenosine triphosphate stores, indicating that toxicity was associated mainly with
the parent drugs. Ponatinib strongly impaired oxidative metabolism but only weakly glycolysis,
and induced apoptosis of HepG2 cells at concentrations higher than steady ‐state plasma concen-
trations in humans. Crizotinib and dasatinib did not significantly affect mitochondrial functions
and inhibited glycolysis only weakly, but induced apoptosis of HepG2 cells. Pazopanib was asso-
ciated with a weak increase in mitochondrial reactive oxygen species accumulation and inhibition
of glycolysis without being cytotoxic. In conclusion, regorafenib and sorafenib are strong mito-
chondrial toxicants and inhibitors of glycolysis at clinically relevant concentrations. Ponatinib
affects mitochondria and glycolysis at higher concentrations than reached in plasma (but possibly
in liver), whereas crizotinib, dasatinib and pazopanib showed no relevant toxicity. Mitochondrial
toxicity and inhibition of glycolysis most likely explain hepatotoxicity associated with regorafenib,
sorafenib and possibly pazopanib, but not for the other compounds investigated.
KEYWORDS
apoptosis, glycolysis, hepatocellular toxicity, mitochondrial toxicity, reactive oxygen species,
Tyrosine kinase inhibitor
1 | INTRODUCTION
Tyrosine kinases (TK) are involved in regulating multiple cellular pro-
cesses, including cellular proliferation, survival and differentiation
(Shah, Morganroth, & Shah, 2013; Shchemelinin, Sefc, & Necas,
2006). Accordingly, deregulation of protein kinases is associated with
many diseases such as autoimmune diseases and cancers (Levitzki &
Gazit, 1995) and defectiveTKs are involved in tumor initiation and pro-
gression (Shchemelinin et al., 2006). Specific TKs have been linked to
certain cancers, making TK inhibitors (TKIs) attractive targeted therapy
for the treatment of cancer (Krause & Van Etten, 2005). The first
approved TKI was imatinib in 2001 for chronic myeloid leukemia
(Cohen, Johnson, & Pazdur, 2005). Since then, the Food and Drug
Administration and the European Medicines Agency have approved
more than 20 TKIs and many more are currently under development.
TKIs have a different toxicological profile than the classical
cytotoxic agents. They are generally less toxic for hematopoiesis, but
Abbreviations: ATP, adenosine triphosphate; CYP, cytochrome P450 enzyme;
DMSO, dimethyl sulfoxide; FCCP, carbonyl cyanide ‐4‐(trifluoromethoxy)
phenylhydrazone; GSH, glutathione (reduced form); PBS, phosphate ‐buffered
saline; ROS, reactive oxygen species; SEM, standard error of the mean; tGSH,
total GSH; TK, tyrosine kinase; TKI, tyrosine kinase inhibitor; TMRM,
tetramethylrhodamine methyl ester; Δψm, mitochondrial membrane potential
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there are concerns regarding toxicity of the skin, gastrointestinal tract,
lungs, cardiovascular system, skeletal muscle and the liver (Breccia &
Alimena, 2013). Hepatotoxicity has been reported for several TKIs,
including regorafenib, sorafenib, ponatinib, crizotinib, dasatinib and
pazopanib (Abou‐Alfa et al., 2006; Bible et al., 2014; Camidge et al.,
2012; Cortes et al., 2013; Di Lorenzo et al., 2009). In a recent review
article, Shah et al. reported that 25 –30% of patients treated with TKIs
in clinical trials showed a low ‐grade elevation in alanine aminotransfer-
ase (<5 times upper limit of normal) and approximately 2% of the
patients developed an alanine aminotransferase increase ≥5 times
upper limit of normal (Shah et al., 2013). A recent meta ‐analysis, which
included more than 3000 patients, reported an approximately twofold
increased risk for hepatotoxicity in patients treated with TKIs com-
pared to control patients (Teo, Ho, & Chan, 2013). Liver failure and
fatalities are rare, but have been reported for crizotinib (Sato et al.,
2014; van Geel et al., 2016), pazopanib (Klempner et al., 2012),
ponatinib (Price, Saleem, Lee, & Steinberg, 2013), regorafenib
(Akamine et al., 2015; Raissouni et al., 2015; Sacre et al., 2016) and
sorafenib (Brandi et al., 2015; Fairfax et al., 2012; Murad, Rabinowitz,
& Lee, 2014; Rao et al., 2013; Yamasaki et al., 2016). The mechanisms
of hepatotoxicity of TKIs are poorly understood, but are probably not
related to kinase inhibition in hepatocytes (Shah et al., 2013). Recent
publications reported mitochondrial toxicity for sorafenib, regorafenib
and pazopanib (Weng et al., 2015; Zhang et al., 2017) as well as for
dasatinib (Xue et al., 2012). Sorafenib, regorafenib and pazopanib
impaired the function of the respiratory chain and decreased the mito-
chondrial membrane potential in isolated rat liver mitochondria (Xue
et al., 2012) and in rat primary hepatocytes (Weng et al., 2015),
whereas dasatanib uncoupled oxidative phosphorylation in isolated
rat liver mitochondria (Xue et al., 2012). Furthermore, we showed
recently that HepG2 cells exposed to imatinib or sunitinib had a
reduced mitochondrial membrane potential, impaired oxygen con-
sumption and increased mitochondrial oxidative stress, eventually
leading to apoptosis and necrosis (Paech, Bouitbir, & Krahenbuhl,
2017). As most TKIs undergo intense hepatic metabolism by cyto-
chrome P450 (CYP) 3A4 (Josephs, Fisher, Spicer, & Flanagan, 2013),
TKI ‐associated hepatotoxicity may not only be due to the parent drug,
but also due to metabolites (Teo, Ho, & Chan, 2015ab).
As the exact hepatotoxic mechanisms of TKIs are currently unclear
and most data currently available were generated in hepatocytes or
liver mitochondria from rats, we decided to investigate the toxicity of
six TKIs associated with hepatotoxicity in human hepatocyte cell lines.
Crizotinib is a specific inhibitor for the mutated anaplastic lymphoma
kinase, dasatinib and ponatinib are multi ‐kinase inhibitors with a high
specificity for the BCR ‐ABL TK receptor and pazopanib, regorafenib
and sorafenib are multi ‐kinase inhibitors with a high specificity for
the vascular endothelial growth factor receptors 1, 2 and 3. We
focused on energy metabolism, as adenosine triphosphate (ATP) is
essential for cell survival and as mitochondrial toxicity is an important
mechanism of non ‐immunologic drug‐associated liver injury (Han
et al., 2013; Yuan & Kaplowitz, 2013). We used two human hepatoma
cell lines, namely HepG2 cells grown either in the presence of glucose
or of galactose, and HepaRG cells. HepG2 cells are well ‐suited for
studying mitochondrial function (Felser, Blum, Lindinger, Bouitbir, &
Krahenbuhl, 2013; Kamalian et al., 2015), but they have a low or
lacking expression of CYP enzymes (Berger et al., 2016). In comparison,
HepaRG cells have a conserved CYP expression, which can be induced
by rifampicin (Berger et al., 2016), rendering them suitable for studying
the potential role of CYP ‐associated metabolites. HepG2 cells were
grown in the presence of glucose or of galactose, as cells grown in
the presence of galactose are forced to generate most ATP by oxida-
tive phosphorylation instead of glycolysis, rendering them sensitive
to mitochondrial toxicants (Kamalian et al., 2015). The investigations
revealed that regorafenib and sorafenib are strong mitochondrial toxi-
cants and inhibitors of glycolysis, whereas the other TKIs investigated
were less toxic.
2 | MATERIALS AND METHODS
2.1 | Chemicals
Crizotinib HCl, dasatinib, pazopanib, ponatinib, regorafenib and soraf-
enib were purchased from Sequoia research products (Pangbourne,
Berks, UK). We prepared stock solutions in dimethyl sulfoxide (DMSO)
and stored them at –20°C. All other chemicals were supplied by Sigma ‐
Aldrich (Buchs, Switzerland), except where indicated.
Because of solubility reasons, we could treat with concentrations
up to 100 μM for crizotinib and dasatinib, up to 50 μM for pazopanib,
ponatinib and sorafenib and up to 20 μM for regorafenib.
2.2 | HepG2 cell culture
The human hepatocellular carcinoma cell line HepG2 was obtained
from the American type culture collection (ATCC, Manassas, VA,
USA). HepG2 cells were cultured under two different conditions, low
glucose and galactose.
HepG2 cells under low glucose conditions were cultured in
Dulbecco's modified Eagle med ium (DMEM containing 5.55 m M [1 g l–1]
glucose, 4 mM L ‐glutamine and 1 mM pyruvate from Invitrogen,
Basel, Switzerland) supplemented with 10% (v/v) heat ‐inactivated fetal
bovine serum (FBS), 2 m M GlutaMax, 10 mM HEPES buffer, 10 m M
non‐essential amino acids, 100 units ml –1 penicillin and 100 μg ml–1
streptomycin.
HepG2 cells under galactose conditions were cultured for at
least 3 weeks before used in the experiments in DMEM (no glucose,
4 mM L ‐glutamine) from Invitrogen supplemented with 10% (v/v)
heat‐inactivated FBS, 10 m M galactose, 2 mM L ‐glutamine, 10 mM
HEPES buffer, 1 m M sodium pyruvate, 100 units ml –1 penicillin and
100 μg ml–1 streptomycin. The FBS was dialyzed through a
Slide‐A‐Lyzer Dialysis Flask (Thermo Scientific, Rheinfach, Switzerland)
to remove glucose according to the manufacturer's protocol.
2.3 | HepaRG cell culture
The HepaRG cell line was provided by Biopredic International (Saint ‐
Gregoire, France). Cells were cultured and differentiated as described
earlier (Gripon et al., 2002). HepaRG cells contain inducible CYPs,
allowing to test the possible contribution of metabolites for toxicity
(Berger et al., 2016). Induction of CYP3A4 and other CYPs was
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achieved by preincubation of differentiated HepaRG cells with 20 μM
rifampicin for 72 hours, with medium change every 24 hours.
All cells were kept at 37°C in a humidified 5% CO 2 cell culture
incubator and passaged using trypsin. The cell number was determined
using a Neubauer hemacytometer and viability was checked using the
trypan blue exclusion method.
2.4 | Membrane toxicity
The integrity of the plasma membrane was assessed by using the
ToxiLight assay from Lonza (Basel, Switzerland) according to the
manufacturer's protocol. This assay measures the release of adenylate
kinase in the extracellular space, which reflects the plasma membrane's
integrity. HepG2 cells (glucose or galactose conditions) and HepaRG
cells (glucose conditions) were grown in a 96 ‐well plate (25 000 cells
per well) and exposed to different concentrations of TKIs (2 –100 μM)
for 24 hours. The negative control was 0.1% DMSO and the positive
control was 0.5% Triton ‐X. After incubation, 20 μl supernatant of each
well was transferred to a new 96 ‐well plate. Then, 50 μl of assay buffer
was added to each well. After incubation in the dark for 5 minutes, the
luminescence was measured using a Tecan M200 Pro Infinity plate
reader (Männedorf, Switzerland). All data were normalized to positive
control incubations containing 0.5% Triton X.
2.5 | Intracellular adenosine triphosphate content
The intracellular ATP content was measured using the CellTiter ‐Glo kit
from Promega (Wallisellen, Switzerland) according to the
manufacturer's protocol. HepG2 cells (glucose or galactose conditions)
and HepaRG cells (glucose conditions) were grown in a 96 ‐well plate
(25 000 cells per well) and exposed to different concentrations of
TKI (2 –100 μM) for 24 hours. The negative control was 0.1% DMSO
and the positive control was 0.5% Triton ‐X. After treatment, medium
was removed to have 50 μl remaining in each well and afterwards
50 μl of assay buffer was added to each well. After incubation in the
dark for 15 minutes, the luminescence was measured using a Tecan
M200 Pro Infinity plate reader. All data were normalized to control
incubations containing 0.1% DMSO.
2.6 | Mitochondrial membrane potential in HepG2
cells
Mitochondrial membrane potential ( Δψm) in HepG2 cells kept under
low glucose conditions was determined using tetramethylrhodamine
methyl ester (TMRM; Invitrogen). TMRM is a cationic fluorescent
probe that accumulates within mitochondria depending on their
Δψm. HepG2 cells were seeded in 24 ‐well plates (200 000 cells per
well) and treated with different concentrations of TKIs (2 –100 μM)
for 24 hours. The negative control was 0.1% DMSO and the positive
control was carbonyl cyanide ‐4 ‐(trifluoromethoxy)phenylhydrazone
(FCCP, 9 μM). FCCP is an uncoupler of mitochondrial oxidative phos-
phorylation and therefore decreases Δψm. FCCP was added cells and
10 minutes later, cells were washed with phosphate ‐buffered saline
(PBS) and suspended in PBS with 100 n M TMRM. After 15 minutes
incubation in the dark, cells were centrifuged and resuspended in
PBS for analyzing them with flow cytometry using a FACSCalibur
(BD Bioscience, Allschwil, Switzerland). FlowJo software v10.0.8
(FlowJo; LCC, Ashland, OR, USA) was used to analyze the data.
2.7 | Cellular oxygen consumption
Cellular respiration in intact cells was measured with a Seahorse XF24
analyzer (Seahorse Biosciences, North Billerica, MA, USA) as described
previously (Felser et al., 2013). HepG2 cells kept under low glucose
conditions were seeded in Seahorse XF 24 ‐well culture plates at 100 000
cells per well in DMEM growth medium and allow to adhere over-
night. Cells were treated with the test compounds (1 –50 μM) for
24 hours. Before the experiment, the medium was replaced with 750 μl
unbuffered DMEM medium (4 m M L ‐glutamate, 1 mM pyruvate,
1 g l–1 glucose, 6 3.3 m M sodium chloride, pH 7.4 ) and equilibrated at
37°C in a CO 2‐free incubator for at least 1 hour. Basal oxygen con-
sumption rate was determined in the presence of glutamate and pyru-
vate (4 and 1 mM, respectively). The proton leak (a marker for
uncoupling) was determined after inhibition of mitochondrial ATP pro-
duction by 1 μM oligomycin (inhibitor of the F 0F1‐ATPase). Afterwards,
the mitochondrial electron transport chain was stimulated maximally
by the addition of the uncoupler FCCP (2 μM). Finally, the
extramitochondrial respiration was estimated after the addition of
complex I inhibitor rotenone (1 μM). For the determination of the basal
respiration, the oxidative leak, and the maximum respiration, the esti-
mate of the extra ‐mitochondrial respiration was subtracted (see
Supporting information Figure S1). Respiration was expressed as oxy-
gen consumption per minute normalized to the protein content of
the incubations. For that, cells were fixed by adding 100 μl of 50%
(w/v) trichloroacetic acid to each well and the plate was stored at
4 °C for 1 hour. Trichloroacetic acid was then removed and the plate
washed three times with MilliQ water. We added 50 μl sulfurhodamine
(0.4 % (w/v) in 1% (v/v) acetic acid) and incubated for 20 minutes at
room temperature to stain the proteins. The plate was then washed
with 1% acetic acid (v/v) and the incorporated dye was solubilized with
100 mM Tris base. The absorbance was determined at 4 90 nm using a
Tecan M200 Pro Infinity plate reader. The protein concentration was
calculated based on a calibration curve with bovine serum albumin.
2.8 | Mitochondrial superoxide accumulation
Mitochondrial superoxide accumulation was measured using the
MitoSOX Red fluorophore probe from Invitrogen, according to the
manufacturer's instructions. The MitoSOX Red mitochondrial superox-
ide indicator is a fluorogenic dye for highly selective detection of
superoxide in the mitochondria ofliving cells. HepG2 cells kept under
low glucose conditions were seeded in 96 ‐well plates (25 000 cells per
well) and treated with test compounds (5 –100 μM) for 24 hours. The
negative control was 0.1% DMSO and the positive control was
50 μM amiodarone. Afterwards, 100 μl PBS with 2.5 μM MitoSOX
was added to each 96 ‐well plate. After incubation at 37°C in the dark
for 10 minutes, the fluorescence was measured using a Tecan M200
Pro Infinity plate reader with an excitation at 510 nm and an emission
at 58 0 nm. We normalized the results to the protein content using a
Pierce BCA Protein Assay Kit fromThermo Fisher Scientific (Waltham,
MA, USA).
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2.9 | Glutathione content
Total glutathione (reduced form) (tGSH) contents were measured using
a previously described enzymatic recycling method (Rahman, Kode, &
Biswas, 2006). The assay is based on the oxidation of GSH by 5,5  ‐
dithio‐bis(2‐nitrobenzoic acid) to the yellow derivative 5  ‐thio‐2‐
nitrobenzoic acid. HepG2 cells kept under low glucose conditions were
seeded in six ‐well plates (600 000 cells per well) and treated with drugs
(5–100 μM) for 24 hours. The negative control was 0.1%DMSO and the
positive control was 100 μM buthionine sulfoximine, a substance known
to reduce the level of tGSH. At the end, the absorbance at 412 nm was
measured every 30 seconds for 2 minutes with a Tecan M200 Pro
Infinity plate reader. The protein content of the cell extracts was deter-
mined with the Pierce Protein Assay Kit fromThermo Fisher Scientific
(Waltham, MA, USA) and the tGSH content was adjusted to protein.
2.10 | Glycolysis
The glycolytic flux was determined via the conversion of [ 3H] ‐glucose
to 3H2O as described before (Vander Heiden et al., 2001). HepG2 cells
kept under low glucose conditions were seeded in six ‐well plates (500 000
cells per well) and treated with drugs (1 –100 μM) for 24 hours.
The positive control was 20 m M 2‐deoxy‐D‐glucose. After treatment,
HepG2 cells were resuspended in 1 ml Krebs buffer (115 m M sodium
chloride, 2 mM potassium chloride, 25 m M sodium bicarbonate, 1 mM
magnesium chloride, 2 mM calcium chloride, 0.25% FBS, pH 7.4) and
incubated for 30 minutes at 37°C. After centrifugation, cell pellets
were resuspended in 0.5 ml Krebs buffer containing 10 m M glucose
and 0.5 μl D‐3H(U) glucose (60 Ci mmol –1, 0.5 μCi per assay; Perkin
Elmer, Schwerzenbach, Switzerland) and incubated for 1 hour at 37°C.
After centrifugation, 50 μl supernatant were transferred to tubes
containing 50 μl 0.2 N HCl. Tubes were transferred to scintillation vials
containing 0.5 ml water and sealed. 3H2Owas allowed to evaporate from
the tube and to condense in the 0.5 ml water for 1 week. Afterwards, the
tubewas removed and the radioactivity of the water wasmeasured using
a Packard (Palo Alto, CA, USA) 19 00 TR liquid scintillation analyzer.
2.11 | Western blotting for markers of apoptosis
HepG2 cells kept under low glucose conditions were seeded in to a six ‐
well plate (500 000 cells per well) and treated with different concen-
trations of TKIs (5 –50 μM) for 24 hours. The negative control was
0.1% DMSO and the positive control was 200 n M staurosporin. After-
wards, HepG2 cells were lysed with RIPA buffer (150 m M sodium chlo-
ride, 1.0% NP ‐40, 0.5% sodium deoxycholate, 0.1% sodium dodecyl
sulfate, 50 m M Tris, pH 8.0) containing complete Mini protease inhibi-
tor cocktail (Roche Diagnostics, Mannheim, Germany). After centrifu-
gation, the supernatant was collected and stored at –80°C. Proteins
were resolved by sodium dodecyl sulfate –polyacrylamide gel electro-
phoresis using commercially available 4 –12% NuPAGE Bis ‐Tris gels
(Invitrogen) and transferred using the Trans ‐Blot Turbo Blotting Sys-
tem (Bio ‐Rad, Cressier, Switzerland). The membranes were incubated
with poly ADP ribose polymerase (PARP; 46D11) rabbit monoclonal
antibody (1:1000; Cell Signaling Technology, Danvers, MA, USA),
anti‐active caspase ‐3 antibody (1:1000, ab32042; Abcam, Cambridge,
UK), and Anti ‐pro Caspase 3 antibody (1:1000, ab32150; Abcam,
Cambridge, UK) antibodies. After washing, membranes were exposed
to secondary antibodies (1:2000; Santa Cruz Biotechnology, Dallas,
TX, USA). Immunoblots were developed using enhanced chemilumi-
nescence (GE Healthcare, Little Chalfont, Bucks, UK). Band intensities
of the scanned images were quantified using the National Institutes of
Health Image J program, v1.47.
2.12 | Annexin V/propidium iodide
To study the mechanisms of cell death, we used the fluorescein
isothiocyanate Annexin V/Dead Cell Apoptosis Kit from Invitrogen
according to the manufacturer's protocol. HepG2 cells kept under
low glucose conditions were seeded in 24 ‐well plates (200 000 cells
per well) and treated with different concentrations of TKIs (5 –50 μM)
for 24 hours. The negative control was 0.1% DMSO. Positive controls
were 200 n M staurosporin for apoptosis and 50 μM amiodarone
for necrosis. The cells were then analyzed with a FACSCalibur
(BD Bioscience) channel FL ‐1 and FL ‐3. FlowJo software v10.0.8 was
used to analyze the data.
2.13 | Statistical analysis
Data are given as the mean ± standard error of the mean (SEM) of at
least three experiments in triplicates. Statistical analyses were per-
formed using GraphPad Prism 6 (GraphPad Software, La Jolla, CA,
USA). For the comparison of treatment groups to the 0.1% DMSO
control group, one ‐way ANOVA was used followed by the Dunnett's
post‐test procedure. The CYP induction experiments in HepaRG cells
were analyzed using two ‐way ANOVA followed by Bonferroni's post
hoc test. P < .05 (*) was considered to be significant.
3 | RESULTS
3.1 | Membrane toxicity and adenosine triphosphate
content in HepG2 cells
Adenylate kinase release was determined as a marker of the plasma
membrane integrity, and the cellular ATP content as a marker of the
energy metabolism. Plasma membrane integrity and ATP content were
assessed using two different media: in one medium the nutrient was
5.5 mM glucose (glucose medium) and in the other one 10 m M galac-
tose (galactose medium). In the presence of glucose, HepG2 cells can
produce ATP not only via oxidative phosphorylation, but also via
glycolysis. In the presence of galactose, cells are forced to produce
ATP mainly via oxidative phosphorylation (Marroquin, Hynes,
Dykens, Jamieson, & Will, 2007). In the presence of galactose,
mitochondrial toxicants have been reported to deplete the cellular
ATP content at lower concentrations than in the presence of glucose
(Kamalian et al., 2015).
The effects of the six TKIs investigated on plasma membrane
integrity and on the cellular ATP content of HepG2 cells exposed for
24 hours are shown in Figures 1(A –F) and in 2(A–F), respectively.
Based on the curves displayed in these figures, the corresponding
EC 50 values were calculated (Table 1). With the exception of
pazopanib, which was not membrane ‐toxic up to 50 μM, the TKIs
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investigated were membrane ‐toxic and decreased the cellular ATP
pool in a concentration ‐dependent fashion. As can be seen in the fig-
ures and as calculated in Table 1, regorafenib and sorafenib were gen-
erally more toxic in the presence of galactose as compared to glucose
(Figures 1E,F and 2E,F). The EC 50 regarding ATP depletion was for
both drugs approximately three times lower in the presence of
galactose than for glucose. Ponatonib was more membrane ‐toxic in
the presence of galactose than for glucose (Figure 1D), ATP depletion
was more accentuated in the presence of glucose (Figure 2D).
Pazopanib was not membrane ‐toxic up to 50 μM (Figure 1C) and
decreased the cellular ATP content only in the presence of galactose
(Figure 2C). Crizotinib and dasatinib were both membrane ‐toxic and
FIGURE 1 Membrane toxicity in HepG2 cells cultured in low glucose or galactose medium. Membrane toxicity was assessed by the release of
adenylate kinase after exposure for 24 hours with crizotinib (A), dasatinib (B), pazopanib (C), ponatinib (D), regorafenib (E) and sorafenib (F).
Data are expressed as the percentage oflysed cells with the values obtained for Triton X 0.1% set as 100%. Data represent the mean ± SEM of at
least three independent experiments. * P < .05 vs. dimethyl sulfoxide control (glucose). +P < .05 vs. dimethyl sulfoxide control (galactose). xP < .05
galactose vs. glucose
TABLE 1 Quantification of membrane toxicity and ATP depletion by tyrosine kinase inhibitors in HepG2 cells
EC 50‐ATP ( μM CE) 50‐MT ( μM) EC 50 ‐ATP glu
EC 50 ‐ATP gal
EC 50‐MT glu
EC 50‐MT galGlucose Galactose Glucose Galactose
Crizotinib 12.2 19.9 16.9 21.7 0.61 0.78
Dasatinib 40.5 94.7 92.0 64.1 0.43 1.44
Pazopanib >50 >50 >50 >50 ND ND
Ponatinib 8.83 17.9 22.0 11.0 0.49 2.00
Regorafenib >20 6.54 >20 >20 >3.06 ND
Sorafenib 16.7 5.51 >50 >50 3.04 ND
gal, galactose; glu, glucose; ND, not determinable.
We calculated the EC 50 for the cellular decrease in the ATP content (EC 50 ‐ATP; drug concentration that causes a 50% decrease in the ATP content com-
pared to 0.1% DMSO control) and the EC 50 for membrane toxicity (EC 50 ‐MT; drug concentration that induces a 50% loss in membrane integrity compared
to the positive control Triton ‐X) according to Swiss et al. (2013) based on the data shown in Figures 1 and 2. Ratios EC 50 ‐ATP glu/EC 50 ‐ATP gal > 2 can be
considered as indicators of mitochondrial toxicity.
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depleted the cellular ATP stores with a tendency for more accentuated
toxicity in the presence of glucose (Figures 1A,B and 2A,B). Similar
results for membrane toxicity and ATP content were obtained after
exposure for 48 hours (data not shown).
A more pronounced toxicity in the presence of galactose as com-
pared to glucose (Marroquin et al., 2007 ) has been proposed to reflect
mitochondrial toxicity. Accordingly, regarding cellular ATP depletion, a
ratio EC 50‐ATP glu/EC 50‐ATP gal > 2 can be considered as indicators of
mitochondrial toxicity (Swiss, Niles, Cali, Nadanaciva, & Will, 2013).
Based on the ratios shown in Table 1, we could assume mitochondrial
toxicity at least for regorafenib and sorafenib, but not for crizotinib,
dasatinib and pazopanib. Ponatinib showed a ratio of 2 for membrane
toxicity (EC 50‐MT glu/EC 50‐MT gal) but <2 for cellular ATP depletion.
3.2 | Membrane toxicity and adenosine triphosphate
content in HepaRG cells
Membrane toxicity and ATP content were also investigated in HepaRG
cells (Figure 3A,B). These incubations were conducted in the glucose
medium, as we wanted to assess the effect on glycolysis. After 24 hours
of treatment, crizotinib and dasatinib were membrane ‐toxic and
decreased the ATP content starting at 20 and 50 μM, respectively.
Ponatinib was membrane ‐toxic starting at 10 μM but a decrease in
ATP content was already observed at 5 μM. Regorafenib and sorafenib
were membrane ‐toxic and decreased the ATP content starting at 5 μM.
Pazopanib did not show anymembrane toxicity or decrease in ATP con-
tent at the tested concentrations (up to 50 μM). CYP induction did not
either affect membrane toxicity or depletion of the cellular ATP pool or
reduced membrane toxicity (by approximately 40% for 5 μM regorafe-
nib and 5 μM sorafenib) or cellular ATP depletion (by 19 % to 45% for
20 μM crizotinib, 50 μM dasatinib, 5 μM regorafenib and 5 μM sorafe-
nib). These findings indicate that the toxicity of the TKIs investigated
is associated mainly with the parent compounds and less with CYP ‐
associated metabolites. Based on these results we decided to pursue
our experiment with the parent compounds using HepG2 cells, which
represent a well ‐characterized human cell system suitable for investi-
gating mitochondrial toxicity of drugs (Felser et al., 2013; Kamalian
et al., 2015). We decided to conduct these experiments in glucose
medium, as the physiological substrate is glucose and not galactose.
3.3 | Effect on mitochondrial membrane potential
To investigate the potential role of mitochondria in the observed
reduction of the cellular ATP content, we first determined the effect
FIGURE 2 Intracellular ATP content in HepG2 cells cultured in low glucose or galactose medium. Intracellular ATP content was measured after
exposure for 24 hours with crizotinib (A), dasatinib (B), pazopanib (C), ponatinib (D), regorafenib (E) and sorafenib (F). Data are expressed as
decrease compared to control incubations containing 0.1% DMSO. ATP content for the control incubations was 13.4 ± 0.9 nmol mg –1 protein
(mean ± SEM, n = 4 incubations). Data represent the mean ± SEM of at least three independent experiments. * P < .05 vs. DMSO control (glucose).
+P < .05 vs. DMSO control (galactose). xP < .05 galactose vs. glucose. DMSO, dimethyl sulfoxide
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of TKIs on the mitochondrial membrane potential ( Δψm) in HepG2
cells. The mitochondrial membrane potential can be considered a
marker for mitochondrial function and integrity (Kaufmann et al.,
2005). We observed a dissipation in Δψm starting at 100 μM for
dasatinib (Figure 4A), at 50 μM for crizotinib and ponatinib (Figure 4
A,B), and at 10 μM for regorafenib and sorafenib (Figure 4B). Pazopanib
did not change the ΔΨm, which is consistent with the observation that
it did not decrease the cellular ATP content.
3.4 | Effect on oxidative metabolism
The observed decrease in the cellular ATP content and in the mito-
chondrial membrane potential could be caused by inhibition and/or
uncoupling of the respiratory chain (Felser et al., 2013 ; Kaufmann
et al., 2005). Therefore, we assessed the oxygen consumption of cells
treated with TKIs to study oxidative mitochondrial metabolism. Crizo-
tinib and pazopanib did not significantly affect mitochondrial oxygen
consumption (Figure 5A,C, respectively). Dasatinib increased oxygen
consumption in the presence of oligomycin in a concentration ‐depen-
dent way starting at 20 μM (Figure 5B), compatible with uncoupling of
oxidative phosphorylation. Ponatinib reduced the basal and maximal
respiration rate starting at 2 μM (Figure 5D). Regorafenib decreased
the maximal and the ATP ‐linked respiration rate in a concentration ‐
dependent manner and increased oxygen consumption in the presence
of oligomycin starting at 2 μM (Figure 5E). Sorafenib decreased the
maximal and ATP ‐linked respiration rate in a concentration ‐dependent
way starting at 1 μM, and increased the oxygen consumption in the
presence of oligomycin and decreased basal respiration starting at
5 μM (Figure 5F).
These results suggest inhibition of the mitochondrial electron
transport chain by ponatinib, regorafenib and sorafenib, and possibly
uncoupling of oxidative phosphorylation by dasatinib, regorafenib
and sorafenib.
3.5 | Effect on mitochondrial reactive oxygen species
accumulation, cellular glutathione and superoxide
dismutase expression
Toxicants inhibiting the function of the mitochondrial electron trans-
port chain can increase mitochondrial production of superoxide (Drose
& Brandt, 2012). Accordingly, we observed an increased mitochondrial
superoxide content starting at 5 μM for ponatinib (Figure 6B), at 10 μM
FIGURE 3 Effect of pretreatment with rifampicin on membrane toxicity and intracellular ATP content in HepaRG cells. HepaRG cells (cultured in
low glucose medium) were pretreated for 7 2 hours with rifampicin and then exposed to drugs for 24 hours. (A) Membrane toxicity, assessed by the
release of adenylate kinase. (B) Intracellular ATP content. Data are expressed as the percentage oflysed cells with the values obtained for Triton X
0.1% set as 100% or as decrease in the cellular ATP content in percentages compared to control incubations containing 0.1% DMSO. Data
represent the mean ± SEM of at least three independent experiments. * P < .05 vs. DMSO control. +P < .05 vs. pretreatment with rifampicin. DMSO,
dimethyl sulfoxide
MINGARD ET AL . 7
MOLECULAR MECHANISMS OF TYROSINE KINASE                                PAPER 2 
INHIBITORS-ASSOCIATED HEPATOTOXICITY 
 85 
for pazopanib, regorafenib and sorafenib (Figure 6A,B) and at 20 μM
for crizotinib and dasatinib (Figure 6A) after 24 hours incubation. The
effect on the mitochondrial superoxide content by pazopanib was
clearly lower as compared to the other TKIs (Figure 6A).
Accumulating reactive oxygen species (ROS) can be degraded by
the glutathione antioxidant system, which is a scavenger offree radi-
cals (Fernandez ‐Checa & Kaplowitz, 2005; Schafer & Buettner,
2001). Accordingly, we observed GSH depletion starting at 10 μM for
dasatinib and sorafenib (Figure 6C,D), at 20 μM for ponatinib and rego-
rafenib (Figure 6D) and at 50 μM for crizotinib (Figure 6C). Pazopanib
did not reduce total GSH content at the concentrations tested in the
experiment (Figure 6C).
3.6 | Glycolysis in HepG2 cells
In the presence of glucose, HepG2 cells can produce ATP also by glycol-
ysis. To investigate the effect of the TKIs on glycolysis, we determined
the glycolytic flux via quantification of the conversion of [ 3 H]glucose
to 3 H2O (Figure 7). Glycolysis was inhibited starting at 2 μM with rego-
rafenib, at 10 μM with sorafenib, at 50 μM with ponatinib (Figure 7B) and
starting at 50 μM with dasatinib (Figure 7A). Pazopanib inhibited glycol-
ysis at 20 μM, but not at 50 μM and crizotinib did not affect the glycolytic
flux at the concentrations tested in the experiment (Figure 7A).
3.7 | Mechanisms of cell death in HepG2 cells
Impairment of mitochondrial function can be associated with cell
destruction by apoptosis and/or necrosis (Green & Reed, 1998).
Activation of caspase 3 is a key event in apoptosis and, together with
cleavage of PARP, a reliable indicator of apoptosis (Bonifacio et al.,
2016). Sorafenib and pazopanib were associated with a concentra-
tion‐dependent increase in caspase 3 activation and in cleavage of
PARP but without reaching statistical significance (Figures 8A,B).
Crizotinib was associated with a significant increase in caspase 3
activation and PARP cleavage starting at 20 μM and dasatinib at 50 μM
(Figure 8A,B). Ponatinib was associated with a strong increase in cas-
pase 3 activation and PARP cleavage starting at 5 μM and regorafenib
with caspase 3 activation starting at 5 μM.
In addition, the annexin V/propidium iodide assay was used to dif-
ferentiate between apoptosis and necrosis (Figure 8C). Crizotinib
induced apoptosis starting at 10 μM and dasatinib and pazopanib
starting at 20 μM. Ponatinib and regorafenib showed apoptosis starting
at 5 μM. Sorafenib caused apoptosis starting at 5 μM and necrosis
starting at 10 μM.
4 | DISCUSSION
We investigated hepatocellular toxicity of six TKIs, which have been
reported to cause liver injury in patients. In HepG2 cells, regorafenib
and sorafenib strongly inhibited mitochondrial oxidative metabolism
and glycolysis, and induced apoptosis and/or necrosis of HepG2 cells.
Ponatinib inhibited mitochondrial oxidative metabolism as potently as
regorafenib but only weakly glycolysis and induced apoptosis of
HepG2 cells. Crizotinib and dasatinib did not affect mitochondrial res-
piration and only weakly glycolysis but induced apoptosis of HepG2
cells. Pazopanib did not affect mitochondrial respiration, inhibited gly-
colysis only weakly and was not cytotoxic.
Regorafenib and sorafenib were overall the most potent mito-
chondrial toxicants of the compounds investigated, which is in agree-
ment with the recent study of Zhang et al. (2017). Both compounds
were membrane ‐toxic and decreased the cellular ATP content at
clearly lower concentrations in the presence of galactose than with
glucose. This has been proposed to be an important marker for mito-
chondrial toxicity (Kamalian et al., 2015; Marroquin et al., 2007). Inter-
estingly, ponatinib inhibited mitochondrial respiration as potently as
regorafenib, but depleted the cellular ATP content less potently under
galactose than under glucose conditions. On the other hand, also crizo-
tinib, dasatinib and pazopanib depleted the cellular ATP content less
potently under galactose than under glucose conditions, but did not
significantly affect mitochondrial respiration. These results suggest
that more potent ATP depletion under galactose than under glucose
conditions is a good parameter for confirming mitochondrial toxicity
of a compound, but may be less well suited for excluding mitochondrial
toxicity. This is an important point that should be studied with a larger
set of well characterized compounds. If true, it would lower the value
of the cellular ATP pool under galactose and glucose conditions as a
screening tool for mitochondrial toxicity.
In agreement with increased toxicity in the presence of galactose
compared to glucose, regorafenib and sorafenib inhibited oxygen con-
sumption of HepG2 cells in the presence of glutamate/pyruvate and
after the addition of the uncoupler FCCP, compatible with a decreased
function of enzyme complexes I, III and/or IV of the electron transport
FIGURE 4 Effect on mitochondrial membrane potential. Membrane
potential was assessed in HepG2 cells cultured in low glucose
medium by tetramethylrhodamine methyl ester fluorescent staining
after drug exposure for 24 hours. All data are expressed as percentage
of control incubations containing 0.1% DMSO. Data represent the
mean ± SEM of at least three independent experiments. * P < .05 vs.
DMSO control (crizotinib, ponatinib), +P < .05 vs. DMSO control
(dasatinib, regorafenib), xP < .05 vs. DMSO control (pazopanib,
sorafenib). DMSO, dimethyl sulfoxide
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chain. As the difference in basal respiration to oligomycin respiration
was reduced in the presence of TKIs compared to control incubations,
they possibly also uncoupled oxidative phosphorylation. Consequently,
they were associated with a decrease in mitochondrial membrane
potential, an increase in the mitochondrial ROS and a decrease in the
cellular GSH content. The effects on mitochondria were all detectable
at concentrations starting between 1 and 10 μM (Table 2), with inhibi-
tion of the electron transport chain starting at 1 –2 μM. The initial
events appear therefore to be inhibition of the electron transport chain
and uncoupling of oxidative phosphorylation, which are followed by a
drop in the mitochondrial membrane potential, increased mitochon-
drial production of ROS (associated with inhibition of enzyme com-
plexes I and/or III of the electron transport chain; Balaban, Nemoto,
& Finkel, 2005), and a drop in the cellular GSH content. A consequence
of these events is the opening of the mitochondrial permeability tran-
sition pore with the release of cytochrome c from the intermembrane
space into the cytosol, which activates the apoptosis pathway. In the
current study, we showed cleavage of caspase 3 and/or PARP, which
are distal events in the apoptosis pathway, for all compounds except
pazopanib and sorafenib and stimulation of apoptosis for all
compounds investigated (Figure 8). Sorafenib and regorafenib
inhibited also glycolysis at low concentrations (Table 2). This dual inhi-
bition of ATP synthesis, mitochondrial toxicity and inhibition of glycol-
ysis, is a likely explanation for the strong effect on the ATP pool in
HepG2 cells by these two compounds.
For sorafenib, it was already known that it could induce ROS accu-
mulation and GSH depletion in HepG2 cells (Chiou et al., 2009). The
reason for the increased mitochondrial ROS concentrations was so
far not known. The current study suggests that the increased ROS con-
centrations are associated with impairment of the activity of the mito-
chondrial electron transport chain (Balaban et al., 2005). Zhang et al.
reported inhibition of mitochondrial respiration in the presence of suc-
cinate, inhibition of complex V and uncoupling of oxidative phosphor-
ylation (Zhang et al., 2017), which is in agreement with our findings. In
clinical studies, sorafenib reached maximal concentrations of approxi-
mately 6.5 μM (Herbrink et al., 2016), which is in the range where we
started to observe mitochondrial toxicity. As liver concentrations may
even be higher for TKIs than plasma concentrations (He et al., 2008;
Lau et al., 2015; Spector et al., 2015), patients treated with sorafenib
may be at risk for liver injury.
FIGURE 5 Mitochondrial respiration in HepG2 cells. HepG2 cells were cultured in low glucose medium. Basal, leak, ATP ‐linked and maximal
respiration after exposure to crizotinib (A), dasatinib (B), pazopanib (C), ponatinib (D), regorafenib (E) and sorafenib (F) for 24 hours. Data
represent the mean ± SEM of at least three independent experiments. * P < .05 vs. DMSO control. DMSO, dimethyl sulfoxide; FCCP, carbonyl
cyanide‐4 ‐(trifluoromethoxy)phenylhydrazone; OCR, oxygen consumption rate; resp., respiration
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Regarding regorafenib, toxic effects have been described in iso-
lated rat liver mitochondria and in primary rat hepatocytes. In these
studies, regorafenib inhibited mitochondrial respiration in the presence
of malate/glutamate, uncoupled oxidative phosphorylation ofisolated
mitochondria and induced mitochondrial swelling by mitochondrial
permeability transition (Weng et al., 2015; Zhang et al., 2017). In pri-
mary rat hepatocytes, regorafenib uncoupled oxidative phosphoryla-
tion, reduced the mitochondrial membrane potential, decreased the
cellular ATP and induced necrosis at concentrations between 2.5 and
15 μM (Weng et al., 2015). These data are in close agreement with
the findings obtained by us, with the exception that we observed apo-
ptosis and not necrosis. This difference may be related to the different
models used. As apoptosis is dependent on ATP (Green & Reed, 1998),
it is possible that the cellular ATP content dropped more rapidly in
primary rat hepatocytes than in the HepG2 cells used by us.
In clinical studies, regorafenib reached plasma concentrations in
the range of 5 μM after a single oral therapeutic dose and approxi-
mately 10 μM under steady ‐state conditions (Shirley & Keating,
2015). These are the concentrations where we started to observe
hepatocellular toxicity. Similar to sorafenib, patients treated with rego-
rafenib may be at risk for liver injury. Taking into account that CYP3A4
is the most important CYP for the metabolism of TKIs (Table 2) and
that hepatocellular toxicity of TKIs was concentration ‐dependent,
patients treated with sorafenib or regorafenib that have a low CYP3A4
activity, e.g., due to co ‐medication with CYP3A4 inhibitors (Teo et al.,
2015), may be at increased risk for hepatotoxicity. In addition,
regarding the mitochondrial toxicity of sorafenib and regorafenib,
patients with pre ‐existing mitochondrial dysfunction may also be at
an increased risk for toxicity. This has, for instance, been described
for valproate (Krahenbuhl, Brandner, Kleinle, Liechti, & Straumann,
2000), in whom an impaired activity of the mitochondrial DNA
polymerase gamma (POLG) is a risk factor for liver failure (Stewart
et al., 2010).
Ponatinib depleted the cellular ATP stores at lower concentrations
in the presence of glucose than galactose, but was membrane ‐toxic at
lower concentrations in the presence of galactose compared to
FIGURE 6 Mitochondrial reactive oxygen species concentration and cellular GSH content. (A,B) Mitochondrial reactive oxygen species
concentration in HepG2 cells cultured in low glucose medium after drug exposure for 24 hours. (C, D) tGSH content in HepG2 cells with low
glucose medium after drug exposure for 24 hours. All data are expressed as fold change to control incubations containing 0.1% DMSO. Data
represent the mean ± SEM of at least three independent experiments. * P < .05 vs. DMSO control (crizotinib, ponatinib), +P < .05 vs. DMSO control
(dasatinib, regorafenib), xP < .05 vs. DMSO control (pazopanib, sorafenib). DMSO, dimethyl sulfoxide; tGSH, total glutathione
FIGURE 7 Glycolysis in HepG2 cells cultured in low glucose medium
after drug exposure for 24 hours. All data are expressed as
percentage of control incubations containing 0.1% DMSO. Rate of
glycolysis for the control incubations was 24.5 ± 1.7 nmol h –1 10 –6
cells (mean ± SEM, n = 35 control incubations). Data represent the
mean ± SEM of at least three independent experiments. * P < .05 vs.
DMSO control (crizotinib, ponatinib), +P < .05 vs. DMSO control
(dasatinib, regorafenib), xP < .05 vs. DMSO control (pazopanib,
sorafenib). DMSO, dimethyl sulfoxide
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glucose (Table 1). Inhibition of glycolysis occurred at clearly higher con-
centrations (starting at 50 μM) than ATP depletion and may therefore
not be relevant for hepatic toxicity of this compound. In the current
study, ponatinib impaired mitochondrial oxidative metabolism starting
at 2 μM. This finding contrasts with the report of Zhang et al. (2017),
who found no mitochondrial toxicity in isolated rat liver mitochondria.
This discrepancy may be explained by the species difference (human
vs. rat) and/or by the different mitochondrial preparations (perme-
abilized cells vs. isolated mitochondria). Typical plasma steady ‐state
concentrations reached with ponatinib are around 0.1 μM (Huynh
et al., 2017), which is approximately 20 times lower than the lowest
concentration associated with inhibition of mitochondrial respiration
in HepG2 cells. Taking into account the findings in animals that the
concentration of TKIs in the liver can be 10 –20 times higher than in
blood (He et al., 2008 ), it appears nevertheless possible that toxic
concentrations can be reached in livers of certain patients.
For crizotinib and desatinib, membrane toxicity and ATP depletion
were not accentuated when glucose was replaced by galactose,
suggesting primarily a non‐mitochondrial mechanism of toxicity. Both
compounds started to induce apoptosis at concentrations in the range
10–20 μM, which, based on our data, was probably not associated with
a mitochondrial mechanism. Typical plasma steady ‐state concentra-
tions reached are 1.9 μM for crizotinib (Kurata et al., 2015) and
0.2 μM for dasatinib (Huynh et al., 2017), which is clearly below the
concentrations where we started to observe cytotoxicity. This
suggests a non‐mitochondrial mechanism of hepatotoxicity for these
compounds.
Pazopanib was not associated with relevant membrane toxicity or
ATP depletion and did not impair mitochondrial respiration in HepG2
cells up to 50 μM, suggesting a non‐mitochondrial mechanism of
hepatotoxicity. It has to be taken into account, however, that very
high exposures can be reached with this compound in humans
-
FIGURE 8 Assessment of apoptosis in HepG2 cells with low glucose medium. (A) Western blot analysis of the expression of active (cleaved) to pro ‐
caspase 3 . (B) Western blot analysis of the expression offull length to cleaved PARP. (C) Apoptosis and necrosis in HepG2 cells after drug exposure
for 24 hours assessed by annexin V/propidium iodide. All data are expressed as fold change to control incubations containing 0.1% DMSO. Data
represent the mean ± SEM of at least three independent experiments. * P < .05 vs. DMSO control. DMSO, dimethyl sulfoxide; PARP, poly ADP
ribose polymerase
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(maximal plasma concentrations up to 100 μM; Herbrink et al., 2016),
for which reason exposure ‐dependent toxicity cannot be completely
excluded.
As reported in a review article (Shah et al., 2013) and in a meta ‐
analysis (Teo et al., 2013), all TKIs investigated in the current study
are associated with liver injury, which is asymptomatic in most
patients. Liver failure is rare, but most case reports can be found for
regorafenib and sorafenib, the most accentuated mitochondrial toxi-
cants and inhibitors of glycolysis in the current study. It is possible that
the accentuated ATP depletion observed in vitro with these drugs is
also clinically relevant in susceptible patients. We did not find a clear
relationship between the dominant TK inhibited and hepatocellular
toxicity of the compounds tested. Although regorafenib and sorafenib,
the most toxic of the TKIs investigated, are both vascular endothelial
growth factor ‐specific multi ‐kinase inhibitors, this is also the case for
pazopanib, which was almost not toxic. We therefore postulate
off ‐target effects unrelated to the pharmacological activity of the
drugs investigated.
Mitochondrial toxicity associated with TKIs is not limited to the
liver, but can affect also other organs. For instance, different TKIs have
been shown to be toxic on isolated rat heart mitochondria (Will et al.,
2008) and mitochondrial toxicity was observed in humans and mice
treated with imatinib (Kerkela et al., 2006). Many of the toxicities
observed in patients treated with these drugs may therefore result
from mitochondrial dysfunction.
In conclusion, regorafenib and sorafenib were strong mitochon-
drial toxicants at concentrations that can be reached in the plasma
and liver of patients treated with these drugs. In addition, they also
inhibited glycolysis, which may enhance their hepatotoxicity. Ponatinib
impaired mitochondrial functions and glycolysis at higher concentra-
tions than reached in plasma in patients but such concentrations may
be reached in the liver. In comparison, crizotinib, dasatinib and
pazotinib showed no relevant mitochondrial toxicity or inhibition of
glycolysis in the concentration range investigated. For these drugs, so
far undefined, non ‐mitochondrial mechanisms have to be postulated.
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Supplementary Fig. S1. Representative scheme of the Seahorse XF24 Analyzer 
experiment. HepG2 cells (100 000 cells/well) in DMEM growth medium were allowed to 
adhere overnight and then treated with the test compounds for 24 h. Before the experiment, 
the medium was replaced with 750 µl unbuffered DMEM medium (4mM L-glutamate, 1 mM 
pyruvate, 1 g/l glucose, 63.3 mM sodium chloride, pH 7.4). After determination of the basal 
oxygen consumption (OCR), 1 µM oligomycin (inhibitor of the F0F1-ATPase) was added for 
the determination of the proton leak and the ATP-linked respiration. Afterwards, 2 µM FCCP 
(mitochondrial uncoupler) was added for maximal stimulation of the mitochondrial electron 
transport chain. Finally, the extramitochondrial respiration was estimated after the addition of 
complex I inhibitor rotenone (1 µM). For the determination of the basal respiration, the 
oxidative leak, and the maximum respiration, the extramitochondrial respiration was 
subtracted. 
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MECHANISMS OF MITOCHONDRIAL TOXICITY OF THE KINASE 
INHIBITORS PONATINIB, REGORAFENIB AND SORAFENIB IN 
HUMAN HEPATIC HEPG2 CELLS 
 
 
Within this article, we will better characterize the mechanisms underlying the mitochondrial 
impairement observed with pozopanib, regorafenib, and sorafenib in more detail in vitro. 
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A B S T R A C T
Previous studies have shown that certain kinase inhibitors are mitochondrial toxicants. In the current in-
vestigation, we determined the mechanisms of mitochondrial impairment by the kinase inhibitors ponatinib,
regorafenib, and sorafenib in more detail. In HepG2 cells cultured in galactose and exposed for 24 h, all three
kinase inhibitors investigated depleted the cellular ATP pools at lower concentrations than cytotoxicity occurred,
compatible with mitochondrial toxicity. The kinase inhibitors impaired the activity of diﬀerent complexes of the
respiratory chain in HepG2 cells exposed to the toxicants for 24 h and in isolated mouse liver mitochondria
exposed acutely. As a consequence, they increased mitochondrial production of ROS in HepG2 cells in a time-
and concentration-dependent fashion and decreased the mitochondrial membrane potential concentration-de-
pendently. In HepG2 cells exposed for 24 h, they induced mitochondrial fragmentation, lysosome content and
mitophagy as well as mitochondrial release of cytochrome c, leading to apoptosis and/or necrosis. In conclusion,
the kinase inhibitors ponatinib, regorafenib, and sorafenib impaired the function of the respiratory chain, which
was associated with increased ROS production and a drop in the mitochondrial membrane potential. Despite
activation of defense measures such as mitochondrial ﬁssion and mitophagy, some cells were liquidated con-
centration-dependently by apoptosis or necrosis. Mitochondrial dysfunction may represent a toxicological me-
chanism of hepatotoxicity associated with certain kinase inhibitors.
1. Introduction
Tyrosine kinases are important enzymes involved in a variety of
biological processes, including cell proliferation, survival, and diﬀer-
entiation (Shah et al., 2013; Shchemelinin et al., 2006). Due to their
role in cell proliferation, expression of defective tyrosine kinases is in-
volved in tumor initiation and progression (Shchemelinin et al., 2006)
and dysregulation of tyrosine kinase expression can be associated with
cancer development (Levitzki and Gazit, 1995). This role of tyrosine
kinases in cancerogenesis has led to the development of a new class of
anticancer drugs, the tyrosine kinase inhibitors (Krause and Van Etten,
2005). Most of them inhibit more than one kinase and are called mul-
tikinase inhibitors (MKIs).
Compared to classical cytotoxic agents, the hepatotoxicity of MKIs is
generally less pronounced, but MKIs are associated for instance with
toxicity of the skin, the intestine, the heart, and the liver (Breccia and
Alimena, 2013). Hepatotoxicity has been reported for several MKIs,
including ponatinib, regorafenib, and sorafenib (Josephs et al., 2013;
Shah et al., 2013; Spraggs et al., 2013). Clinical trials indicated a low
grade elevation in alanine aminotransferase (ALT) and/or aspartate
aminotransferase (AST) in 25–30% and a high grade elevation ( > 5
times upper limit of normal) in approximately 2% of patients treated
with MKIs (Shah et al., 2013). A recent meta-analysis including more
than 18,000 patients demonstrated an elevated risk of hepatotoxicity
associated with tyrosine kinase inhibitors (Ghatalia et al., 2015) with
an incidence of hepatic failure of 0.8%. Fatalities are fortunately rare,
but have been reported for several MKIs including pazopanib
(Klempner et al., 2012) and regorafenib (Mir et al., 2016).
The exact mechanism of MKI-induced hepatotoxicity has not been
completely elucidated; however, it may be related to mitochondrial
https://doi.org/10.1016/j.tox.2018.01.005
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damage. Recent publications suggest hepatic mitochondrial toxicity for
dasatinib (Xue et al., 2012), lapatenib (Eno et al., 2016), and regor-
afenib (Weng et al., 2015; Zhang et al., 2017), and sorafenib and pa-
zopanib (Zhang et al., 2017). Our group has shown recently in HepG2
cells that exposure to imatinib or sunitinib reduced the mitochondrial
membrane potential, and was associated with impaired oxygen con-
sumption and mitochondrial oxidative stress (Paech et al., 2017a). In a
second recent publication, we reported that regorafenib, ponatinib and
sorafenib inhibited mitochondrial oxidative metabolism and glycolysis,
and induced apoptosis and/or necrosis of HepG2 cells at concentrations
reachable in humans (Mingard et al., 2017). Importantly, MKIs cannot
only damage hepatic mitochondria, but have also been described to be
toxic for cardiac mitochondria, supporting the notion that MKIs are
mitochondrial toxicants (Kerkela et al., 2006; Will et al., 2008).
Mitochondria are dynamic organelles, which have diﬀerent possi-
bilities to react after a toxic insult. A decrease in the mitochondrial
membrane potential is associated with mitochondrial ﬁssion, with the
aim to separate the defective and the functioning parts of the mi-
tochondria (Westermann, 2010). Fission is initiated by recruitment of
the dynamin-related protein 1 (DRP1) to the outer mitochondrial
membrane by mitochondrial ﬁssion 1 (FIS1) (Palmer et al., 2011). After
ﬁssion, the mitochondrial network has a fragmented appearance and
the defective mitochondrial fragments can undergo mitophagy, which
can be regarded as a protective process to remove damaged mi-
tochondria (Ding and Yin, 2012). If the toxic insult is too pronounced,
mitochondrial repair by ﬁssion and mitophagy is impossible and cells
either undergo necrosis when the cellular ATP level is low or apoptosis,
which is ATP-dependent. The induction of cell death can be initiated by
release of cytochrome c out of damaged mitochondria into the cyto-
plasm (Green and Reed, 1998).
Based on these considerations, the aim of the current study was to
investigate in more detail the mechanisms underlying the mitochon-
drial toxicity of ponatinib, regorafenib, and sorafenib in HepG2 cells.
We determined the cellular ATP content and mitochondrial reactive
oxygen species (ROS) production using a medium containing galactose,
since HepG2 cells grown in galactose generate ATP mainly in mi-
tochondria and are sensitive to mitochondrial toxicants (Brecht et al.,
2017; Kamalian et al., 2015). In addition, we also determined the ef-
fects of the toxicants on the activity of the individual enzyme complexes
of the mitochondrial electron transport chain and on the consequences
resulting from impaired activity of these enzyme complexes, in parti-
cular on mitochondrial ﬁssion, mitophagy, and cell death.
2. Materials and methods
2.1. Chemicals
Ponatinib, regorafenib, and sorafenib were purchased from Sequoia
research products (Pangbourne, UK). We prepared stock solutions in
dimethylsulfoxide (DMSO) and stored them at −20 °C. All other che-
micals were supplied by Sigma-Aldrich (Buchs, Switzerland), except
where indicated.
2.2. HepG2 cell culture
The human hepatocellular carcinoma cell line HepG2 was obtained
from the American type culture collection (ATCC, Manassas, VA, USA).
HepG2 cells were cultured under two diﬀerent conditions, low glucose
and galactose.
HepG2 cells under low glucose conditions were cultured in
Dulbecco’s Modiﬁed Eagle Medium (DMEM containing 5.55mM (1 g/l)
glucose, 4 mM L-glutamine, and 1mM pyruvate from Invitrogen, Basel,
Switzerland) supplemented with 10% (v/v) heat-inactivated fetal bo-
vine serum (FBS), 2 mM GlutaMax, 10mM HEPES buﬀer, 10mM non-
essential amino acids, 100 units/ml penicillin, and 100 μg/ml strepto-
mycin.
HepG2 cells under galactose conditions were ﬁrst cultured in low
glucose medium. On the day of the experiment, HepG2 cells were
centrifuged, the supernatant was removed and cells were resuspended
in galactose medium (Dulbecco’s Modiﬁed Eagle Medium (DMEM, no
glucose, 4 mM L-glutamine) from Invitrogen (Basel, Switzerland) sup-
plemented with 10% (v/v) heat-inactivated FBS, 10mM galactose,
2 mM L-glutamine, 10mM HEPES buﬀer, 1 mM sodium pyruvate, 100
units/ml penicillin, and 100 μg/ml streptomycin) for 4 h or 24 h before
starting the treatment (Swiss and Will, 2011). The FBS was dialyzed
through a Slide-A-Lyzer Dialysis Flask (Thermo Scientiﬁc, Reinach,
Switzerland) to remove glucose according to the manufacturer’s pro-
tocol. All experiments were performed under glucose medium except
the release of adenylate kinase, the intracellular ATP content and the
mitochondrial superoxide accumulation, which were performed under
galactose medium.
All cells were kept at 37 °C in a humidiﬁed 5% CO2 cell culture
incubator and passaged using trypsin. The cell number was determined
using a Neubauer hemacytometer and viability was checked using the
trypan blue exclusion method.
2.3. Isolation of mouse liver mitochondria
The experiments were performed in accordance with the institu-
tional guidelines for the care and use of laboratory animals. Male
C57BL/6J mice (n=3, age 7–10 weeks) were purchased from Charles
River Laboratories (Sutzfeld, Germany) and housed in a standard fa-
cility with 12 h light–dark cycles and controlled temperature
(21–22 °C). The mice were fed a standard pellet chow and water ad
libitum.
Liver mitochondria were isolated by diﬀerential centrifugation as
described before (Hoppel et al., 1979). The mitochondrial protein
content was determined using the Pierce BCA protein assay kit from
Merck (Zug, Switzerland).
2.4. Membrane toxicity
Membrane toxicity was assessed by using the ToxiLight assay from
Lonza (Basel, Switzerland) according to the manufacturer’s protocol.
This assay measures the release of adenylate kinase (AK) in the
medium, which reﬂects the plasma membrane’s integrity. HepG2 cells
in galactose conditions were grown in a 96-well plate (25′000 cells/
well) and exposed to diﬀerent concentrations of MKIs (5–50 μM) for
24 h. The plasma concentrations of ponatinib, regorafenib and sor-
afenib are in the range of 0.1, 2.5 and 5 to 10 μM, respectively
(Herbrink et al., 2016; Huynh et al., 2017; Sunakawa et al., 2014).
Since the liver concentration of MKIs can be considerably higher than
the plasma concentrations (Lau et al., 2015), it can be assumed that at
least the lowest concentrations used can be reached in the liver in vivo.
The negative control was 0.1% DMSO and the positive control was
0.5% Triton-X. After incubation, 20 μL supernatant of each well was
transferred to a new 96-well plate. Then, 50 μL of assay buﬀer was
added to each well. After incubation in the dark for 5min, the lumi-
nescence was measured using a Tecan M200 Pro Inﬁnity plate reader
(Männedorf, Switzerland). All data were normalized to positive control
incubations containing 0.5% Triton X (set at 100% cell lysis).
2.5. Intracellular ATP content
The intracellular ATP content was measured using the CellTiter-Glo
kit from Promega (Wallisellen, Switzerland) according to the manu-
facturer’s protocol. HepG2 cells in galactose conditions were grown in a
96-well plate (25,000 cells/well) and exposed to diﬀerent concentra-
tions of MKI (5–50 μM) for 24 h. The negative control was 0.1% DMSO
and the positive control was 0.5% Triton-X. After treatment, medium
was removed in order to have 50 μL remaining in each well and after-
wards 50 μL of assay buﬀer was added to each well. After incubation in
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the dark for 15min, the luminescence was measured using a Tecan
M200 Pro Inﬁnity plate reader (Männedorf, Switzerland). All data were
normalized to control incubations containing 0.1% DMSO.
2.6. Activity of speciﬁc enzyme complexes of the mitochondrial electron
transport chain
The activity of speciﬁc enzyme complexes of the respiratory chain
was analyzed using an Oxygraph-2k high-resolution respirometer
equipped with DataLab software (Oroboros instruments, Innsbruck,
Austria) as described previously (Paech et al., 2017b). HepG2 cells
under low glucose conditions were treated with test compounds
(1–10 μM) for 24 h. Afterwards, they were suspended in MiR05 (mi-
tochondrial respiration medium containing 0.5 mM EGTA, 3mM mag-
nesium chloride, 20mM taurine, 10mM potassium dihydrogen phos-
phate, 20mM HEPES, 110mM sucrose, 1 g/l fatty-acid free bovine
serum albumin, and 60mM lactobionic acid, pH 7.1) and transferred to
the pre-calibrated Oxygraph chamber (Pesta and Gnaiger, 2012).
Respiratory capacities through complexes I, II, III, and IV were as-
sessed in HepG2 cells permeabilized with digitonin (10 μg/1 million
cells). Complexes I and III were analyzed using L-glutamate/malate (10
and 2mM, respectively) as substrates followed by the addition of ade-
nosine-diphosphate (ADP; 2.5 mM). Then, the oxidative leak, a marker
for uncoupling, was identiﬁed by the assessment of the residual oxygen
consumption after addition of oligomycin (1 μM). After that, we de-
termined the maximal oxidative capacity in the presence of L-gluta-
mate/malate with the addition of FCCP (1 μM) followed by inhibition of
complex I with rotenone (0.5 μM). Afterwards, duroquinol (500 μM)
was added to investigate complex III activity.
Complexes II and IV were analyzed using succinate/rotenone
(10mM and 0.5 μM, respectively) as substrates followed by the addition
of ADP (2.5mM). The oxidative leak was identiﬁed by the assessment of
the residual oxygen consumption after addition of oligomycin (1 μM),
followed by the addition of FCCP (1 μM) in order to evaluate the un-
coupling capacity. After this, the inhibitor antimycin A (2.5 μM) was
added to block complex III. Subsequently, N,N,N’,N’-tetramethyl-1,4-
phenylendiamine/ascorbate (0.5 and 2mM, respectively) were added
to investigate complex IV.
The integrity of the outer mitochondrial membrane was conﬁrmed
by the absence of a stimulatory eﬀect of exogenous cytochrome c
(10 μM) on respiration. Respiration was expressed as pmol O2 per
second per mg protein. Protein concentrations were determined using
the Pierce BCA protein assay kit from Merck (Zug, Switzerland).
2.7. Activity of enzyme complexes of the electron transport chain in isolated
mitochondria
The individual activities of mitochondrial enzyme complexes (I–IV)
were assessed by well-established spectrophotometric methods
(Krahenbuhl et al., 1991; Krahenbuhl et al., 1994) in isolated mouse
liver mitochondria, which had been kept frozen at −80 °C.
Brieﬂy, for complex I, we used the conversion of NADH to NAD
using decylubiquinone as an electron acceptor monitoring at 340 nm.
The activity of complex II was based on the conversion of oxidized
dichloroindophenol to its reduced form at 600 nm using succinate as
substrate. For complex III, we used decylubiquinol as a substrate and
determined the conversion of ferricytochrome c to ferrocytochrome c at
550 nm. For complex IV, we followed the conversion of ferrocyto-
chrome c to ferricytochrome c at 550 nm using ubiquinole as substrate.
The activity of the respective enzyme complexes was determined as the
diﬀerence in the presence of speciﬁc inhibitors (rotenone for complex I,
thenoyltriﬂuroacetone for complex II, antimycin A for complex III, and
sodium azide for complex IV).
The activitiy of mitochondrial enzyme complex V was assessed in
freshly-isolated mouse liver mitochondria using an Oxygraph-2k high-
resolution respirometer equipped with DataLab software (Oroboros
instruments, Innsbruck, Austria). Freshly-isolated mouse liver mi-
tochondria were suspended in MiR06 (mitochondrial respiration
medium containing 0.5 mM EGTA, 3mM magnesium chloride, 20mM
taurine, 10mM potassium dihydrogen phosphate, 20mM HEPES,
110mM sucrose, 1 g/L fatty-acid free bovine serum albumin, 60mM
lactobionic acid, and 280 units/ml catalase, pH 7.1) and 250 μg mi-
tochondria were transferred to the pre-calibrated Oxygraph chamber
and treated for 15min with drugs. The respiratory capacity through
complex V was analyzed using adenosine-diphosphate (ADP; 2.5 mM)
followed by N,N,N’,N’-tetramethyl-1,4-phenylendiamine/ascorbate (0.5
and 2mM, respectively). Afterwards, complex V was inhibited by ad-
dition of oligomycin (2 μg/ml). Activity of complex V was calculated by
the diﬀerence of both states. The activity of each complex was ex-
pressed as nmol per minute per mg protein.
2.8. Mitochondrial superoxide accumulation
Mitochondrial superoxide accumulation was measured using the
MitoSOX Red ﬂuorophore probe from Invitrogen (Basel, Switzerland),
according to the manufacturer’s manual. The MitoSOX Red mitochon-
drial superoxide indicator is a ﬂuorogenic dye for highly selective de-
tection of superoxide in the mitochondria of living cells. HepG2 cells
kept under galactose condition were seeded in 96-well plates (25,000
cells/well) and treated with test compounds (5–50 μM) for 24 h. The
negative control was 0.1% DMSO and the positive control was 50 μM
amiodarone. Afterwards, 100 μL phosphate buﬀered saline (PBS) with
2.5 μMMitoSOX was added to each 96-well. After incubation at 37 °C in
the dark for 10min, the ﬂuorescence was measured using a Tecan M200
Pro Inﬁnity plate reader (Männedorf, Switzerland) with an excitation at
510 nm and an emission at 580 nm. We normalized the results to the
protein content using Pierce BCA Protein Assay Kit from Thermo Fisher
Scientiﬁc (Waltham, MA, USA).
2.9. Western blotting
HepG2 cells kept under low glucose condition were seeded in 6
well-plate (500′000 cells/well) and treated with diﬀerent concentra-
tions of MKIs (2–20 μM) for 24 h. The negative control was 0.1% DMSO.
Afterwards, HepG2 cells were lysed with RIPA buﬀer (150mM sodium
chloride, 1.0% NP-40, 0.5% sodium deoxycholate, 0.1% sodium do-
decyl sulphate, 50mM Tris, pH 8.0) containing complete Mini protease
inhibitor cocktail (Roche Diagnostics, Mannheim, Germany). After
centrifugation, the supernatant was collected and stored at −80 °C.
Proteins were resolved by SDS-PAGE using commercially available
4–12% NuPAGE Bis-Tris gels (Invitrogen, Basel, Switzerland) and
transferred using the Trans-Blot Turbo Blotting System (Bio-Rad,
Cressier, Switzerland). The membranes were incubated with Anti-SOD2
antibody (ab16956, Abcam, Cambridge, UK), Anti-OPA1 antibody
(ab157457, Abcam, Cambridge, UK), Anti-TTC11 antibody (ab71498,
Abcam, Cambridge, UK), Anti-MAP1LC3A antibody (ab168803, Abcam,
Cambridge, UK), Anti-Bcl2 antibody (ab692, Abcam, Cambridge, UK),
Caspase-3 antibody (8G10, Cell Signaling Technology, Danvers, USA),
and GAPDH (sc-365062, Santa Cruz Biotechnology, Dallas, USA) anti-
bodies. After washing, membranes were exposed to secondary anti-
bodies (Santa Cruz Biotechnology, Dallas, USA). Immunoblots were
developed using Clarity Western ECL Substrate (Bio-Rad Laboratories,
Hercules, USA). Protein expression was quantiﬁed using the Fusion
Pulse TS device (Vilber Lourmat, Oberschwaben, Germany).
2.10. Mitochondrial membrane potential
Mitochondrial membrane potential (Δψm) in HepG2 cells kept under
low glucose conditions was determined using tetramethylrhodamine
methyl ester (TMRM, Invitrogen, Basel, Switzerland). TMRM is a ca-
tionic ﬂuorescent probe that accumulates within mitochondria de-
pending on their Δψm. HepG2 cells were seeded in 24-well plates
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(200,000 cells/well) and treated with diﬀerent concentrations of MKIs
(2–50 μM) for 24 h. The negative control was 0.1% DMSO and the po-
sitive control carbonyl cyanide-4-(triﬂuoromethoxy)phenylhydrazone
(FCCP, 9 μM). FCCP is an uncoupler of mitochondrial oxidative phos-
phorylation and therefore decreases Δψm. FCCP was added to the cells
and ten minutes later, cells were washed with PBS and suspended in
PBS with 100 nM TMRM. After 15min incubation in the dark, cells
were centrifuged and resuspended in PBS for analyzing them with ﬂow
cytometry using a FACSCalibur (BD Bioscience, Allschwil, Switzerland).
FlowJo software v10.0.8 (FlowJo, LCC, Ashland, OR, USA) was used to
analyze the data.
2.11. Fission, mitophagy and apoptosis determined by microscopy
HepG2 cells under low glucose conditions were seeded in 8 well μ-
Slide (ibidi, Martinsried, Germany) and treated with MKIs for 24 h at
the concentrations indicated in the respective ﬁgures. Afterwards, cells
were stained with 75 nM mitotracker (Thermo Fisher Scientiﬁc,
Waltham, MA, USA), 50 nM lysotracker (Thermo Fisher Scientiﬁc,
Waltham, MA, USA) and 1.8 μM Hoechst 33258 for 1 h. After staining,
cells were washed twice with PBS and mounted with antifade-mounting
medium (Thermo Fisher Scientiﬁc, Waltham, MA, USA). Cells were
imaged on an Olympus IX83 microscope with a magniﬁcation of 100×
(Olympus, Shinjuku, Japan).
2.12. Quantiﬁcation of cytochrome c in cytoplasm
For the quantiﬁcation of cytochrome c, cytoplasm and mitochondria
were separated using a Mitochondrial/Cytosol Fractionation Kit
(ab65320, Abcam, Cambridge, UK). Afterwards, the cytochrome c
content in the cytosolic fraction was quantiﬁed by western blotting
using Anti-cytochrome C antibody (ab133504, Abcam, Cambridge, UK).
2.13. Annexin V/Propidium iodide
To study the mechanisms of cell death, we used the FITC Annexin
V/Dead Cell Apoptosis Kit from Invitrogen (Basel, Switzerland) ac-
cording to the manufacturer’s protocol. HepG2 cells kept under low
glucose conditions were seeded in 24-well plates (200,000 cells/well)
and treated with diﬀerent concentrations of MKIs (5–10 μM) for 24 h.
The negative control was 0.1% DMSO. Positive controls were 200 nM
staurosporin for apoptosis and 50 μM amiodarone for necrosis. The cells
were then analyzed with a FACSCalibur (BD Bioscience, Allschwill,
Switzerland) channel FL-1 and FL-3. FlowJo software v10.0.8 was used
to analyze the data.
2.14. Statistical analysis
Data are given as the mean ± standard error of the mean (SEM) of
at least three experiments in triplicates. Statistical analyses were per-
formed using GraphPad Prism 6 (GraphPad Software, La Jolla, CA,
USA). For the comparison of treatment groups to the 0.1% DMSO
control group, one-way ANOVA was used followed by the Dunnett’s
posttest procedure. P-values< 0.05 (*) were considered signiﬁcant.
3. Results
3.1. Cytotoxicity and ATP content in HepG2 cells
AK release was determined as a marker of membrane toxicity, and
the cellular ATP content as an estimate for mitochondrial function. For
that, HepG2 cells were switched to 10mM galactose medium at least
4 h before starting the treatment (Kamalian et al., 2015). In the pre-
sence of glucose, HepG2 cells can produce ATP not only via oxidative
phosphorylation, but also via glycolysis. By using galactose, cells are
forced to produce ATP mainly via oxidative phosphorylation
(Marroquin et al., 2007). In the presence of galactose, mitochondrial
toxicants deplete therefore the cellular ATP content at lower con-
centrations (Brecht et al., 2017; Kamalian et al., 2015).
The eﬀects of ponatinib, regorafenib, and sorefenib on the in-
tracellular ATP content and on membrane toxicity in HepG2 cells 4 h
after replacement of glucose by galactose are shown in Fig. 1A and B.
All three MKIs investigated decreased the intracellular ATP content and
were membrane toxic in a concentration-dependent manner. In the
presence of ponatinib, almost no ATP was left at 20 μM, while only 20%
of the cells were lysed at this concentration, suggesting that mi-
tochondrial toxicity precedes membrane toxicity. Regorafenib de-
creased the ATP content and was membrane toxic starting (the term
starting reﬂects the lowest concentration at which a signiﬁcant diﬀer-
ence to control incubations was observed) at 5 μM and 20 μM, respec-
tively. Sorafenib was starting to decrease the cellular ATP content at
5 μM and to be membrane toxic at 10 μM. Similar results were obtained
when the medium was changed from glucose to galactose 24 h before
starting the treatment with the toxicants (Supplementary Fig. S1).
These results suggested that ponatinib, regorafenib, and sorafenib
were mitochondrial toxicants. The results are compatible with previous
observations by us in the presence of a low glucose medium (Mingard
et al., 2017).
3.2. Eﬀect on enzyme complexes of the electron transport chain
In order to analyze the mechanism of mitochondrial toxicity in more
detail, we ﬁrst determined the eﬀect of these compounds on the re-
spiratory capacity of HepG2 cells using a high-resolution respirometry
Fig. 1. Intracellular ATP content and cytotoxicity in HepG2 cells with galactose medium. Intracellular ATP content (A) and cytotoxicity (B) were measured after exposure for 24 h with
ponatinib, regorafenib, and sorafenib. HepG2 cells were switched to 10mM galactose medium 4 h before starting the treatment. Data are expressed as the decrease compared to control
incubations containing 0.1% DMSO. The ATP content for the control incubations was 13.4 ± 0.9 nmol/mg protein (mean ± SEM, n=4 control incubations). Cytotoxicity data are
expressed as the percentage of lysed cells with the values obtained for Triton X 0.1% set as 100%. Data represent the mean ± SEM of at least three independent experiments. *p < 0.05
versus DMSO 0.1% control.
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system.
Ponatinib inhibited the enzyme complexes I and II starting at 10 μM
and 2 μM, respectively (Fig. 2A and B), and regorafenib started to in-
hibit the maximal capacity of complex I starting at 2 μM (Fig. 2C and
D). Sorafenib started to inhibit complex I and complex III already at
1 μM (Fig. 2E and F).
3.3. Eﬀect on activity of enzyme complexes of the electron transport chain
in isolated mitochondria
The activity of individual complexes I–IV of the electron transport
chain (ETC) was determined using frozen mouse liver mitochondria; for
complex V, freshly isolated mitochondria were used.
Ponatinib inhibited the activity of complexes I, III, and V of the ETC
starting at 20 μM (Fig. 3A, C, and E). Regorafenib inhibited the activity
of complexes II, III, and V in a dose-dependent fashion starting at 5 μM,
10 μM, and 5 μM, respectively (Fig. 3B, C, and E). The activity of
complexes II, III, IV, and V was decreased with sorafenib starting at
5 μM (Fig. 3B–E).
3.4. Eﬀect on mitochondrial ROS accumulation and SOD2 expression
Toxicants inhibiting the function of the mitochondrial electron
transport chain, especially complexes I and III, can increase mi-
tochondrial production of superoxide (Drose and Brandt, 2012). In the
current study, in HepG2 cells under galactose conditions, we found a
dose- and time-dependent mitochondrial superoxide accumulation for
all three toxicants investigated (Fig. 4A–C). After incubation for 24 h,
mitochondrial ROS accumulation started at 5 μM for ponatinib and at
10 μM for regorafenib and sorafenib. Compared to previous ﬁndings in
low glucose medium and after an incubation for 24 h, mitochondrial
ROS accumulation started at the identical concentration for ponatinib,
but at lower concentrations for regorafenib and sorafenib (10 μM vs.
20 μM) (Mingard et al., 2017).
Accumulating ROS can be degraded by superoxide dismutase (SOD).
SOD2 is located in the mitochondrial matrix (Bresciani et al., 2015).
Fig. 2. Eﬀect on respiratory capacities through complexes I, II, III, and IV measured on the Oxygraph-2k-high-resolution respirometer in HepG2 cells. Activity of complex I and III (A) and
of complex II and III (B) on HepG2 cells cultured with low glucose after ponatinib exposure for 24 h. Activity of complex I and III (C) and of complex II and III (D) on HepG2 cells cultured
with low glucose after regorafenib exposure for 24 h. Activity of complex I and III (E) and of complex II and III (F) on HepG2 cells cultured with low glucose after sorafenib exposure for
24 h. Data represent the mean ± SEM of at least three independent experiments. *p < 0.05 versus DMSO 0.1% control.
F. Paech et al. 7R[LFRORJ\²

MOLECULAR MECHANISMS OF TYROSINE KINASE                                PAPER 3 
INHIBITORS-ASSOCIATED HEPATOTOXICITY 
 99 
 
 
 
 
 
 
Despite the increase in mitochondrial ROS production, the protein ex-
pression of SOD2 showed no signiﬁcant increase (Fig. 4D and E). It is
possible that the exposure to the toxicants and to mitochondrial ROS
was too short for induction of SOD2.
Another potential consequence of the inhibition of the respiratory
chain is a decrease in the mitochondrial membrane potential. As shown
in Fig. 4F, after incubation for 24 h, this decrease started at 20 μM for
ponatinib, and at 10 μM for regorafenib and sorafenib.
3.5. Fission and fusion in HepG2 cells
In reality, mitochondria build a network and continually fuse and
divide (Westermann, 2010) (Fig. 5, Supplementary Fig. 2). Several
studies have shown that these processes have important consequences
for the morphology and function of mitochondria (Detmer and Chan,
2007a,b) and that they can be inﬂuenced by mitochondrial toxicants,
which decrease the mitochondrial membrane potential (Westermann,
Fig. 3. Eﬀect on the individual activity of the enzyme complexes of the electron transport chain in isolated mouse liver mitochondria. Activity of Complex I (A), complex II (B), complex
III (C), complex IV (D), and complex V (E) of the respiratory chain after exposure with ponatinib, regorafenib, and sorafenib for 15min. Data represent the mean ± SEM of at least three
independent experiments. *p < 0.05 versus DMSO 0.1% controls.
Fig. 4. Mitochondrial ROS accumulation and SOD2 expression. Mitochondrial ROS production by HepG2 cells cultured with galactose medium during exposure to ponatinib (A),
regorafenib (B), and sorafenib (C) for 6 to 48 h. (D) and (E) SOD2 protein expression and (F) mitochondrial membrane potential in HepG2 cells cultured with low glucose medium exposed
to diﬀerent concentrations of the toxicants for 24 h. ROS data are expressed as the increase in percent relative to control incubations set at 100%. SOD2 protein expression is shown as fold
change to control incubations. The mitochondrial membrane potential is expressed as the percentage relative to control incubations set at 100%. All data represent the mean ± SEM of at
least three independent experiments. *p < 0.05 versus respective DMSO 0.1% control incubations.
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2010). Opa1 is an important protein involved in mitochondrial fusion
(Chen et al., 2016) and Fis1 in mitochondrial ﬁssion (Zungu et al.,
2011).
As shown in Fig. 5 and supplementary Figs. 3–8, the morphology of
the mitochondrial network changed with increasing concentrations of
the toxicants. Under control conditions (DMSO 0.1%), mitochondria
formed a dense network and almost no fragmentation was detectable
(Supplementary Fig. 2). With increasing concentrations of the toxicants
and with increasing exposure time, this network became more and
more fragmented for all toxicants investigated.
The protein expression of Opa1 was reduced numerically without
reaching statistical signiﬁcance by regorafenib, but was not aﬀected by
ponatinib and sorafenib (Fig. 6A). Fis1 protein expression was in-
creased numerically without reaching statistical signiﬁcance by pona-
tinib but remained unaﬀected by regorafenib and sorafenib (Fig. 6B).
As described above, the morphological ﬁndings suggested a shift
from fusion to ﬁssion in HepG2 cells treated with the MKI inhibitors
(Fig. 5 and Supplementary Figs. 2–8). This shift can be regarded as a
consequence of the impaired activity of the mitochondrial respiratory
chain with mitochondrial accumulation of ROS and decrease in the
mitochondrial membrane potential in the presence of the MKI in-
hibitors.
3.6. Mitophagy in HepG2 cells
Mitophagy represents the selective removal of mitochondria (or
parts of mitochondria) by autophagy. Damaged mitochondria recruit
parkin to the outer membrane which ubiquitinates mitochondrial outer
membrane proteins and thereby induces the formation of the autop-
hagosome (Youle and van der Bliek, 2012). During this process, the
cytosolic microtubule-associated protein light chain 3 (LC3)-I is con-
jugated with phosphatidylethanolamine to form lipidated LC3-II, which
is an integral membrane component of the autophagosome. Lipidation
of LC3-I to LC3-II is a key process in the formation of the phagophore
(Hamacher-Brady and Brady, 2016) and the ratio LC3II/LC3I is con-
sidered to be a marker of autophagy.
First, we evaluated mitophagy in HepG2 cells exposed to MKIs
(ponatinib at 0.5 and 5 μM; regorafenib and sorafenib at 1 and 10 μM)
for 1, 3, 6 and 24 h. Ponatinib was associated with an increased number
of lysosomes already starting after one hour of exposure at both con-
centrations (Supplementary Figs. 3 and 4). At both concentrations,
there were lysosomes containing mitochondria (starting at 24 h at
0.5 μM and at 3 h at 5 μM), indicating mitophagy (Fig. 5 and Supple-
mentary Figs. 3 and 4). In support of these ﬁndings, as shown in Fig. 6C
and D, ponatinib was associated with a signiﬁcant increase in the
LC3II/LC3I ratio, demonstrating the formation of autophagosomes.
Compared to control incubations, also regorafenib was associated
with an increased number of lysosomes staring 1 h after exposure
(Supplementary Figs. 5 and 6). As shown in Fig. 5 and in Supplemen-
tary Figs. 5 and 6, regorafenib was associated with mitophagy, which
was visbile starting at 3 h after exposure at both concentrations. In
contrast to these microscopic ﬁndings, regorafenib did not aﬀect the
LC3II/LC3I ratio (Fig. 6C and D).
Exposure of HepG2 cells to sorafenib was associated with an
Fig. 5. Morphology of HepG2 cells under control conditions (DMSO 0.1%) and after exposure to toxicants for 24 h. HepG2 cells were exposed to 0.5 μM (low concentration) or 5 μM (high
concentration) ponatinib, or 1 μM (low concentration) or 10 μM (high concentration) regorafenib or sorafenib for 24 h. Cells were stained with mitotracker (mitochondria, green),
Hoechst 33258 (nuclei, blue) and lysotracker (lysosomes, red) as described in Methods. Open arrows indicate mitochondrial ﬁssion and closed arrows mitophagy (lysosomes containing
mitochondria become yellow). Purple lysosomes indicate apoptosis. (For interpretation of the references to colour in this ﬁgure legend, the reader is referred to the web version of this
article.)
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increase in the number of lysosomes starting 1 h after exposure (sup-
plementary Figs. 7 and 8). Furthermore, sorafenib induced mitophagy
at both concentrations, starting at 3 h (1 μM) or at 1 h (10 μM) after
exposure. Sorafenib numerically increased the LC3II/LC3I ratio, but
this increase did not reach statistical signiﬁcance (Fig. 6C and D).
These ﬁndings indicate that the three MKIs investigated induce
mitochondrial ﬁssion and mitophagy in a time and concentration de-
pendent fashion, but, concerning mitophagy, possibly with diﬀerent
mechanisms.
3.7. Mechanisms of cell death in HepG2 cells
When the damage to the mitochondria is too extensive, repair by
mitochondrial ﬁssion and mitophagy is impossible and the cells un-
dergo apoptosis or necrosis (Youle and van der Bliek, 2012). As shown
in Fig. 7A, all MKIs investigated induced creased early apoptosis of
HepG2 cells at 5 μM and 10 μM to a diﬀerent extent. Sorafenib also
increased cell necrosis at 10 μM. Release of cytochrome c from damaged
mitochondria into the cytoplasm is an initial trigger for cell death
(Green and Reed, 1998). As shown in Fig. 7B, ponatinib, regorafenib,
and sorafenib were all associated with an increase of cytochrome c in
the cytoplasm starting at 5 μM, 10 μM, and 2 μM, respectively.
Apoptosis can be associated with a decrease of the anti-apoptotic
protein Bcl2. As shown in Fig. 7C, the MKIs investigated did not sig-
niﬁcantly aﬀect the protein expression of Bcl2. We also determined
activation of caspase 3 as a marker of apoptosis. As shown in Fig. 7D,
ponatinib and regorafenib signiﬁcantly increased the activation of
caspase 3, whereas sorafenib did not aﬀect activation of caspase 3.
Moreover, the exposure with ponatinib, regorafenib and, to lesser ex-
tent, also sorafenib were associated with an increase in the number of
lysosomes containing nuclei at diﬀerent time points after exposure to
the toxicants (purple color in lysosomes in Fig. 5 and Supplementary
Figs. 3–8), supporting described in Fig. 7.
These results show that both apoptosis (for all MKIs investigated)
and necrosis (for sorafenib) are mechanisms for cell death associated
with the MKIs investigated.
4. Discussion
The current study showed that ponatinib, regorafenib, and sorafenib
are mitochondrial toxicants that impair the activity of the respiratory
chain. In HepG2 cells exposed for 24 h, the main eﬀects were observed
on complex I (all three compounds), complex II (ponatinib), and com-
plex III (sorafenib), and in isolated mouse liver mitochondria exposed
acutely on complex I (ponatinib), complex II (sorafenib), complex III
(all compounds), complex IV (regorafenib), and complex V (all com-
pounds) of the respiratory chain. Moreover, we showed that the im-
pairment of mitochondrial respiration by MKIs in HepG2 cells was as-
sociated with an increase in mitochondrial ﬁssion and mitophagy and in
some cells with mitochondrial release of cytochrome c leading to
apoptosis and/or necrosis.
The observation that the three MKIs ponatinib, regorafenib, and
sorafenib impair mitochondrial function is not new. We have published
recently that these three MKIs inhibit mitochondrial respiration in
permeabilized HepG2 cells exposed for 24 h in the presence of gluta-
mate, which is a complex I-linked substrate (Mingard et al., 2017). In
their recent publication, Zhang et al. have shown that, after acute ex-
posure, regorafenib and sorafenib impaired the function of isolated rat
liver mitochondria at concentrations reached in humans, whereas po-
natinib showed no mitochondrial toxicity (Zhang et al., 2017). Regor-
afenib and sorafenib both stimulated state 4 respiration in the presence
of glutamate and succinate, suggesting uncoupling of oxidative phos-
phorylation. In addition, regorafenib inhibited complex II and sorafenib
complex V of the respiratory chain. Regarding sorafenib, mitochondrial
toxicity has also been described in human neuroblastoma cells (Bull
et al., 2012), in H9c2 myoblastic cells (Will et al., 2008) and in HepG2
Fig. 6. Protein expression of Opa1, Fis1 and LC3 in HepG2 cells. HepG2 cells were treated with the toxicants for 24 h and western blots were performed as described in Methods. (A) Opa1
protein expression. (B) Fis1 protein expression. (C) Expression of LC3II and LC3I given as the ratio LC3II/LC3I. (D) Western blot of LC3I and LC3II. Protein expression data are shown
relative to control incubations. Data represent the mean ± SEM of at least three independent experiments. *p < 0.05 versus DMSO 0.1% control.
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cells (Chiou et al., 2009). In the studies of Will et al. and Zhang et al.,
acute exposure of isolated mitochondria to sorafenib was associated
with uncoupling of the respiratory chain and inhibition of complex II,
III, and IV of the respiratory chain (Will et al., 2008; Zhang et al., 2017),
which agrees well with the results of the current study. After long-term
exposure of human neuroblastoma cells to sorafenib, complex I has
been reported to be damaged and to have a decreased activity (Bull
et al., 2012), which agrees with the data obtained in the current study
in HepG2 cells exposed for 24 h. Regarding regorafenib, mitochondrial
toxicity on acutely exposed isolated rat liver mitochondria has not only
been shown by Zhang et al. (Zhang et al., 2017), but also by Weng et al.
(Weng et al., 2015). In both studies, regorafenib uncoupled oxidative
phosphorylation, and Weng et al. showed also mitochondrial swelling
and a decrease in the mitochondrial membrane potential. The current
study revealed inhibition of complex II, III, and V of the respiratory
chain of acutely exposed mouse liver mitochondria, which at least
partially agrees with the study of Zhang et al. who showed inhibition of
complex II (Zhang et al., 2017). Importantly, similar to sorafenib, long-
term exposure of HepG2 cells resulted in a diﬀerent pattern, since, in
the current study mainly complex I was aﬀected. For ponatinib, Zhang
et al. reported no mitochondrial toxicity after acute exposure of rat liver
mitochondria (Zhang et al., 2017), which contrasts with the ﬁndings of
the current study, showing inhibition of complex I, III, and V. This
diﬀerence may be due to diﬀerent susceptibility of rat and mouse liver
mitochondria to this compound. Importantly, long-term exposure of
HepG2 cells was associated with a decreased function of complex I and
II, again showing that acute exposure and long-term exposure can yield
diﬀerent results. The results for long-term exposure are compatible
those reported by Talbert et al. in human induced pluripotent stem cell-
derived cardiomyocytes, where 5–10 μM ponatinib was associated with
increased mitochondrial ROS production and lipid accumulation
(Talbert et al., 2015), suggesting mitochondrial toxicity.
As mentioned above, the current study showed that acute and long-
term exposure can aﬀect mitochondrial functions diﬀerently. Beside the
longer treatment, the actual exposure to the toxicants at the time point
of the assays may also have been diﬀerent. Before the determination of
mitochondrial function, we removed the cell supernatant and replaced
it with buﬀer containing no toxicant and permeabilized the HepG2
cells. The actual concentration of the toxicants in mitochondria of
HepG2 cells may therefore have been considerably lower than in the
acutely exposed isolated mitochondria. Experiments in suitable models
for acute exposure, e.g. in isolated mitochondria, and for long-term
exposure, e.g. in suitable cell models, are therefore necessary to obtain
a more complete picture of mitochondrial toxicity associated with ki-
nase inhibitors.
A consequence of the inhibition of complex I and III of the electron
transport chain is an increase in mitochondrial ROS production (Drose
and Brandt, 2012), which was observed in the current study in time-
and concentration-dependent fashion. Mitochondrial ROS production in
HepG2 cells exposed for 24 h and 48 h started at similar concentrations
than inhibition of the electron transport chain, supporting the notion
that ROS production is a consequence of the inhibition of the electron
transport. Another consequence of the inhibition of the respiratory
chain is a drop in the mitochondrial membrane potential, since fewer
protons are pumped from the mitochondrial matrix into the inter-
membrane space. Increased mitochondrial ROS and decreased mi-
tochondrial membrane potential are triggers for mitochondrial ﬁssion
(Palmer et al., 2011; Westermann, 2010; Youle and van der Bliek,
2012), which was observed for the three MKIs investigated. Mi-
tochondrial ﬁssion can be accompanied by mitophagy, since damaged
Fig. 7. Cell death associated with multikinase inhibitors. (A) Induction of apoptosis and necrosis of HepG2 cells treated with the toxicants for 24 h as determined by staining with annexin
V/propidium iodide. (B) Quantiﬁcation of cytochrome c in the cytosol of HepG2 cells (C) Protein expression of Bcl2. (D) Protein expression of caspase 3 and cleaved caspase 3. Cell
populations are displayed as the percentage of healthy, apoptotic, and necrotic cells of the respective cell population. Protein expression is shown relative to control incubations. Data
represent the mean ± SEM of at least three independent experiments. *p < 0.05 versus DMSO 0.1% control.
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mitochondria are potentially dangerous for cells and should be removed
(Ding and Yin, 2012; Hamacher-Brady and Brady, 2016). Indeed, mi-
tophagy was also increased in the presence the three MKIs investigated
in a time and concentration dependent fashion. In agreement with the
current study, an increase in mitophagy has also been described in
primary rat hepatocytes exposed for 7 h to regorafenib by Weng et al.
(Weng et al., 2015). In contrast to Weng et al., we observed an increase
in LC3-II, a marker of autophagy (Ding and Yin, 2012) only for pona-
tinib and sorafenib (for sorafenib only numerically), but not for re-
gorafenib. In their review, Ding and Yin also described direct lysosomal
removal of mitochondria without formation of an autophagosome (Ding
and Yin, 2012), which may explain this ﬁnding.
Mitophagy is a protective mechanism of cells to avoid apoptosis or
necrosis (Ding and Yin, 2012; Hamacher-Brady and Brady, 2016;
Palikaras and Tavernarakis, 2014). When the toxic insult is too intense,
however, the protective mechanisms including mitophagy are over-
whelmed and cells are liquidated. As our study showed, these events
can be observed concomitantly; some cells were going to recover while
others sustained apoptosis (for all MKIs) and necrosis (for 10 μM sor-
afenib). In their recent article, Zhang et al. described that inhibition of
complex III and V by sorafenib was associated with the stabilization of
the protein kinase PINK1 on the outer mitochondrial membrane (Lang
et al., 2002). PINK1 attracted and activated (phosphorylated) Parkin,
which triggered apoptosis (and not mitophagy) due to ubiquitination
and proteolytic degradation of Mcl-1. In the current study, in HepG2
cells, sorafenib did not aﬀect Mcl-1 expression and we observed both,
mitophagy and apoptosis. It therefore seems that the actions of sor-
afenib on mitophagy and apoptosis are cell speciﬁc.
In conclusion, the MKIs sorafenib, regorafenib, and ponatinib de-
creased the activity of the enzyme complexes of the respiratory chain in
acutely exposed mouse liver mitochondria and in mitochondria of
HepG2 cells exposed for 24 h. Impairment of the activity of the re-
spiratory chain was associated with cellular ATP depletion, mitochon-
drial ROS production, and a drop in the mitochondrial membrane po-
tential. This triggered mitochondrial ﬁssion and mitophagy as
protective mechanisms. Despite these protective measures, some cells
progressed to apoptosis or necrosis in concentration-dependent fashion.
Mitochondrial dysfunction may represent a cause for hepatotoxicity
associated with these compounds.
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Supplementary Fig. S1. Intracellular ATP content and cytotoxicity in HepG2 cells with 
galactose medium. Cytotoxicity was assessed by the release of adenylate kinase. Intracellular 
ATP content (A) and cytotoxicity (B) were measured after exposure for 24 hours with 
ponatinib, regorafenib, and sorafenib. HepG2 cells were switched to 10 mM galactose 
medium 24 h before starting the treatment. Data are expressed as the decrease compared to 
control incubations containing 0.1% DMSO. Cytotoxicity data are expressed as the 
percentage of lysed cells with the values obtained for Triton X 0.1% set as 100%. Data 
represent the mean±SEM of at least three independent experiments. *p < 0.05 versus DMSO 
0.1% control. 
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Supplementary Fig. S2. Morphology of HepG2 cells. HepG2 cells were cultured in the 
presence of 0.1% DMSO and stained with mitotracker (mitochondria), Hoechst 33258 
(nuclei) and lysotracker (lysosomes) as described in Methods. Mitochondria form a network 
and there are only few lysosomes. Mitophagy (mitochondria in lysosomes rendering 
lysosomes yellow in merge) is absent. There is also no apoptosis (lysosomes digesting nuclear 
fragments are purple in merge). 
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Supplementary Fig. S3. Effect of ponatinib 0.5 µM on the morphology of HepG2 cells. 
HepG2 cells were exposed to 0.5 µM ponatinib for 1h, 3h, 6h or 24h. Cells were stained with 
mitotracker (mitochondria), Hoechst 33258 (nuclei) and lysotracker (lysosomes) as described 
in Methods. Open arrows indicate mitochondrial fission and closed arrows mitophagy 
(lysosomes containing mitochondria are yellow in merge). Purple lysosomes in merge 
indicate apoptosis. 
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Supplementary Fig. S4. Effect of ponatinib 5 µM on the morphology of HepG2 cells. 
HepG2 cells were exposed to 5 µM ponatinib for 1h, 3h or 24h. Cells were stained with 
mitotracker (mitochondria), Hoechst 33258 (nuclei) and lysotracker (lysosomes) as described 
in Methods. Open arrows indicate mitochondrial fission and closed arrows mitophagy 
(lysosomes containing mitochondria are yellow in merge). Purple lysosomes in merge 
indicate apoptosis (lysosomes digesting nuclear debris appear purple). 
Ponatinib 5 µM
mitochondria nuclei lysosomes merge
50 μm 50 μm 50 μm 50 μm
50 μm 50 μm 50 μm 50 μm
50 μm 50 μm 50 μm 50 μm
1h
3h
24h
MOLECULAR MECHANISMS OF TYROSINE KINASE                                PAPER 3 
INHIBITORS-ASSOCIATED HEPATOTOXICITY 
 109 
 
Supplementary Fig. S5. Effect of regorafenib 1 µM on the morphology of HepG2 cells. 
HepG2 cells were exposed to 1 µM regorafenib for 1h, 3h, 6h or 24h. Cells were stained with 
mitotracker (mitochondria), Hoechst 33258 (nuclei) and lysotracker (lysosomes) as described 
in Methods. Open arrows indicate mitochondrial fission and closed arrows mitophagy 
(lysosomes containing mitochondria are yellow in merge). Purple lysosomes in merge 
indicate apoptosis (lysosomes digesting nuclear debris appear purple). 
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Supplementary Fig. S6. Effect of regorafenib 10 µM on the morphology of HepG2 cells. 
HepG2 cells were exposed to 10 µM regorafenib for 1h, 3h, 6h or 24h. Cells were stained 
with mitotracker (mitochondria), Hoechst 33258 (nuclei) and lysotracker (lysosomes) as 
described in Methods. Open arrows indicate mitochondrial fission and closed arrows 
mitophagy (lysosomes containing mitochondria are yellow in merge). Purple lysosomes in 
merge indicate apoptosis (lysosomes digesting nuclear debris appear purple). 
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Supplementary Fig. S7. Effect of sorafenib 1 µM on the morphology of HepG2 cells. 
HepG2 cells were exposed to 1 µM sorafenib for 1h, 3h, 6h or 24h. Cells were stained with 
mitotracker (mitochondria), Hoechst 33258 (nuclei) and lysotracker (lysosomes) as described 
in Methods. Open arrows indicate mitochondrial fission and closed arrows mitophagy 
(lysosomes containing mitochondria are yellow in merge). Purple lysosomes in merge 
indicate apoptosis (lysosomes digesting nuclear debris appear purple). 
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Supplementary Fig. S8. Effect of sorafenib 10 µM on the morphology of HepG2 cells. 
HepG2 cells were exposed to 10 µM sorafenib for 1h, 3h, 6h or 24h. Cells were stained with 
mitotracker (mitochondria), Hoechst 33258 (nuclei) and lysotracker (lysosomes) as described 
in Methods. Open arrows indicate mitochondrial fission and closed arrows mitophagy 
(lysosomes containing mitochondria are yellow in merge). Purple lysosomes in merge 
indicate apoptosis (lysosomes digesting nuclear debris appear purple). 
 
 
 
  
Sorafenib 1 µM
1h
mitochondria
3h
6h
nuclei lysosomes merge
24h
50 μm 50 μm 50 μm 50 μm
50 μm 50 μm 50 μm 50 μm
50 μm 50 μm 50 μm 50 μm
50 μm 50 μm 50 μm 50 μm
MOLECULAR MECHANISMS OF TYROSINE KINASE                                PAPER 4 
INHIBITORS-ASSOCIATED HEPATOTOXICITY 
 113 
 
4 PAPER 4 
 
 
SUNITINIB INDUCES HEPATOCYTE MITOCHONDRIAL DAMAGE 
AND APOPTOSIS IN MICE 
 
 
Within this article, we switched to the in vivo situation and will investigate the mechanisms of 
hepatotoxicity for sunitinib in mice. 
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A B S T R A C T
Reports concerning hepatic mitochondrial toxicity of sunitinib are conﬂicting. We therefore decided to conduct a
toxicological study in mice. After having determined the highest dose that did not aﬀect nutrient ingestion and
body weight, we treated mice orally with sunitinib (7.5mg/kg/day) for 2 weeks. At the end of treatment, peak
sunitinib plasma concentrations were comparable to those achieved in humans and liver concentrations were
approximately 25-fold higher than in plasma. Sunitinib did not aﬀect body weight, but increased plasma ALT
activity 6-fold. The activity of enzyme complexes of the electron transport chain (ETC) was decreased nu-
merically in freshly isolated and complex III activity signiﬁcantly in previously frozen liver mitochondria. In
previously frozen mitochondria, sunitinib decreased NADH oxidase activity concentration-dependently in both
treatment groups. The hepatic mitochondrial reactive oxygen species (ROS) content and superoxide dismutase 2
expression were increased in sunitinib-treated mice. Protein and mRNA expression of several subunits of mi-
tochondrial enzyme complexes were decreased in mitochondria from sunitinib-treated mice. Protein expression
of PGC-1α, citrate synthase activity and mtDNA copy number were all decreased in livers of sunitinib-treated
mice, indicating impaired mitochondrial proliferation. Caspase 3 activation and TUNEL-positive hepatocytes
were increased in livers of sunitinib-treated mice, indicating hepatocyte apoptosis. In conclusion, sunitinib
caused concentration-dependent toxicity in isolated mitochondria at concentrations reached in livers in vivo and
inhibited hepatic mitochondrial proliferation. Daily mitochondrial insults and impaired mitochondrial pro-
liferation most likely explain hepatocellular injury observed in mice treated with sunitinib.
1. Introduction
Sunitinib is a multikinase inhibitor that was approved by the Food
and Drug Administration (FDA) in 2006 for the treatment of patients
with advanced renal cell carcinoma, and later for patients with gas-
trointestinal stromal tumor and patients with chronic myeloid leukemia
with disease progression on imatinib or intolerance to imatinib
(Goodman et al., 2007; Motzer et al., 2009). Sunitinib inhibits various
receptor-associated kinases, for example the kinase of the vascular en-
dothelial growth factor receptors (VEGFR) 1–3 (Mendel et al., 2003), of
the platelet-derived growth factor receptors (PDGFR) α and β
(Roskoski, 2007), of the fetal liver tyrosine kinase receptor 3 (FLT3)
(O’Farrell et al., 2003), of the stem cell factor receptor (c-kit) (Abrams
et al., 2003), and of the colony stimulating factor 1 receptor (CSF1R)
(Murray et al., 2003). Accordingly, sunitinib inhibits angiogenesis,
tumor growth and metastasis formation (Faivre et al., 2006).
Although the use of sunitinib is quite safe, the drug is associated
with potentially severe adverse reactions including fatigue (Bello et al.,
2006), hypertension (Motzer et al., 2009), hematotoxicity (Motzer
et al., 2009), and, less frequently, posterior encephalopathy (Cumurciuc
et al., 2008), cardiotoxicity (Demetri et al., 2006) and hepatotoxicity
(Mueller et al., 2008). In clinical trials, the frequency of elevated serum
transaminases in patients treated with sunitinib was 40–60% for all
grades and 2–5% for grade 3 and 4 (≥5 times upper limit of normal)
(Shah et al., 2013). Sunitinib-associated liver failure was observed in
0.3% of the patients and fatalities have been reported (Guillen et al.,
2016).
The underlying mechanisms of the hepatotoxicity associated with
sunitinib and with other kinase inhibitors are currently not fully elu-
cidated. In HepG2 cells, we showed previously that sunitinib impaired
oxygen consumption, reduced the mitochondrial membrane potential
and increased mitochondrial reactive oxygen species (ROS) production
https://doi.org/10.1016/j.tox.2018.07.009
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(Paech et al., 2017a). These ﬁndings occurred at concentrations that
can be reached in patients, suggesting that hepatotoxicity associated
with sunitinib can be caused by mitochondrial dysfunction. This in-
terpretation is supported by similar ﬁndings with other kinase in-
hibitors, e.g. dasatinib (Xue et al., 2012) and regorafenib (Weng et al.,
2015). In addition, in a recent study, the kinase inhibitors sorafenib,
regorafenib and pazopanib impaired oxidative phosphorylation of rat
liver mitochondria (Zhang et al., 2017). In the study of Zhang et al.
sunitinib was, however, not toxic for isolated rat liver mitochondria.
Considering hepatic mitochondrial toxicity of sunitinib, so far only
studies with isolated rat liver mitochondria (Zhang et al., 2017) and
HepG2 cells (Paech et al., 2017a) have been published, whereas in vivo
studies are lacking. For this reason, we decided to investigate the he-
patotoxic potential of sunitinib in mice in vivo. In addition, we planned
to isolate and characterize liver mitochondria and to test direct eﬀects
of sunitinib on these mitochondria. The current investigation could help
to resolve the discrepancy between the study in isolated rat liver mi-
tochondria (no toxicity) (Zhang et al., 2017) and in HepG2 cells (mi-
tochondrial toxicity) (Paech et al., 2017a). In order to reach our aims,
we ﬁrst performed a dose-ﬁnding study aiming at ﬁnding a sunitinib
dose that did not interfere with food intake and body weight of the
animals. After that, we investigated the eﬀect of sunitinib on liver
morphology and composition as well as on the function of the mi-
tochondrial respiratory chain and on mechanism of cell death in mice
treated with this compound.
2. Materials and methods
2.1. Chemicals
Sunitinib was purchased from Carbosynth (San Diego, CA, USA). All
other chemicals used in this study were purchased from Sigma-Aldrich
(Buchs, Switzerland), if not indicated diﬀerently.
2.2. Animals
Male C57BL/6NRj mice (n= 32, age 7–10 weeks) were purchased
from Elevage Janvier (Le Genest-Saint-Isle, France) and were acclima-
tized one week prior to the start of the study. The animals were housed
in a standard facility with 12 h light-dark cycles and controlled tem-
perature (21–22 °C). The mice were fed a standard pellet chow and
water ad libitum. Experiments were reviewed and accepted by the
cantonal veterinary authority of Basel, Switzerland (License 2873) and
were performed in agreement with the guidelines for care and use of
laboratory animals.
2.3. Study design and sunitinib administration
This study was performed in two steps. For the dose ﬁnding study
(Part 1), 12 mice were randomly assigned to one of the 4 groups after
one week of acclimatization: (1) animals treated with water for 14 days
(n=3); (2) animals treated with 5mg/kg/day sunitinib for 14 days
(n=3); (3) animals treated with 10mg/kg/day sunitinib for 7 days
(n=3); (4) animals treated with 20mg/kg/day sunitinib for 7 days
(n=3).
For the part 2, 20mice were randomly divided into two groups after
one week of acclimatization: (1) animals treated with water for 14 days
(n=10); (2) animals treated with sunitinib (7.5 mg/kg/day for 14
days; n= 10). This dose of sunitinib was determined according to the
results of the part 1.
Sunitinib was dissolved in water and the animals were treated once
daily by oral gavage. Food and water consumption and changes in body
weight were examined every day.
2.4. Sample collection
After the treatment for 7 or 14 days, the mice were anesthetized
with an intraperitoneal application of ketamine (100mg/kg) and xy-
lazine (10mg/kg). Then, blood was collected into heparin-coated tubes
by intracardiac puncture. Plasma was separated by centrifugation at
3000 g for 15min. The liver was immediately collected, weighed, and a
part of the tissue was immediately frozen in isopentane cooled by liquid
nitrogen and stored at −80 °C for later biochemical or histological
analysis. The rest of the liver was used to isolate mitochondria. Plasma
samples were kept at −80 °C until analysis.
2.5. Plasma and liver parameters
Mouse plasma was analyzed for the activity of alanine amino-
transferase using the Alanine Aminotransferase Activity Assay Kit
(Buchs, Switzerland). The liver glycogen content was determined after
enzymatic digestion as glucose as described previously (Lang et al.,
2002).
Plasma and liver concentrations of sunitinib (Toronto Research
Chemicals, Ontario, Canada) were determined by liquid chromato-
graphy tandem mass spectrometry (LC–MS/MS). The LC–MS/MS
system consisted of a Nexera SIL-30AC autosampler, a column-oven
(CTO-20AC), four HPLC pumps (LC30AD), and a system controller
(CBM-20 A), all acquired from Shimadzu (Kyoto, Japan). The UPLC
system was coupled to a 5500 Q-Trap triple quadrupole mass spectro-
meter from AB Sciex (Concord, Canada), equipped with a turbo elec-
trospray ionization source.
Plasma samples were precipitated with internal standard solution
(5 ng/ml sunitinib-d10 [Toronto Research Chemicals, Ontario, Canada]
in methanol) in a ratio of 1:20 (v/v). The suspension was centrifuged at
3220× g for 30min (Eppendorf Centrifuge 5810R) before 5 μL of the
sample was injected into the system. Approximately 10mg of liver was
homogenized with a vibrating microbead homogenizer (Mikro-
Dismembrator, Sartorius, Palaiseau, France) during 1min at 2000 rpm.
The liver tissue was extracted with 1mL of methanol:water (1:1 v/v),
containing 2.5 ng/ml sunitinib-d10. The samples were centrifuged at
3220 x g for 30min and 5 μL supernatant were applied into the LC–MS/
MS system. The samples were separated on a Kinetex F5 analytical
column (50× 2.1mm, 2.6 μm 100 A, Phenomenex, Torrance, CA, USA)
at 50 °C. The mobile phase A was water and mobile phase B methanol,
both supplemented with 0.1% formic acid. Samples were loaded onto
the analytical column using 20% mobile phase B. After 0.25min the
gradient was linearly increased within 1.5 min, reaching 95% mobile
phase B. The column was washed for 0.5min at 95% and thereafter
reconditioned for another 0.3 min at 20% mobile phase B. The retention
time of sunitinib was 1.6 min.
Sunitinib (399.1→ 283.1m/z) and sunitinib-d10 (409.2→ 283.1m/
z) were analyzed in the positive mode by multiple reaction monitoring
(MRM). The ion spray voltage was 5500 eV, the probe temperature was
500 °C, and the dwell time was 150ms for each analyte.
2.6. Histological analysis of liver tissue
Cross sections (10 μm) with a cryostat microtome (CM1950, Leica,
Wetzlar, Germany) were ﬁxed with paraformaldehyde 4%. All sections
were stained with hematoxylin eosin for a coarse assessment of tissue
damage.
The glycogen content was investigated using periodic acid Schiﬀ
staining on paraformaldehyde ﬁxed sections. For that, sections were
incubated in 0.5% periodic acid for 8min, washed in running water for
5min and in distilled water twice for several seconds. Afterwards, they
were incubated in Schiﬀ’ s solution for 10min, followed by 0.5% so-
dium metabisulﬁte 3 times for 3min each. Finally, cover slips were
placed on glass slides with a mounting medium and observed under a
light microscope.
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Lipid accumulation was investigated by Oil red O staining of frozen
liver sections. Oil red O was freshly diluted (3:2 in distilled water) from
a stock solution in isopropanol (0.5 g in 100ml) and sections were in-
cubated for 15min. After incubation, the slides were rinsed with 60%
isopropanol, counterstained with haematoxylin and coverslipped in
aqueous mountant. Collagen for ﬁbrosis was detected by staining sec-
tions with 0.1% Sirius Red.
Pictures were captured on an Olympus IX83 microscope (60x ob-
jective; Olympus, Volketswil, Switzerland). The stained sections were
investigated for pathological changes in the liver with the examiner
blinded regarding the treatment of the animals.
2.7. Isolation of mouse liver mitochondria
Liver mitochondria were isolated by diﬀerential centrifugation as
described before (Hoppel et al., 1979). The mitochondrial protein
content was determined using the Pierce BCA protein assay kit from
Merck (Zug, Switzerland).
2.8. Mitochondrial membrane potential
The mitochondrial membrane potential (ΔΨm) was determined
using the [phenyl-3H]-tetraphenylphosphonium bromide uptake assay.
Freshly isolated mouse-liver mitochondria (100 μg protein/ml) were
washed with incubation buﬀer (137.3mM sodium chloride, 4.74mM
potassium chloride, 2.56mM calcium chloride, 1.18mM potassium
phosphate, 1.18mM magnesium chloride, 10mM HEPES, 1 g/l glucose,
pH 7.4). Mitochondria were then incubated at 37 °C in buﬀer con-
taining 0.5 μl/ml [phenyl-3H]-tetraphenylphosphonium bromide
(40 Ci/mmol, Anawa trading SA, Wangen, Switzerland). After 15min,
the suspension was centrifuged and the mitochondrial pellet re-
suspended twice in fresh non-radioactive incubation buﬀer. The
radioactivity of the pellet was measured on a Packard 1900 TR liquid
scintillation analyzer. For the interpretation, we set the total count
([3H]-TPP (0.5 μl/ml)) as 100%.
2.9. Activity of speciﬁc enzyme complexes of the mitochondrial electron
transport chain in freshly isolated mouse liver mitochondria
The activity of speciﬁc enzyme complexes of the respiratory chain
was analyzed using an Oxygraph-2k high-resolution respirometer
equipped with DataLab software (Oroboros instruments, Innsbruck,
Austria) as described previously (Paech et al., 2017b). Freshly isolated
liver mitochondria (250 μg protein/chamber) were suspended in mi-
tochondrial respiration medium MiR06 (mitochondrial respiration
medium containing 0.5mM EGTA, 3mM magnesium chloride, 20mM
taurine, 10mM potassium dihydrogen phosphate, 20mM HEPES,
110mM sucrose, 1 g/l fatty-acid free bovine serum albumin, 60mM
lactobionic acid, and 280 U/ml catalase, pH 7.1) and transferred to the
pre-calibrated Oxygraph chamber (Pesta and Gnaiger, 2012).
Complexes I and III were analyzed using L-glutamate and malate (10
and 2mM, respectively) as substrates followed by the addition of ade-
nosine-diphosphate (ADP; 2.5 mM). Then, we added oligomycin (2.5
μM) for the determination of the leak-state respiration. This was fol-
lowed by the addition of FCCP (1 μM) to reach a full stimulation of the
electron transport chain. After that, we added rotenone (0.5 μM) as an
inhibitor of complex I. Afterwards, duroquinol (500 μM) was added to
investigate complex III activity, followed by the complex III inhibitor
antimycin A (2.5 μM).
Complexes II and IV were analyzed using succinate and rotenone
(10mM and 0.5 μM, respectively) as substrates followed by the addition
of ADP (2.5 mM). Then, we added oligomycin (2.5 μM) for the de-
termination of the leak-state respiration. This was followed by the ad-
dition of FCCP (1 μM) to reach a full stimulation of the electron
transport chain.
Then, we added the complex III inhibitor antimycin A (2.5 μM).
N,N,N’,N’-tetramethyl-1,4-phenylendiamine and ascorbate (0.5 and
2mM, respectively) were then added to investigate complex IV, fol-
lowed by the complex IV inhibitor KCN (1mM). The integrity of the
outer mitochondrial membrane was conﬁrmed by the absence of a
stimulatory eﬀect of exogenous cytochrome c (10 μM) on respiration.
2.10. Activity of enzyme complexes of the electron transport chain in
previously frozen liver mitochondria
The individual activities of mitochondrial enzyme complexes (I-IV)
were assessed by well-established spectrophotometric methods
(Krahenbuhl et al., 1991, 1994) in isolated frozen mouse liver mi-
tochondria.
Brieﬂy, for complex I, we used the conversion of NADH to NAD
using decylubiquinone as an electron acceptor and monitoring at
340 nm. The activity of complex II was based on the conversion of
oxidized dichloroindophenol to its reduced form at 600 nm using suc-
cinate as substrate. For complex III, we used decylubiquinol as a sub-
strate and determined the conversion of ferricytochrome c to ferrocy-
tochrome c at 550 nm. For complex IV, we followed the conversion of
ferrocytochrome c to ferricytochrome c at 550 nm using ubiquinol as
substrate. The activity of the respective enzyme complexes was de-
termined as the diﬀerence in the presence of speciﬁc inhibitors (rote-
none for complex I, thenoyltriﬂuroacetone for complex II, antimycin A
for complex III and sodium azide for complex IV).
2.11. Activity of the mitochondrial NADH oxidase
The activity of the NADH oxidase was determined with previously
frozen mitochondria using a Oxygraph-2k high-resolution respirometer
equipped with DataLab software (Oroboros instruments, Innsbruck,
Austria) as described previously (Krahenbuhl et al., 1991).
2.12. Levels of mRNA expression
Total RNA was extracted and puriﬁed from liver using the Qiagen
Rneasy mini extraction kit (Qiagen, Hombrechtikon, Switzerland) and
RNA quality was evaluated with the NanoDrop 2000 (Thermo
Scientiﬁc, Wohlen, Switzerland). The Qiagen omniscript system was
used to synthesize cDNA from 1 μg RNA. The expression of mRNA was
assessed using SYBR Green real-time PCR (Roche Diagnostics, Rotkreuz,
Switzerland). Quantiﬁcation was performed using the comperative-
threshold cycle method. We used GAPDH as an endogenous reference
after evaluation. The Ct values observed for mRNA form livers of con-
trol and sunitinib-treated mice were 19.57 and 19.70, respectively. The
primers used were purchased from Mycrosynth (Balgach, Switzerland)
and are listed in Table S1.
2.13. Western blotting
Liver samples (20mg) were homogenized with a vibrating mi-
crobead homogenizer (Mikro-Dismembrator, Sartorius, Palaiseau,
France) during 1min at 2000 rpm. The resulting tissue samples were
suspended in RIPA (150mM sodium chloride, 1.0% NP-40, 0.5% so-
dium deoxycholate, 0.1% sodium dodecyl sulphate, 50mM Tris, pH
8.0) buﬀer, centrifuged and the supernatant was collected. Proteins
(10 μg) were resolved by SDS-PAGE using commercially available
4–12% NuPAGE Bis-Tris gels (Invitrogen, Basel, Switzerland) and
transferred using the Trans-Blot Turbo Blotting System (Bio-Rad,
Cressier, Switzerland). The membranes were incubated with Total
OXPHOS Rodent WB Antibody Cocktail (1:500, ab110413, Abcam,
Cambridge, UK), Anti-SOD2 antibody (1:2000, ab16956, Abcam,
Cambridge, UK), Caspase-3 Rabbit antibody (1:1000, 8G10, Cell
Signaling Technology, Cambridge, UK), and Anti-PCG1 alpha (1:1000,
ab106814, Abcam, Cambridge, UK) antibodies. After washing, mem-
branes were exposed to secondary antibodies (Santa Cruz
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Biotechnology, Dallas, USA). Immunoblots were developed using
Clarity Western ECL Substrate (Bio-Rad Laboratories, Hercules, USA).
Protein expression was quantiﬁed using the Fusion Pulse TS device
(Vilber Lourmat, Oberschwaben, Germany).
2.14. Mitochondrial superoxide content
Mitochondrial superoxide was determined using the MitoSOX Red
ﬂuorophore probe from Invitrogen (Basel, Switzerland), according to
the manufacturer’s manual. The MitoSOX Red mitochondrial super-
oxide indicator is a ﬂuorogenic dye for selective detection of superoxide
in the mitochondria of living cells. Mitochondria (200 μg protein) were
incubated for 10min at 37 °C with 2.5 μM MitoSOX together with L-
glutamate (10mM) and L-malic acid (2mM). Afterwards, the ﬂuores-
cence was measured using a Tecan M200 Pro Inﬁnity plate reader
(Männerdorf, Switzerland) with an excitation at 510 nm and an emis-
sion at 580 nm. The superoxide concentration increased linearly over
10min. The MitoSOX signal was adjusted to the citrate synthase ac-
tivity.
2.15. GSH content
Glutathione (GSH) levels in mouse liver were determined by
LCeMS/MS. A 10mM stock solution of GSH was prepared in water
supplemented with 2% formic acid. GSH-d5 was used as internal
standards (1 mM in DMSO). The thiol group of GSH was derivatized
with N-ethylmaleimide (NEM) in order to inhibit autoxidation to GSSG
(Lang et al., 2002). GSH and GSH-d5 were incubated for 1 h in the
derivatization solution to form GSH-NEM and GSH-NEM-d5. Calibra-
tion line of GSH-NEM (250 μM–0.25 μM) was prepared in the deriva-
tization solution. Internal standard solution of GSH-NEM-d5 was made
in 2% formic acid (1 μM).
Approximately 10mg of liver was homogenized with a vibrating
microbead homogenizer (Mikro-Dismembrator, Sartorius, Palaiseau,
France) during 1min at 2000 rpm. The liver tissue was extracted with
1ml per 10mg tissue of the derivatization solution. Samples were
vortex-mixed and incubated for 1 h in order to derivatize GSH. Mouse
liver homogenate samples were centrifuged at 16,100 g for 10min
(Eppendorf 5415 R centrifuge, Hamburg, Germany) and the super-
natant was transferred in another tube. Calibrators and mouse liver
homogenate samples were diluted with internal standard solution in a
ratio of 1:3 (v/v) and 2.5 μl were injected into the LC–MS/MS system. A
Shimadzu HPLC (Kyoto, Japan) which was coupled to an API 4000
QTrap tandem mass spectrometer (ABSciex, Concord, Canada) was used
to determine the GSH-NEM levels in mouse liver. The analytes were
positively charged by electro spray ionization and analyzed with
scheduled multiple reaction monitoring. The ion spray voltage was
5500 eV and the probe temperature was 700 °C. The following masses
were used: 433.1 → 304.0m/z for GSH-NEM and 438.1 → 304.1m/z
for GSH-NEM-d5.
GSH-NEM was separated on a Luna omega polar C18 analytical
column (50mm× 2.1mm, 1.6 μm, Phenomenex, Torrance, CA, USA) at
45 °C and a ﬂow rate of 0.4mL/min. Water (mobile phase A) and
acetonitrile (mobile phase B) both supplemented with 0.1% acetic acid
were used as mobile phases. Samples were loaded onto the analytical
column using 0% mobile phase B and were inline diluted via a T union
with mobile phase A during the ﬁrst 0.5min of each run. After 0.5min
the gradient was linearly increased within 1.25min, reaching 95%
mobile phase B. The column was washed for 0.5 min at 95% mobile
phase B and thereafter reconditioned for another 0.75min at 0% mobile
phase B. The retention time of GSH-NEM was 1.62min. The limits of
quantiﬁcation for sunitinib were 0.63 nmol/L (0.25 mg/mL) in plasma
and 31.4 nmol/kg (12.5 ng/g) in liver.
2.16. Citrate synthase
Liver samples (20mg) were homogenized with a vibrating mi-
crobead homogenizer (Mikro-Dismembrator, Sartorius, Palaiseau,
France) in RIPA (150mM sodium chloride, 1.0% NP-40, 0.5% sodium
deoxycholate, 0.1% sodium dodecyl sulphate, 50mM Tris, pH 8.0)
buﬀer. Citrate synthase activity was determined in the supernatant by
spectrophotometry (Tecan M200 Pro Inﬁnity plate reader, Männedorf,
Switzerland) using a 96-well plate as described earlier (Srere, 1969).
2.17. Mitochondrial DNA copy number
Total DNA was extracted using the DNeasy Blood and Tissue Kit
(Qiagen, Hombrechtikon, Switzerland) following the manufacturer’s
instructions. The concentration of the extracted DNA was measured
spectrophotometrically at 260 nm with the NanoDrop 2000 (Thermo
Scientiﬁc, Wohlen, Switzerland). Afterwards, DNA was diluted in RNase
free water to a ﬁnal concentration of 10 ng/μL. The expression of the
mitochondrial COX2 and nuclear hexokinase 2 genes (see Suppl.
Table 1 for primers) was evaluated using SYBR Green real-time PCR
(Roche Diagnostics, Rotkreuz, Basel) and was performed on an ABI
PRISM 7700 sequence detector (PE Biosystems, Rotkreuz, Switzerland).
Quantiﬁcation was performed using the comparative-threshold cycle
method (Quiros et al., 2017)
2.18. TUNEL assessment of apoptosis
TUNEL staining of nuclei positive for DNA strand breaks was per-
formed using the Click-iT TUNEL Alexa Fluor 647 Imaging Assay
(Invitrogen, Basel, Switzerland) on randomly selected slides with sec-
tions (10 μm) of frozen liver samples. Sections were prepared using a
cryostat microtome (CM1950, Leica, Wetzlar, Germany) according to
the manufacturer’s manual. After staining, the sections were embedded
with ProLong diamond antifade mountant with DAPI (Life
Technologies, Wohlen, Switzerland) and were investigated with a
ﬂuorescence microscope (×20 objective; Olympus IX83, Volketswil,
Switzerland). TUNEL positive cells were calculated by counting the
number of TUNEL-stained nuclei. This number was divided by the total
number of nuclei and multiplied by 100 in order to obtain the per-
centage of TUNEL positive cells.
2.19. Statistical analysis
Data are given as the mean ± standard error of the mean (SEM).
Statistical analyses were performed by unpaired Student t-tests using
GraphPad Prism 7 (GraphPad Software, La Jolla, CA, USA). P-va-
lues< 0.05 (*) were considered to be signiﬁcant.
3. Results
3.1. Dose ﬁnding study
The goal of the ﬁrst part of this project was to determine the optimal
dose of sunitinib for the second part of the project. For that, we treated
mice with 5, 10 or 20mg/kg per day. In comparison to control mice,
mice treated with 10mg/kg/day or 20mg/kg/day consumed less food
and water, and showed a decrease in body weight already after three or
one day, respectively (Fig. 1A–C). In addition, they appeared to be less
mobile than control mice. Therefore, we stopped the treatment with
these dosages already after 7 days and sacriﬁced these mice. In contrast,
we did not observe changes in water and food intake, body weight or
mobility in mice treated 5mg/kg/day compared to control mice
(Fig. 1A–C). Of note, mice treated with sunitinib showed a non-sig-
niﬁcant, dose-dependent decrease in liver weight (Fig. 1D). Based on
these data, we performed the second part of this animal study with
7.5 mg/kg/day sunitinib for 14 days.
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3.2. Principle study
3.2.1. Characterization of the animals
A daily dose of 7.5 mg/kg sunitinib for 14 days had no signiﬁcant
eﬀect on food and water intake and on body weight compared to ve-
hicle-treated control mice (Table 1). Liver, heart and kidney weight
were also not aﬀected by the treatment with sunitinib. However, the
weight of the gastrocnemius muscle was signiﬁcantly reduced. After 14
days, sunitinib-treated mice had a 5.8-fold increase in plasma levels of
alanine aminotransferase (ALT) compared to control mice, indicating
hepatocyte damage. At this time point, the sunitinib plasma trough
concentration was 3.19 ± 1.38 nmol/L (1.27 ± 0.55 ng/mL) and the
corresponding liver concentration 92.2 ± 48.4 nmol/kg
(36.7 ± 19.3 ng/g) in sunitinib-treated mice. In control mice, sunitinib
was not detected in plasma or liver.
3.2.2. Liver histology
As shown in supplementary Fig. S1, hematoxylin-eosin stained liver
sections showed no pathological changes in liver architecture and no
inﬂammatory inﬁltrates or hepatocyte necrosis in sunitinib-treated and
control livers. Furthermore, we did not observe any change in the liver
content of fat or glycogen and of ﬁbrosis between control and sunitinib-
treated mice. In agreement with the histological analysis, the hepatic
glycogen content was not signiﬁcantly diﬀerent between control and
sunitinib-treated animals (1.87 ± 0.51 vs. 2.31 ± 0.81 μmol/mg
protein in control vs. sunitinib-treated mice; mean ± SEM, n=10 per
group).
3.2.3. Metabolic function of isolated liver mitochondria
Since sunitinib is a known mitochondrial toxicant in HepG2 cells
(sunitinib reduced the mitochondrial membrane potential and inhibited
complex I of the respiratory chain (Paech et al., 2017a)), we assessed
the impact of sunitinib on oxidative metabolic function in isolated
mouse liver mitochondria. Treatment with sunitinib for 14 days did not
signiﬁcantly impair the mitochondrial membrane potential of isolated
liver mitochondria (Fig. 2A), whereas the activity of the complexes III
and IV of the respiratory chain was reduced by 23% and 19%, respec-
tively, but without reaching statistical signiﬁcance (Fig. 2B).
In order to investigate these results further, we determined the ac-
tivities of the individual mitochondrial enzyme complexes (I–IV) using
spectrophotometric methods (Krahenbuhl et al., 1991, 1994) in freeze/
thawed mouse liver mitochondria. Treatment with sunitinib was
Fig. 1. Dose ﬁnding study.
(A) Body weight of sunitinib-treated and control mice. (B) Average daily food intake of sunitinib-treated and control mice. (C) Average daily water intake of
sunitinib-treated and control mice. (D) Liver weight/body weight ratio. Data are expressed as mean ± SEM.
Table 1
Characterization of the animals. Mice were treated with sunitinib 7.5 mg/kg for
14 days. Body weight and intake of food and water of the animals were de-
termined daily. The organ weights were normalized to the body weight at study
end. ALT activity in plasma was determined by a spectrophotometric assay.
Data are presented as mean ± SEM.
Control
(n= 10)
Sunitinib
(n= 10)
Body weight, start of study (g) 24.8 ± 0.6 25.0 ± 0.5
Body weight, end of study (g) 25.0 ± 0.6 25.4 ± 0.4
Change in body weight (%) 1.1 ± 1.4 1.5 ± 1.0
Food intake (g/animal/day) 3.96 ± 0.23 3.83 ± 0.11
Average water intake (g/animal/day) 4.66 ± 0.30 4.89 ± 0.20
Liver weight (mg/g bw) 45.8 ± 0.6 44.7 ± 1.1
Heart weight (mg/g bw) 4.29 ± 0.07 4.07 ± 0.07
Kidney weight (mg/g bw) 6.65 ± 0.10 6.50 ± 0.09
Gastrocnemius (mg/g bw) 6.15 ± 0.20 5.56 ± 0.10*
ALT (U/L) in plasma 1.8 ± 0.8 10.6 ± 4.9*
* p < 0.05 vs. control group.
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associated with a signiﬁcant reduction of the complex III activity
(p < 0.05), whereas the activity of complexes I, II and IV was not
signiﬁcantly aﬀected (Fig. 2C).
In order to investigate the acute eﬀect of sunitinib on mitochondria
and to answer the question whether liver mitochondria isolated from
sunitinib-treated mice were more susceptible to exogenous sunitinib
than mitochondria from control mice, we determined the activity of the
NADH oxidase under basal conditions and in the presence of increasing
concentrations of exogenous sunitinib using freeze/thawed mitochon-
dria (Fig. 2D). Under basal conditions (absence of exogenous sunitinib),
mitochondria from sunitinib-treated mice showed an 8% decrease in
the NADH oxidase activity compared to mitochondria from control
mice (p= 0.261). In both mitochondria from control and from suni-
tinib-treated mice, exogenous sunitinib decreased NADH oxidase ac-
tivity compared to basal values, reaching statistical signiﬁcance at 5
μM. This decrease reached 50% and 47% at 100 μM sunitinib in mi-
tochondria from control and sunitinib-treated mice, respectively. In
order to answer the question, whether mitochondria from sunitinib-
treated mice are more susceptible to exogenous sunitinib than control
mitochondria, we calculated the diﬀerence between basal activities and
activities in the presence of sunitinib for both mitochondria from su-
nitinib-treated and control mice (Fig. 2E). Since the diﬀerence between
the two curves did not reach statistical signiﬁcance at any concentra-
tion studied, we concluded that mitochondria from sunitinib-treated
mice were not more susceptible to exogenous sunitinib than mi-
tochondria from control mice.
3.2.4. Composition of mitochondrial enzyme complexes
In order to ﬁnd out potential reasons for the observed decrease in
the activity of the enzyme complexes of the electron transport chain
with sunitinib long-term treatment, we analyzed mRNA and protein
expression of subunits of these enzyme complexes. As shown in Fig. 3A,
the mRNA expression of SDHA (subunit of complex II) was signiﬁcantly
reduced (p=0.03). In addition, the mRNA expression of nuclear sub-
units of complex I, III, and V, and of a mitochondrial subunit of complex
I, were reduced numerically without reaching statistical signiﬁcance
(Fig. 3A and B). Similarly, western blot analysis of the enzyme com-
plexes of the respiratory chain showed a reduced protein content of
protein subunits of complexes III–V by 29%, 32%, and 27%, respec-
tively, in mitochondria from sunitinib-treated vs. control mice. In
comparison, the protein content of subunits of complex I and II was not
aﬀected by treatment with sunitinib (Fig. 3C and supplementary Fig.
S2).
3.2.5. Mitochondrial superoxide content and antioxidative defense
Toxicants inhibiting complex I and/or III of the electron transport
chain can stimulate mitochondrial production of superoxide (Drose and
Brandt, 2012). To assess the mitochondrial superoxide content, we
stimulated the respiration of isolated liver mitochondria with glutamate
and malate. The superoxide anion content increased by 36% in liver
mitochondria from sunitinib-treated mice in the presence of glutamate
and malate as substrates (Fig. 4A).
Long-term increase in the mitochondrial and cellular ROS content
Fig. 2. Liver mitochondrial function.
(A) Mitochondrial membrane potential was measured with the [phenyl-3H]-tetra-phenylphosphonium bromide uptake assay in freshly isolated liver mitochondria of
sunitinib-treated and control mice. (B) Electron transport chain activities in freshly isolated liver mitochondria of sunitinib-treated and control mice measured with
an Oxygraph-2k high-resolution respirometer. (C) Activity of the enzyme complexes of the electron transport chain in previously frozen liver mitochondria of
sunitinib-treated and control mice. Complex activities were determined using established spectrophotometric methods in frozen and re-thawed liver mitochondria.
*p < 0.05 vs. control. (D) Activity of NADH oxidase in previously frozen mitochondria in the presence of exogenous sunitinib. *p < 0.05 vs. respective basal
activity (absence of sunitinib). (E) Diﬀerence between basal NADH oxidase activities (in the absence of sunitinib) and activities obtained in the presence of sunitinib
in previously frozen liver mitochondria. There were no signiﬁcant diﬀerences between the two groups. Data are expressed as mean ± SEM. N=10 independent
experiments performed with samples from 10 diﬀerent animals in each group.
F. Paech et al. 7R[LFRORJ\²

MOLECULAR MECHANISMS OF TYROSINE KINASE                                PAPER 4 
INHIBITORS-ASSOCIATED HEPATOTOXICITY 
 120 
 
 
 
 
 
 
can lead to induction of the antioxidative defense system. SOD2 is an
enzyme in the mitochondrial matrix which degrades superoxide anions
and which can be upregulated under conditions of increased mi-
tochondrial ROS content (Felser et al., 2013). Indeed, sunitinib-treat-
ment was associated with an increase in the protein expression of the
mitochondrial superoxide dismutase (SOD2) by 40% (p < 0.05, Fig. 4B
and C), suggesting also an increase in SOD2 activity.
Glutathione is an important antioxidative substance which is in-
volved in the degradation of ROS (Fernandez-Checa and Kaplowitz,
2005). As shown in Fig. 4D, the hepatic glutathione content was de-
creased by 14% in sunitinib-treated compared to control mice, which
was close to statistical signiﬁcance (p=0.0531). Interestingly, the
mRNA expression of glutathione synthetase was increased 1.5-fold in
livers of mice treated with sunitinib compared to the control group,
possibly representing a compensatory reaction regarding the increase in
the cellular ROS content and the continuous consumption of glu-
tathione for ROS degradation (Fig. 4E) (Mari and Cederbaum, 2000).
3.2.6. Markers of mitochondrial proliferation
Hepatic mitochondrial insults can be associated with proliferation
of mitochondria (Krahenbuhl et al., 1992, 1990). Citrate synthase, a
marker of the mitochondrial content, was reduced by 16% (p < 0.05)
in sunitinib-treated mice compared to control mice (Fig. 5A). Moreover,
mitochondrial DNA copy number was also decreased by 30% with the
sunitinib treatment (Fig. 5B). Assuming impaired mitochondrial pro-
liferation, we also determined the protein expression of PGC-1α, which
is a master regulator of mitochondrial biosynthesis (Palikaras and
Tavernarakis, 2014). PGC-1α protein expression was reduced by 32%
with sunitinib treatment (p < 0.05, Fig. 5C and D). These ﬁndings
indicated that sunitinib suppressed mitochondrial proliferation and
thereby blocked the compensation of the sunitinib-associated mi-
tochondrial toxicity by mitochondrial proliferation.
3.2.7. Mechanism of cell death
Mitochondrial damage can lead to leakage of cytochrome c from the
intermembrane space into the cytoplasm, which can induce hepatocyte
apoptosis and/or necrosis. Cleavage and activation of caspase 3 is a key
event in apoptosis (Bonifacio et al., 2016). The determination of full-
length (pro)caspase 3 revealed two bands; the upper band at 35 kD was
used for the determination of the protein concentration (Fig. 6A). The
lower band was diﬀerent from the band for cleaved caspase 3, which
was detected at 19 kD. The ratio of the hepatic protein content of
cleaved caspase 3 to procaspase 3 was increased after treatment with
sunitinib (p < 0.05, Fig. 6A and B). In agreement, TUNEL staining
showed that the proportion of nuclei positive for DNA strand breaks
doubled with sunitinib treatment, reaching statistical signiﬁcance
(Fig. 6C and D). Augmented hepatocyte damage is compatible with the
observed increase in the activity of ALT in plasma of mice treated with
sunitinib.
4. Discussion
The study demonstrates that mice treated with 7.5mg sunitinib per
kg body weight for 14 days developed hepatocellular injury (increased
activity of ALT in plasma), which was most likely caused by direct liver
mitochondrial toxicity of sunitinib. In addition, sunitinib inhibited the
proliferation of liver mitochondria.
The ﬁrst part of the study revealed that doses of ≥10mg/kg
Fig. 3. mRNA and protein expression of subunits of enzyme complexes of the respiratory chain in liver tissue.
(A) mRNA expression of nuclear subunits of complexes I–V. (B) mRNA expression of mitochondrial subunits of complexes I–V. (C) Western blot analysis of the
expression of subunits of complexes I–V. Data are expressed as mean ± SEM. N=10 independent experiments performed with samples from 10 diﬀerent animals in
each group. *p < 0.05 vs. control group.
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impaired food and water intake and led to a decrease in body weight of
the animals treated. Since it would have been diﬃcult to diﬀerentiate
between direct drug eﬀects on the liver and secondary eﬀects related to
impaired food and water intake, we decided to study a dose which did
not aﬀect food and water consumption. The observation that a dose of
≥10mg/kg was toxic was surprising, since studies have been published
with much higher doses in mice where no adverse eﬀects on food and
water consumption and on body weight have been reported (Haznedar
et al., 2009). Based on the results in the pilot study, we decided to treat
the mice with 7.5 mg sunitinib per kg body weight for 14 days.
We have shown previously that sunitinib directly impairs the
function of mitochondria in HepG2 cells and in HepaRG cells (Paech
et al., 2017a). Sunitinib depleted the ATP content of HepG2 and He-
paRG cells at lower concentrations than membrane toxicity occurred,
and reduced cellular oxygen consumption, impaired the activity of
complex I of the electron transport chain, increased mitochondrial ROS
production and induced apoptosis in HepG2 cells. In contrast, in a re-
cent study in isolated rat liver mitochondria, sunitinib showed no
toxicity at clinically relevant concentrations (Zhang et al., 2017). This
diﬀerence may be explained by the diverse experimental models used –
human cell lines in the study of Paech et al. and isolated rat liver
mitochondria in the study of Zhang et al. – and by the diﬀerent ex-
perimental settings. While Zhang et al. studied acute eﬀects on freshly
isolated mitochondria (Zhang et al., 2017), the cell lines used in the
study of Paech et al. were exposed for 6–48 h (Paech et al., 2017a).
These observations suggest that for the assessment of mitochondrial
toxicity associated with sunitinib both the experimental model used and
the experimental settings are important factors.
In the current study, the investigation of the NADH oxidase activity
revealed that sunitinib was directly toxic on previously frozen mouse
liver mitochondria and that mitochondria from mice treated with su-
nitinib were not more susceptible to exogenous sunitinib than mi-
tochondria from control mice. As mentioned above, the detection of
direct mitochondrial toxicity of sunitinib disagrees with the ﬁndings of
Zhang et al. (Zhang et al., 2017), but is in accordance with our previous
ﬁndings (Paech et al., 2017a). Based on the determined hepatic suni-
tinib concentrations and pharmacokinetic calculations (see below), we
can assume that the maximal hepatic concentrations after oral ingestion
of sunitinib exceeded the concentrations needed for mitochondrial
toxicity. It is therefore likely that mitochondrial damage occurred after
every ingestion of sunitinib, leading to death of susceptible hepatocytes
with a concomitant increase in the plasma ALT activity (see Fig. 6E).
Fig. 4. Hepatic mitochondrial superoxide content and anti-oxidative systems.
(A) The mitochondrial superoxide content was measured with MitoSOX Red reagent in freshly isolated liver mitochondria of sunitinib-treated and control mice
incubated with malate/glutamate over 10min and was related to citrate synthase. (B) Western blots showing the expression levels of SOD2 and GAPDH. Numbers
indicate individual mice (1–10 = control mice, 11–20 sunitinib-treated mice) (C) Quantiﬁcation of SOD2 protein expression normalized against GAPDH. (D) mRNA
expression levels of glutathione synthetase. Data are expressed as mean ± SEM. N=10 independent experiments performed with samples from 10 diﬀerent animals
in each group. *p < 0.05 vs. control group.
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The observations that the NADH oxidase activity was not sig-
niﬁcantly impaired in mitochondria from sunitinib-treated mice in the
absence of exogenous sunitinib and that mitochondria from sunitinib-
treated mice were not more susceptible to exogenous sunitinib than
mitochondria from control mice suggest that the mitochondria could
recover almost completely between the individual sunitinib doses. In
agreement with these ﬁndings, the mitochondrial membrane potential,
a sensitive marker of mitochondrial damage (Felser et al., 2013), was
not signiﬁcantly decreased in liver mitochondria of sunitinib-treated
mice. In addition, the activity of the electron transport chain enzyme
complexes determined in freshly isolated liver mitochondria were also
not signiﬁcantly decreased in sunitinib-treated mice, again suggesting
an almost complete recovery after the acute mitochondrial insults. On
the other hand, complex III activity was decreased in isolated, freeze-
thawed mitochondria and ROS production by mitochondria from su-
nitinib-treated mice was signiﬁcantly increased, suggesting an in-
complete recovery from the acute mitochondrial insults by sunitinib.
Even if a permanent damage in liver mitochondria from sunitinib-
treated mice existed after stopping treatment with sunitinib, the mi-
tochondrial impairment would hardly be strong enough to be of tox-
icological relevance. As discussed above and as illustrated in Fig. 6E,
the data of the current study suggest that the repetitive mitochondrial
insults after every ingestion are responsible for liver injury in mice
treated with sunitinib.
Interestingly, we observed decreases in citrate synthase activity, in
the mitochondrial DNA copy number and in the protein expression of
PGC-1α, a key regulator of energy metabolism and mitochondrial bio-
genesis (Liang and Ward, 2006; Scarpulla, 2011), in livers of mice
treated with sunitinib. These ﬁndings were compatible with impaired
hepatic mitochondrial proliferation, possibly explaining reduced mRNA
and protein expression as well as impaired activity of complex III of the
electron transport chain in the liver of sunitinib-treated mice. In
agreement and support of this hypothesis, hepatocytes isolated from
PGC-1α knock-out mice had impaired oxygen consumption, suggesting
impaired mitochondrial function (Leone et al., 2005). Impaired activity
of complex I and III of the mitochondrial electron transport chain is a
likely reason for increased mitochondrial superoxide production (Drose
and Brandt, 2012; Felser et al., 2013), which we observed in liver mi-
tochondria from sunitinib-treated mice. Since mitochondrial stress such
as increased mitochondrial ROS content and decreased cellular ATP
content are established stimulators of PGC-1α expression (Liang and
Ward, 2006; Scarpulla, 2011), the observed decrease in the hepatic
expression of PGC-1α in mice treated with sunitinib was not expected.
The most likely explanation for these ﬁndings is that the multikinase
inhibitor sunitinib itself suppressed the expression of PGC-1α. How
exactly sunitinib could impair protein expression of PGC-1α is, to the
best of our knowledge, not directly deducible from its pharmacological
properties has to be assessed in future studies.
As mentioned above, decreases in the activity of the mitochondrial
enzyme complexes I and III can be associated with increased mi-
tochondrial superoxide production (Drose and Brandt, 2012; Felser
et al., 2013). Mitochondria can degrade superoxide anion by SOD2,
which is expressed in the mitochondrial matrix (Bresciani et al., 2015).
If mitochondrial superoxide production exceeds the capacity of SOD2,
oxidative damage to lipids, proteins and DNA is possible. As shown in
the current and in preceding investigations (Felser et al., 2013), SOD2
Fig. 5. Hepatic mitochondrial proliferation.
(A) Activity of the citrate synthase of sunitinib-treated and control mice. (B) Mitochondrial DNA copy number. (C) Western blots showing the expression levels of
PGC-1α and GAPDH. Numbers indicate individual mice (1–10 = control mice, 11–20 sunitinib-treated mice) (D) Quantiﬁcation of PGC-1α protein expression
normalized against GAPDH. Data are expressed as mean ± SEM. N=10 independent experiments performed with samples from 10 diﬀerent animals in each group.
*p < 0.05 vs. control group.
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can be upregulated in order to counteract increased mitochondrial
production of ROS. A further consequence of an increased mitochon-
drial ROS content is induction of the mitochondrial permeability tran-
sition, eventually leading to rupture of the outer mitochondrial mem-
brane with leakage of cytochrome c and other pro-apoptotic factors into
the cytoplasm and induction of apoptosis and/or necrosis (Carraro and
Bernardi, 2016; Jaeschke et al., 2012). In the current study, we could
demonstrate an increase in the activation of caspase 3 and of TUNEL-
positive hepatocytes, indicating stimulation of hepatocyte apoptosis in
mice treated with sunitinib. The observed increase in the serum ALT
activity in mice treated with sunitinib suggests that a small portion of
hepatocytes was also eliminated by necrosis. Increased mitochondrial
production of ROS, which is most likely a consequence of the inhibition
of the electron transport chain, appears therefore to be an important
factor for liver toxicity of sunitinib (see Fig. 6E).
In the current study, we determined a sunitinib plasma concentra-
tion of 3.18 nmol/L. This concentration is lower than typical plasma
concentrations in humans treated with sunitinib, which are in a range
of 0.1 to 0.2 μmol/L (Herbrink et al., 2016; Huynh et al., 2017). It has to
be taken into account, however, that we determined trough values and
that we administered a single dose every 24 h. Assuming a plasma half-
life of approximately 4 h after oral administration in mice (Haznedar
et al., 2009), the calculated maximal plasma concentration is in the
range of 0.2 μmol/L, which agrees well with the plasma concentrations
observed in humans. In comparison, the liver concentration was ap-
proximately 25 times higher, which is in agreement with previous
studies showing much higher liver than plasma concentrations (Chen
et al., 2015; Lau et al., 2015). Similar to plasma, the half-life of the
hepatic elimination of sunitinib reported by Lau et al (Lau et al., 2015)
was also in the range of 4 h. The calculated maximal concentration in
the liver is therefore in the range of 5–10 nmol/g liver. At concentra-
tions in this range (5–10 μmol/L), we started to observe mitochondrial
dysfunction in HepG2 cells exposed to sunitinib for 24 h (Paech et al.,
2017a) and impairment of mitochondrial NADH oxidase in the current
study (Fig. 2D). This comparison shows that sunitinib could reach po-
tentially toxic concentrations in the livers of the mice treated in the
current study. If the tissue distribution of sunitinib is similar between
mice and humans, this would also be the case for humans.
In conclusion, mice treated daily with 7.5mg/kg sunitinib for 14
days exhibited hepatocellular liver injury caused most likely by direct,
concentration-dependent toxicity of sunitinib. These repetitive mi-
tochondrial insults were associated with an increase in the
Fig. 6. Assessment of cell death and overall eﬀect of sunitinib.
(A) Western blots showing the protein content of full-length and cleaved caspase 3. Full-length caspase was quantiﬁed using the upper band at 35 kD. Numbers
indicate individual mice (1–10 = control mice, 11–20 sunitinib-treated mice) (B) Quantiﬁcation of active (cleaved) to full-length caspase 3 protein expression. (C)
Nuclei were stained with DAPI shown in blue and TUNEL nuclei were visualized with magenta ﬂuorescein in liver of sunitinib-treated and control mice. (D) The
percentage of TUNEL positive cells was calculated by counting the number of TUNEL-stained nuclei divided by the total number of nuclei multiplied by 100. At least
5 randomly chosen sections from every animal were investigated. (E). Schematic representation of the eﬀects of sunitinib on mouse livers. Sunitinib inhibits complex
I and III activity of the electron transport chain, which decreases the mitochondrial membrane potential (MMP) and cellular ATP content, and increases the cellular
ROS content. Decreases in the MMP and cellular ATP content are associated with apoptosis and necrosis. An increase in cellular ROS induces nuclear translocation of
Nrf2, increasing the transcription of SOD2 and glutathione synthetase. Sunitinib reduces the expression of PGC-1α, which impairs mitochondrial proliferation. The
reduction of the MMP and the cellular ATP content by sunitinib has been shown in a previous publication (Paech et al., 2017a). Data are expressed as mean ± SEM.
N=10 independent experiments performed with samples from 10 diﬀerent animals in each group. *p < 0.05 vs. control group. (For interpretation of the references
to colour in this ﬁgure legend, the reader is referred to the web version of this article.)
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mitochondrial ROS content, leading to hepatocyte injury. In addition,
sunitinib impaired hepatic mitochondrial proliferation, which may
have contributed to hepatic mitochondrial toxicity.
Financial support
The study was supported by a grant from the Swiss National Science
foundation to SK (SNF 31003A_156270)
Conﬂict of interest
None of the authors has a conﬂict of interest regarding this study.
Appendix A. Supplementary data
Supplementary material related to this article can be found, in the
online version, at doi:https://doi.org/10.1016/j.tox.2018.07.009.
References
Abrams, T.J., Lee, L.B., Murray, L.J., Pryer, N.K., Cherrington, J.M., 2003. SU11248 in-
hibits KIT and platelet-derived growth factor receptor beta in preclinical models of
human small cell lung cancer. Mol. Cancer Ther. 2, 471–478.
Bello, C.L., Sherman, L., Zhou, J., Verkh, L., Smeraglia, J., Mount, J., Klamerus, K.J.,
2006. Eﬀect of food on the pharmacokinetics of sunitinib malate (SU11248), a multi-
targeted receptor tyrosine kinase inhibitor: results from a phase I study in healthy
subjects. Anticancer Drugs 17, 353–358.
Bonifacio, A., Mullen, P.J., Mityko, I.S., Navegantes, L.C., Bouitbir, J., Krahenbuhl, S.,
2016. Simvastatin induces mitochondrial dysfunction and increased atrogin-1 ex-
pression in H9c2 cardiomyocytes and mice in vivo. Arch. Toxicol. 90, 203–215.
Bresciani, G., da Cruz, I.B., Gonzalez-Gallego, J., 2015. Manganese superoxide dismutase
and oxidative stress modulation. Adv. Clin. Chem. 68, 87–130.
Carraro, M., Bernardi, P., 2016. Calcium and reactive oxygen species in regulation of the
mitochondrial permeability transition and of programmed cell death in yeast. Cell
Calcium 60, 102–107.
Chen, X., Wang, Z., Liu, M., Liao, M., Wang, X., Du, H., Chen, J., Yao, M., Li, Q., 2015.
Determination of sunitinib and its active metabolite, N-desethyl sunitinib in mouse
plasma and tissues by UPLC-MS/MS: assay development and application to phar-
macokinetic and tissue distribution studies. Biomed. Chromatogr. 29, 679–688.
Cumurciuc, R., Martinez-Almoyna, L., Henry, C., Husson, H., de Broucker, T., 2008.
Posterior reversible encephalopathy syndrome during sunitinib therapy. Rev. Neurol.
(Paris) 164, 605–607.
Demetri, G.D., van Oosterom, A.T., Garrett, C.R., Blackstein, M.E., Shah, M.H., Verweij,
J., McArthur, G., Judson, I.R., Heinrich, M.C., Morgan, J.A., Desai, J., Fletcher, C.D.,
George, S., Bello, C.L., Huang, X., Baum, C.M., Casali, P.G., 2006. Eﬃcacy and safety
of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of
imatinib: a randomised controlled trial. Lancet 368, 1329–1338.
Drose, S., Brandt, U., 2012. Molecular mechanisms of superoxide production by the mi-
tochondrial respiratory chain. Adv. Exp. Med. Biol. 748, 145–169.
Faivre, S., Delbaldo, C., Vera, K., Robert, C., Lozahic, S., Lassau, N., Bello, C., Deprimo, S.,
Brega, N., Massimini, G., Armand, J.P., Scigalla, P., Raymond, E., 2006. Safety,
pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyr-
osine kinase inhibitor, in patients with cancer. J. Clin. Oncol. 24, 25–35.
Felser, A., Blum, K., Lindinger, P.W., Bouitbir, J., Krahenbuhl, S., 2013. Mechanisms of
hepatocellular toxicity associated with dronedarone–a comparison to amiodarone.
Toxicol. Sci. 131, 480–490.
Fernandez-Checa, J.C., Kaplowitz, N., 2005. Hepatic mitochondrial glutathione: transport
and role in disease and toxicity. Toxicol. Appl. Pharmacol. 204, 263–273.
Goodman, V.L., Rock, E.P., Dagher, R., Ramchandani, R.P., Abraham, S., Gobburu, J.V.,
Booth, B.P., Verbois, S.L., Morse, D.E., Liang, C.Y., Chidambaram, N., Jiang, J.X.,
Tang, S., Mahjoob, K., Justice, R., Pazdur, R., 2007. Approval summary: sunitinib for
the treatment of imatinib refractory or intolerant gastrointestinal stromal tumors and
advanced renal cell carcinoma. Clin. Cancer Res. 13, 1367–1373.
Guillen, S.S., Meijer, M., de Jongh, F.E., 2016. Lethal acute liver failure in a patient
treated with sunitinib. BMJ Case Rep. 2016.
Haznedar, J.O., Patyna, S., Bello, C.L., Peng, G.W., Speed, W., Yu, X., Zhang, Q.,
Sukbuntherng, J., Sweeny, D.J., Antonian, L., Wu, E.Y., 2009. Single- and multiple-
dose disposition kinetics of sunitinib malate, a multitargeted receptor tyrosine kinase
inhibitor: comparative plasma kinetics in non-clinical species. Cancer Chemother.
Pharmacol. 64, 691–706.
Herbrink, M., de Vries, N., Rosing, H., Huitema, A.D., Nuijen, B., Schellens, J.H., Beijnen,
J.H., 2016. Quantiﬁcation of 11 therapeutic kinase inhibitors in human plasma for
therapeutic drug monitoring using liquid chromatography coupled with tandem mass
spectrometry. Ther. Drug Monit. 38, 649–656.
Hoppel, C., DiMarco, J.P., Tandler, B., 1979. Riboﬂavin and rat hepatic cell structure and
function. Mitochondrial oxidative metabolism in deﬁciency states. J. Biol. Chem.
254, 4164–4170.
Huynh, H.H., Pressiat, C., Sauvageon, H., Madelaine, I., Maslanka, P., Lebbe, C.,
Thieblemont, C., Goldwirt, L., Mourah, S., 2017. Development and validation of a
simultaneous quantiﬁcation method of 14 tyrosine kinase inhibitors in human plasma
using LC-MS/MS. Ther. Drug Monit. 39, 43–54.
Jaeschke, H., McGill, M.R., Ramachandran, A., 2012. Oxidant stress, mitochondria, and
cell death mechanisms in drug-induced liver injury: lessons learned from acet-
aminophen hepatotoxicity. Drug Metab. Rev. 44, 88–106.
Krahenbuhl, S., Ray, D.B., Stabler, S.P., Allen, R.H., Brass, E.P., 1990. Increased hepatic
mitochondrial capacity in rats with hydroxy-cobalamin[c-lactam]-induced methyl-
malonic aciduria. J. Clin. Invest. 86, 2054–2061.
Krahenbuhl, S., Chang, M., Brass, E.P., Hoppel, C.L., 1991. Decreased activities of ubi-
quinol:ferricytochrome c oxidoreductase (complex III) and ferrocytochrome c:oxygen
oxidoreductase (complex IV) in liver mitochondria from rats with hydroxycobalamin
[c-lactam]-induced methylmalonic aciduria. J. Biol. Chem. 266, 20998–21003.
Krahenbuhl, S., Krahenbuhl-Glauser, S., Stucki, J., Gehr, P., Reichen, J., 1992.
Stereological and functional analysis of liver mitochondria from rats with secondary
biliary cirrhosis: impaired mitochondrial metabolism and increased mitochondrial
content per hepatocyte. Hepatology 15, 1167–1172.
Krahenbuhl, S., Talos, C., Wiesmann, U., Hoppel, C.L., 1994. Development and evaluation
of a spectrophotometric assay for complex III in isolated mitochondria, tissues and
ﬁbroblasts from rats and humans. Clin. Chim. Acta 230, 177–187.
Lang, C., Schafer, M., Varga, L., Zimmermann, A., Krahenbuhl, S., Krahenbuhl, L., 2002.
Hepatic and skeletal muscle glycogen metabolism in rats with short-term cholestasis.
J. Hepatol. 36, 22–29.
Lau, C.L., Chan, S.T., Selvaratanam, M., Khoo, H.W., Lim, A.Y., Modamio, P., Marino,
E.L., Segarra, I., 2015. Sunitinib-ibuprofen drug interaction aﬀects the pharmacoki-
netics and tissue distribution of sunitinib to brain, liver, and kidney in male and
female mice diﬀerently. Fundam. Clin. Pharmacol. 29, 404–416.
Leone, T.C., Lehman, J.J., Finck, B.N., Schaeﬀer, P.J., Wende, A.R., Boudina, S., Courtois,
M., Wozniak, D.F., Sambandam, N., Bernal-Mizrachi, C., Chen, Z., Holloszy, J.O.,
Medeiros, D.M., Schmidt, R.E., Saﬃtz, J.E., Abel, E.D., Semenkovich, C.F., Kelly, D.P.,
2005. PGC-1alpha deﬁciency causes multi-system energy metabolic derangements:
muscle dysfunction, abnormal weight control and hepatic steatosis. PLoS Biol. 3,
e101.
Liang, H., Ward, W.F., 2006. PGC-1alpha: a key regulator of energy metabolism. Adv.
Physiol. Educ. 30, 145–151.
Mari, M., Cederbaum, A.I., 2000. CYP2E1 overexpression in HepG2 cells induces glu-
tathione synthesis by transcriptional activation of gamma-glutamylcysteine synthe-
tase. J. Biol. Chem. 275, 15563–15571.
Mendel, D.B., Laird, A.D., Xin, X., Louie, S.G., Christensen, J.G., Li, G., Schreck, R.E.,
Abrams, T.J., Ngai, T.J., Lee, L.B., Murray, L.J., Carver, J., Chan, E., Moss, K.G.,
Haznedar, J.O., Sukbuntherng, J., Blake, R.A., Sun, L., Tang, C., Miller, T., Shirazian,
S., McMahon, G., Cherrington, J.M., 2003. In vivo antitumor activity of SU11248, a
novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and
platelet-derived growth factor receptors: determination of a pharmacokinetic/phar-
macodynamic relationship. Clin. Cancer Res. 9, 327–337.
Motzer, R.J., Hutson, T.E., Tomczak, P., Michaelson, M.D., Bukowski, R.M., Oudard, S.,
Negrier, S., Szczylik, C., Pili, R., Bjarnason, G.A., Garcia-del-Muro, X., Sosman, J.A.,
Solska, E., Wilding, G., Thompson, J.A., Kim, S.T., Chen, I., Huang, X., Figlin, R.A.,
2009. Overall survival and updated results for sunitinib compared with interferon
alfa in patients with metastatic renal cell carcinoma. J. Clin. Oncol. 27, 3584–3590.
Mueller, E.W., Rockey, M.L., Rashkin, M.C., 2008. Sunitinib-related fulminant hepatic
failure: case report and review of the literature. Pharmacotherapy 28, 1066–1070.
Murray, L.J., Abrams, T.J., Long, K.R., Ngai, T.J., Olson, L.M., Hong, W., Keast, P.K.,
Brassard, J.A., O’Farrell, A.M., Cherrington, J.M., Pryer, N.K., 2003. SU11248 in-
hibits tumor growth and CSF-1R-dependent osteolysis in an experimental breast
cancer bone metastasis model. Clin. Exp. Metastasis 20, 757–766.
O’Farrell, A.M., Abrams, T.J., Yuen, H.A., Ngai, T.J., Louie, S.G., Yee, K.W., Wong, L.M.,
Hong, W., Lee, L.B., Town, A., Smolich, B.D., Manning, W.C., Murray, L.J., Heinrich,
M.C., Cherrington, J.M., 2003. SU11248 is a novel FLT3 tyrosine kinase inhibitor
with potent activity in vitro and in vivo. Blood 101, 3597–3605.
Paech, F., Bouitbir, J., Krahenbuhl, S., 2017a. Hepatocellular toxicity associated with
tyrosine kinase inhibitors: mitochondrial damage and inhibition of glycolysis. Front.
Pharmacol. 8, 367.
Paech, F., Messner, S., Spickermann, J., Wind, M., Schmitt-Hoﬀmann, A.H., Witschi, A.T.,
Howell, B.A., Church, R.J., Woodhead, J., Engelhardt, M., Krahenbuhl, S., Maurer,
M., 2017b. Mechanisms of hepatotoxicity associated with the monocyclic beta-lactam
antibiotic BAL30072. Arch. Toxicol. 91, 3647–3662.
Palikaras, K., Tavernarakis, N., 2014. Mitochondrial homeostasis: the interplay between
mitophagy and mitochondrial biogenesis. Exp. Gerontol. 56, 182–188.
Pesta, D., Gnaiger, E., 2012. High-resolution respirometry: OXPHOS protocols for human
cells and permeabilized ﬁbers from small biopsies of human muscle. Methods Mol.
Biol. 810, 25–58.
Quiros, P.M., Goyal, A., Jha, P., Auwerx, J., 2017. Analysis of mtDNA/nDNA ratio in
mice. Curr. Protoc. Mouse Biol. 7, 47–54.
Roskoski Jr., R., 2007. Sunitinib: a VEGF and PDGF receptor protein kinase and angio-
genesis inhibitor. Biochem. Biophys. Res. Commun. 356, 323–328.
Scarpulla, R.C., 2011. Metabolic control of mitochondrial biogenesis through the PGC-1
family regulatory network. Biochim. Biophys. Acta 1813, 1269–1278.
Shah, R.R., Morganroth, J., Shah, D.R., 2013. Hepatotoxicity of tyrosine kinase inhibitors:
clinical and regulatory perspectives. Drug Saf. 36, 491–503.
Srere, P.A., 1969. [1] Citrate synthase. Methods Enzymol. 13, 3–11.
Weng, Z., Luo, Y., Yang, X., Greenhaw, J.J., Li, H., Xie, L., Mattes, W.B., Shi, Q., 2015.
Regorafenib impairs mitochondrial functions, activates AMP-activated protein ki-
nase, induces autophagy, and causes rat hepatocyte necrosis. Toxicology 327, 10–21.
Xue, T., Luo, P., Zhu, H., Zhao, Y., Wu, H., Gai, R., Wu, Y., Yang, B., Yang, X., He, Q.,
2012. Oxidative stress is involved in Dasatinib-induced apoptosis in rat primary he-
patocytes. Toxicol. Appl. Pharmacol. 261, 280–291.
Zhang, J., Salminen, A., Yang, X., Luo, Y., Wu, Q., White, M., Greenhaw, J., Ren, L.,
Bryant, M., Salminen, W., Papoian, T., Mattes, W., Shi, Q., 2017. Eﬀects of 31 FDA
approved small-molecule kinase inhibitors on isolated rat liver mitochondria. Arch.
Toxicol. 91, 2921–2938.
F. Paech et al. 7R[LFRORJ\²

MOLECULAR MECHANISMS OF TYROSINE KINASE                                PAPER 4 
INHIBITORS-ASSOCIATED HEPATOTOXICITY 
 125 
 
Supplementary Fig. S1. Histological analysis of liver sections. Cross sections (10 µm) were 
fixed and stained as described below. Staining with hematoxylin eosin was performed 
paraformaldehyde 4% fixed sections for a coarse assessment of tissue damage. Lipid 
accumulation was investigated by Oil red O staining from sections of frozen liver. The 
glycogen content was investigated using periodic acid Schiff staining on paraformaldehyde 
4% fixed sections. Collagen for fibrosis was detected by staining paraformaldehyde 4% fixed 
sections with 0.1% Sirius Red. No differences were detectable between sections from control 
and sunitinib-treated animals. 
 
 
Hematoxylin-eosin
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Supplementary Fig. S2. Western blot of subunits of the mitochondrial enzyme 
complexes I-V. Western blots were performed as described in Methods. Numbers indicate 
individual mice (1-10 = control mice, 11-20 sunitinib-treated mice). 
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Tyrosine kinase inhibitors are a new class of anticancer drugs that have revolutionized the 
treatment of certain cancers. They are usually well tolerated with lower toxicity than classical 
chemotherapeutic agents but still with a narrow therapeutic window. While hepatotoxicity is 
known for most TKIs, underlying mechanisms are only partially clarified. We therefore aimed 
to investigate the detailed in vitro and in vivo mechanisms of hepatotoxicity of ten TKIs, 
which have been reported to cause liver injury in patients. 
 
We found that regorafenib and sorafenib were strong mitochondrial toxicants at 
concentrations that can be reached in plasma and liver of patients treated with these drugs. 
They inhibited mitochondrial oxidative metabolism, uncoupled mitochondrial oxidative 
phosphorylation, increased mitochondrial formation of ROS, and induced apoptosis and/or 
necrosis in HepG2 cells. In addition, they also inhibited glycolysis, which may enhance their 
hepatotoxicity. Imatinib, lapatinib, ponatinib, and sunitinib impaired mitochondrial function 
and glycolysis at higher concentrations than reached in plasma in patients but such 
concentrations may be reached in the liver. Imatinib, lapatinib, and sunitinib reduce the 
mitochondrial membrane potential, are associated with ROS formation, induce apoptosis, and 
impair glycolysis in HepG2 cells. In addition, imatinib and sunitinib were associated with 
impaired mitochondrial oxidative metabolism and reduced cellular GSH levels. Ponatinib 
strongly inhibited mitochondrial oxidative metabolism and increased mitochondrial ROS 
formation but only weakly glycolysis and induced apoptosis of HepG2 cells. In comparison, 
crizotinib, dasatinib, erlotinib, and pazopanib showed no relevant mitochondrial toxicity or 
inhibition of glycolysis in the concentration range investigated. For these drugs, so far 
undefined, non-mitochondrial mechanisms of hepatotoxicity have to be postulated. In 
addition, mice treated with 7.5 mg/kg sunitinib for 14 days had increased transaminase levels, 
inhibited mitochondrial oxidative metabolism, increased ROS formation, reduced 
mitochondrial biogenesis, and induced apoptosis. 
 
 
1 REGORAFENIB AND SORAFENIB 
 
Regorafenib and sorafenib were the most potent mitochondrial toxicants in vitro in our study, 
which is in agreement with the recent study of Zhang et al. (Zhang et al. 2017b). Regorafenib 
and sorafenib decreased the intracellular ATP content and were cytotoxic at lower 
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concentrations in the presence of galactose medium, which has been suggested to be an 
important marker for mitochondrial toxicity (Kamalian et al. 2015; Marroquin et al. 2007). 
Regorafenib and sorafenib inhibited mitochondrial oxidative metabolism by inhibiting 
complex I and/or III of the ETC in HepG2 cells and complex II (sorafenib), complex III 
(both), complex IV (regorafenib), and complex V (both) in isolated mitochondria exposed 
acutely. It is known that inhibition of complex I and complex III of the electron transport 
chain is related to an increased mitochondrial ROS formation (Drose and Brandt 2012). This 
ROS formation is associated with reduction of cellular GSH stores and induction of 
mitochondrial membrane permeability transition (Green and Reed 1998; Kaufmann et al. 
2005). Increased mitochondrial ROS formation was shown for regorafenib and sorafenib. 
Mitochondrial ROS formation started at similar concentrations as the inhibition of ETC, 
supporting that ROS formation is a consequence of ETC inhibition. In addition, at the same 
concentrations we showed decreases in the GSH content and in the mitochondrial membrane 
potential.  
Increased mitochondrial ROS and decreased mitochondrial membrane potential could activate 
mitochondrial fission (Palmer et al. 2011; Westermann 2010; Youle and van der Bliek 2012), 
which we showed for regorafenib and sorafenib. Fission creates smaller mitochondria which 
may be eliminated by mitophagy to remove damaged and potentially dangerous mitochondria 
(Archer 2013). Actually, we could observe an increased mitophagy after treatment with 
regorafenib and sorafenib. As mitophagy is used to remove damaged mitochondria, it is a 
protective mechanism of cells to avoid apoptosis or necrosis (Ding and Yin 2012; Hamacher-
Brady and Brady 2016; Palikaras and Tavernarakis 2014). However, when the mitochondria 
are too damaged, mitophagy is overwhelmed and cells are eliminated. Indeed, we could 
observe apoptosis for regorafenib and sorafenib and necrosis for sorafenib. 
Furthermore, both compounds inhibited glycolysis at similar concentrations as observed for 
mitochondrial inhibition. The dual inhibition of ATP synthesis by ETC inhibition and 
inhibition of glycolysis is a likely explanation for the strong effects of regorafenib and 
sorafenib on the ATP pool.  
 
Our findings for regorafenib and sorafenib are for the most part consistent with previous 
observations. Regarding regorafenib, Zhang et al. and Weng et al. have shown that 
regorafenib impaired the mitochondrial function at concentrations that are reached in humans 
(Weng et al. 2015; Zhang et al. 2017b). In both studies, regorafenib uncoupled oxidative 
phosphorylation, showed mitochondrial swelling, and a decreased mitochondrial membrane 
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potential, which is in agreement with our findings. Regorafenib inhibited complex II in 
isolated rat liver mitochondria (Zhang et al. 2017b), which is in partial agreement with our 
findings of complex II, III, and V inhibition in acutely exposed isolated mice liver 
mitochondria. In agreement with our study, increased mitophagy has been described in 
primary rat hepatocytes exposed with regorafenib (Weng et al. 2015). Regorafenib has been 
associated with induction of necrosis in rat hepatocytes (Weng et al. 2015), whereas we 
observed apoptosis. This may be explained be the different cell models that were used. 
Apoptosis is dependent on ATP (Wang and Youle 2009) while necrosis does not need ATP. It 
is therefore possible that the intracellular ATP content dropped more rapidly in rat 
hepatocytes than in the HepG2 cells we used. 
 
Regarding regorafenib, Weng et al. postulated that uncoupling of OXPHOS is the initial event 
leading to downstream effects (Fig. 33) (Weng et al. 2015). Mitochondrial membrane 
potential, ATP shortage, and triggered mitochondrial permeability transition were following 
events at later time points. The ATP shortage was associated with AMPK and autophagy 
activation. Regorafenib-induced hepatocyte death was predominantly due to necrosis and not 
apoptosis, very likely because of the lack of sufficient ATP. 
In our study, we observed uncoupling of OXPHOS starting at 2 µM after 24 h treatment with 
regorafenib. Mitochondrial membrane potential decrease and ATP shortage started at 10 µM 
after 24 h treatment and thus at higher concentration as uncoupling of OXPHOS. 
Unfortunately, we did not investigate time dependency of these events. But concerning 
concentrations, we could confirm that uncoupling of OXPHOS and eventually complex 
inhibition of the ETC are the initial events leading afterwards to ATP shortage, decreased 
mitochondrial membrane potential, ROS formation, mitophagy, and apoptosis. 
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Figure 33: Postulated mechanism for regorafenib toxicity according to (Weng et al. 
2015). Uncoupling of OXPHOS is the initial event leading to the downstream effects ATP 
shortage, mitochondrial membrane disruption, and mitochondrial permeability transition. 
 
Sorafenib-associated toxicity has been studied by several groups and mitochondrial toxicity 
has been described in human neuroblastoma cells (Bull et al. 2012), in H9c2 myoblastic cells 
(Will et al. 2008), HepG2 cells (Chiou et al. 2009), and isolated rat liver mitochondria (Zhang 
et al. 2017b). Zhang et al. have shown that sorafenib impaired the mitochondrial function 
after acute exposure in concentrations that are reached in humans (Zhang et al. 2017b). 
Sorafenib showed uncoupling of the respiratory chain and inhibition of complex II/III and IV 
in acutely exposed mitochondria (Will et al. 2008; Zhang et al. 2017b), which agrees with our 
observations. Bull et al. showed complex I inhibition after long-term exposure of human 
neuroblastoma cells with sorafenib (Bull et al. 2012). These data are in agreement with our 
long-term data after 24 hours exposure. In addition, sorafenib induced ROS accumulation and 
GSH depletion in HepG2 cells at concentrations below patient plasma concentrations (Chiou 
et al. 2009), which agree with our findings.  
 
In their recent article, Zhang et al. suggested the model that sorafenib inhibits both receptor 
tyrosine kinases signaling and mitochondrial quality control pathways to cause tumor 
suppression (Figure 34) (Zhang et al. 2017a). Sorafenib shuts down both PI3K/AKT and 
MEK pathways, both of which are known to regulate transcription of Bcl-2 and Mcl-1. In 
addition, sorafenib inhibits the activity of complex II/III and complex V of the ETC, followed 
by depolarization of the mitochondrial membrane potential and stabilization of the protein 
kinase PINK1 in the outer mitochondrial membrane, which leads to Parkin phosphorylation. 
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Parkin ubiquitylates numerous substrates on mitochondria, including Mcl-1, and lowers the 
overall levels of the anti-apoptotic Bcl-2 proteins triggering apoptosis and not mitophagy 
(Zhang et al. 2017a). In our study, sorafenib was also associated with inhibited complexes of 
the ETC and depolarized mitochondrial membrane potential. But sorafenib did not affect Mcl-
1 expression in HepG2 cells and we detected both, mitophagy and apoptosis. It therefore 
seems that the activation of sorafenib on mitophagy and apoptosis are cell specific.  
 
 
Figure 34: Proposed model for sorafenib induced cellular response via kinase-dependent 
or mitochondrion-dependent pathways (Zhang et al. 2017a).  
 
It is known that sorafenib (Figure 35) induces apoptosis through a caspase-independent 
mechanism, activates the pro-apoptotic Bak and Bax proteins, reduces the mitochondrial 
membrane potential, down-regulates the levels of the anti-apoptotic Bcl-2 and Bcl-xL 
proteins, and releases cytochrome c from mitochondria in malignant cells (Panka et al. 2006). 
In addition, apoptosis was related to the induction of stress of the endoplasmic reticulum, 
down-regulation of the anti-apoptotic protein Mcl-1, and pronounced ROS generation 
(Rahmani et al. 2007). It is possible that the mitochondrial toxicity in hepatocytes follows a 
similar pathway as we also observed depolarization of the mitochondrial membrane potential, 
ROS formation, and release of cytochrome c into the cytoplasm. 
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Figure 35: Proposed model of perifosine/sorafenib mechanism of action (Locatelli et al. 
2013). Perifosine/sorafenib treatment triggers necroptotic cell death that is mediated by ROS 
production. Upregulation of TRIB3 leads to activation of Bax, mitochondrial outer membrane 
permeabilization, release of cytochrome c, and apoptosis-inducing factor (AIF), ultimately 
leading to caspase-independent necroptosis. 
 
 
2 PONATINIB 
 
Ponatinib impaired mitochondrial function and glycolysis at higher concentrations than 
reached in patient plasma, but such concentrations may be reached in the liver. Ponatinib 
depleted intracellular ATP stores at lower concentrations than cytotoxicity occurred and was 
more cytotoxic under galactose conditions compared to glucose conditions. Both are markers 
of mitochondrial toxicity (Kamalian et al. 2015; Marroquin et al. 2007). Ponatinib inhibited 
the mitochondrial oxidative metabolism by inhibiting complexes I and II in HepG2 cells and 
complexes I, III, and V in isolated mitochondria and consequently increased mitochondrial 
ROS formation at the same concentrations as ETC inhibition as ROS formation is associated 
with complex I and III inhibition (Drose and Brandt 2012). Increased ROS formation is also 
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related to reduced GSH stores and induction of mitochondrial membrane permeability 
transition, which is further associated with mitochondrial swelling, rupture of the outer 
mitochondrial membrane, and release of cytochrome c into the cytoplasm, which induces cell 
death through apoptosis and/or necrosis (Antico Arciuch et al. 2012; Green and Reed 1998; 
Kaufmann et al. 2005). We could demonstrate a decrease in GSH content and in 
mitochondrial membrane potential and a release of cytochrome c into the cytoplasm for 
ponatinib. In addition, impairment of mitochondria was associated with increased 
mitochondrial fission and mitophagy as increased mitochondrial ROS and decreased 
mitochondrial membrane potential are associated with mitochondrial fission (Palmer et al. 
2011; Westermann 2010; Youle and van der Bliek 2012). Mitophagy is a protective 
mechanism for the cells to avoid apoptosis or necrosis. But at higher concentrations, ponatinib 
induced apoptosis, suggesting that mitophagy is overwhelmed and damaged cells are 
eliminated. Furthermore, inhibition of glycolysis occurred at 10-times higher concentrations 
than ATP depletion, suggesting that inhibition of glycolysis is not the main mechanism of 
ponatinib-induced hepatotoxicity.  
 
Another study in acutely exposed isolated rat liver mitochondria did not find mitochondrial 
toxicity for ponatinib (Zhang et al. 2017b). These findings are in contrast to our observations 
but these results were obtained in different cell systems and species compared to our study, 
which perhaps explains the different findings. Talbert et al. reported that ponatinib is 
associated with ROS formation and lipid accumulation in human induced pluripotent stem 
cell-derived cardiomyocytes (Talbert et al. 2015), suggesting mitochondrial toxicity.  
 
 
3 SUNITINIB 
 
Sunitinib also impaired mitochondrial function and glycolysis at higher concentrations than 
reached in plasma in patients, but such concentrations may be reached in the liver. Sunitinib 
impaired the mitochondrial function by inhibiting complex I. As a consequence sunitinib 
induced oxidative stress, GSH depletion, and mitochondrial membrane potential decrease. 
This is associated with the release of cytochrome c and finally with induction of apoptosis. 
All these effects occurred in a concentration range between 1 µM and 20 µM of sunitinib. 
Moreover, sunitinib inhibited glycolysis at 20 µM. The plasma concentrations that are reached 
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in patients are between 0.1 µM and 0.3 µM (Di Gion et al. 2011) and therefore 10-100 times 
lower than the concentrations where mitochondrial effects occurred.  
 
Our in vitro investigations are in agreement with another study in mouse liver mitochondria 
where sunitinib induced loss in mitochondrial membrane potential and inhibited complex II 
(Porceddu et al. 2012). In contrast, a study in isolated rat liver mitochondria did not show any 
mitochondrial toxicity due to sunitinib (Zhang et al. 2017b). This may reflect species 
differences (human versus rat) or that the duration of exposure is important for the 
mitochondrial impairment as this study treated the rat mitochondria for 5 to 30 minutes 
whereas we treated the HepG2 cells for 48 hours. In addition, our study showed that ATP 
depletion and cytotoxicity were time dependent. 
 
A daily dose of 7.5 mg/kg/day sunitinib for 14 days induced hepatocellular injury, which was 
related to mitochondrial damage and hepatocyte apoptosis. Treatment with 7.5 mg/kg/day 
sunitinib for 14 days had no effects on the food and water intake, body weight or liver weight. 
But our investigations showed a decreased activity of all complexes of the electron transport 
chain with a significant decrease for complex III activity. In addition, the protein content of 
subunits of complexes III, IV, and V were decreased, maybe explaining the decreased 
complex III activity. Moreover, the citrate synthase activity, which is a marker for the 
mitochondrial content, was significantly decreased due to sunitinib-treatment. Furthermore, 
the key regulator of energy metabolism and mitochondrial biogenesis PGC-1α (Lynch et al. 
2017) was decreased. Impaired mRNA expression of subunits of complexes of the respiratory 
chain is in agreement with impaired mitochondrial biogenesis in sunitinib-treated mice. As 
previously mentioned, inhibition of complex I and complex III of the electron transport chain 
is related to increased mitochondrial ROS formation (Drose and Brandt 2012). Indeed, we 
observed an increased mitochondrial ROS formation in mice treated with sunitinib. 
Mitochondrial superoxide can be degraded by SOD2, an important member of the antioxidant 
system, and SOD2 can be upregulated as a response to increased mitochondrial ROS (Felser 
et al. 2013) which was shown in our in vivo study. Further consequences of complex 
inhibition and increased ROS formation are the mitochondrial permeability transition 
induction (Antico Arciuch et al. 2012), leading to outer mitochondrial membrane rupture, 
release of cytochrome c, and finally apoptosis. Indeed, we could show increased caspase 3 
activation, increased TUNEL-positive hepatocytes and increased ALT levels, indicating 
hepatocyte apoptosis in mice treated with sunitinib. 
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The sunitinib plasma concentration in mice was 3.18 nmol/l, whereas the liver concentration 
was 92 nmol/kg. Typical Cmax concentration of patients treated with sunitinib are between 
0.1 µM and 0.3 µM (Di Gion et al. 2011). However, we determined trough values 24 hours 
after the last sunitinib administration. Therefore, the calculated maximal plasma concentration 
in mice is around 0.2 µmol/l, if we assume a plasma half-life of 4 hours in mice (Haznedar et 
al. 2009). This concentration agrees well with the plasma concentrations observed in humans. 
Importantly, the liver concentration in mice was 26-fold higher than in plasma, which is in 
agreement with previous studies also showing higher liver than plasma concentrations (He et 
al. 2008; Lau et al. 2015; Spector et al. 2015).  
Taking the 26-fold higher liver concentrations into consideration, concentrations between 
0.1 µM and 0.3 µM in plasma of patients would give concentrations between 2.6 µM and 
7.8 µM in the liver of patients. In our in vitro study, we could see a decreased membrane 
potential and ROS formation already at 1 µM and 2 µM, respectively, whereas ATP depletion 
occurred at 5 µM, demonstrating that mitochondrial impairment occurs at concentrations 
relevant for patients. 
 
At the moment, there are no in vivo studies regarding hepatotoxicity of sunitinib in vivo. 
Maayah et al. investigated the effects of 25, 50, and 100 mg/kg sunitinib treatment for 15 and 
30 days in Wistar albino rats on cardiotoxicity (Maayah et al. 2014). Sunitinib treatment 
caused increase in cardiac enzymes in plasma, changes in histopathology, and induction in 
several hypertrophic markers. Chu et al. treated mice for 12 days with 40 mg/kg/day sunitinib 
and investigated abnormalities of cardiomyocytes on transmission electron microscopy with 
mitochondrial swelling and degenerative changes including membrane whorls, effaced 
cristae, and induction of apoptosis (Chu et al. 2007). These findings are going in the same 
direction as our observations of hepatocyte injury with impaired mitochondria and induction 
of apoptosis. 
 
Abdel-Aziz et al. proposed a mechanism for sunitinib-induced cognitive defects (Abdel-Aziz 
et al. 2016). Sunitinib is interfering with VEGF/VEGFR2/mTOR signaling. In addition, 
sunitinib induced chromatin fragmentation and distortion of mitochondrial cristae architecture 
via increasing p53 and caspase 3 while reducing Bcl-2 and nuclear factor kappa B (NFκB) 
levels eventually resulting in apoptotic cell death. Furthermore, sunitinib switched off 
autophagic recycling machinery through decreasing beclin-1, Atg-5 and increasing 
SQTSM1/p62, resulting in accumulation of dysfunctional autophagosomes. Therefore, 
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increased apoptosis and decreased autophagy leading to the sunitinib-induced effects. In our 
study, we could show increased caspase 3 cleavage and induction of apoptosis, but we did not 
investigate the other mentioned pathways. 
 
 
Figure 36: Mechanistic insights into sunitinib-induced cognitive deficits (Abdel-Aziz et 
al. 2016). Sunitinib interfered with VEGF/VEGFR2/mTOR signaling. Furthermore, sunitinib 
induced chromatin fragmentation and distortion of mitochondrial cristae architecture via 
increasing p53 and caspase 3 while reducing Bcl-2 and nuclear factor kappa B (NFκB) levels 
eventually ensuing apoptotic cell death. In addition, sunitinib switched off autophagic 
recycling machinery through decreasing beclin-1, Atg-5 and increasing SQTSM1/p62, 
resulting in accumulation of dysfunctional autophagosomes. 
 
 
4 IMATINIB 
 
Imatinib impaired the mitochondrial function by inhibiting complex III, inducing oxidative 
stress, and GSH depletion, reducing the mitochondrial membrane potential, releasing 
cytochrome c, and finally inducing apoptosis through caspase 3 and PARP cleavage at a 
concentration range between 5 µM and 50 µM. In addition, imatinib inhibited glycolysis at 
50 µM. The plasma concentration for imatinib reached in patients is 3.2 µM (Bolton et al. 
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2004). The mitochondrial impairment and inhibition of glycolysis started at higher 
concentrations than reached in plasma in patients. However, several studies showed that liver 
concentrations of TKIs are 8, 35, and 10 fold increased compared to plasma concentrations 
(He et al. 2008; Lau et al. 2015; Spector et al. 2015). Therefore, such concentrations where 
mitochondrial impairment takes place may be reached in the liver of patients treated with 
imatinib. A study in isolated rat liver mitochondria showed decreased mitochondrial oxidative 
metabolism and release of cytochrome c at 60 µM and 100 µM (Zhang et al. 2017b). These 
findings are in agreement with our observations. 
 
In isolated cardiomyocytes, imatinib (Figure 37) resulted in increased endoplasmic reticulum 
stress due to Abl kinase inhibition, leading to TIM23 degradation. TIM23 is essential for 
protein import into the mitochondrial matrix, and thus unfolded proteins accumulate in the 
mitochondrial intermembrane space leading to a collapse of the mitochondrial membrane 
potential and mitochondrial death pathways. In addition, impaired protein import will 
negatively affect major mitochondrial metabolic pathway such as mitochondrial DNA 
synthesis, TCA, β-oxidation, and heme synthesis (Varga et al. 2015). Another study showed 
that imatinib induces mitochondrial transmembrane permeability dissipation and activation of 
caspase 3 and 9, demonstrating that the effect of imatinib is at the mitochondrial level 
(Jacquel et al. 2003). In addition, imatinib decreased the expression of the anti-apoptotic 
proteins Bcl-2, Bcl-xL, and Mcl-1 and increased the expression of the pro-apoptotic Bim 
(Jacquel et al. 2003). Kerkela et al. also showed endoplasmic reticulum stress, collapse of the 
mitochondrial membrane potential, release of cytochrome c into the cytosol, reduced cellular 
ATP content, and cell death in cardiomyocytes (Kerkela et al. 2006). In our studies, we found 
ATP depletion, release of cytochrome c, and apoptosis at 5 µM or 10 µM, whereas complex 
III inhibition, oxidative stress, and GSH depletion started at 50 µM. We can therefore 
hypothesize that imatinib-induced hepatotoxicity could be in a similar pathway as in 
cardiomyocytes. Unfortunately, we did not measure endoplasmic reticulum stress in our 
study. 
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Figure 37: Mechanisms of imatinib cardiotoxicity (Varga et al. 2015). Inhibition of Abl 
kinase by imatinib induces mitochondrial dysfunction due to endoplasmic reticulum stress, 
leading to TIM23 degradation. Consequently, unfolded proteins accumulate in the 
mitochondrial intermembrane space leading to a collapse of the mitochondrial membrane 
potential and mitochondrial death pathways. Moreover, impaired protein import will 
negatively affect major mitochondrial metabolic pathway such as mitochondrial DNA 
synthesis, TCA, β-oxidation, and heme synthesis. TIM: translocase of the inner membrane, 
TOM: translocase of the outer membrane 
 
 
5 LAPATINIB 
 
Lapatinib impaired mitochondrial function and glycolysis at higher concentrations than 
reached in plasma in patients but such concentrations may be reached in the liver. Lapatinib 
decreased the mitochondrial membrane potential, induced oxidative stress, induced apoptosis, 
and decreased glycolysis in HepG2 cells at 20 µM, which is above the 4.8 µM plasma 
concentration in patients. Lapatinib showed a more pronounced cytotoxicity and intracellular 
ATP reduction in the presence of glucose medium, which favors glycolysis, compared to 
galactose medium, which favors mitochondrial ATP production. This supports the hypothesis 
that the mechanism of hepatotoxicity of lapatinib partially involved mitochondria and, 
possibly to a larger extent, inhibition of glycolysis and other non-mitochondrial-toxicity 
pathways. Lapatinib did not impair the oxidative metabolism, but decreased the mitochondrial 
membrane potential, increased mitochondrial oxidative stress, and was associated with the 
release of cytochrome c into the cytoplasm and induction of apoptosis. CYP induction 
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increased the toxicity of lapatinib, suggesting the formation of toxic metabolites. This is in 
agreement with two other studies where CYP3A4 induction in HepaRG cells was involved in 
lapatinib-induced hepatotoxicity (Hardy et al. 2014) and where the O-dealkylated lapatinib 
metabolite induced oxidative stress, reduced oxygen consumption, and decreased GSH levels 
(Eno et al. 2016). Another study in isolated rat liver mitochondria showed that lapatinib 
released cytochrome c at 10-fold Cmax, but did not impair the oxidative metabolism, did not 
reduce the mitochondrial membrane potential, did not affect mitochondrial swelling and did 
not increase oxidative stress (Zhang et al. 2017b). These findings are in agreement with our 
observations that mitochondrial impairment is not the main mechanism of hepatotoxicity of 
lapatinib. 
 
Castellino et al. proposed several lapatinib-induced hepatotoxicity mechanisms (Figure 38) 
(Castellino et al. 2012). First, several lapatinib metabolites by CYP3A4 in the liver could 
form reactive electrophilic intermediates that could contribute to hepatotoxicity. These 
metabolites could form glutathione and cysteinglycine conjugates (Teng et al. 2010). In 
addition, lapatinib is a mechanism-based inactivator of CYP3A4 (Teng et al. 2010). Secondly, 
a pharmacogenetic analysis of patients with metastatic breast cancer experiencing liver injury 
with lapatinib exposure reported a significant association with the HLA-DQA1*02:01 and 
ALT elevation suggesting adaptive immune system activation (Spraggs et al. 2011). 
Furthermore, the interaction with drug transporters is involved either directly or indirectly in 
the underlying mechanism of hepatotoxicity (Polli et al. 2008). In addition, inhibition of bile 
salt efflux pump by lapatinib has been investigated leading to interruption of bile salt export 
and causing cholestatic liver damage (Castellino et al. 2012). Feng et al. suggested a 
combination of direct cytotoxicity to mitochondria and inhibition of bile salt efflux to explain 
the clinical hepatotoxicity observed in a structural similar TKI (Feng et al. 2009). Regarding 
our results, we observed cytotoxicity in hepatocytes at 10 µM whereas other mitochondrial 
impairment started at higher concentrations. We did not measure transporter or bile salt efflux 
in our study. It is therefore difficult to say if we have a similar pathway in HepG2 cells, but 
the fact that CYP induction by rifampicin in HepaRG cells increased the ATP reduction, 
suggests that lapatinib metabolites contribute to the lapatinib-induced hepatotoxicity. 
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Figure 38: Possible lapatinib hepatotoxicity mechanisms (Castellino et al. 2012). GI: 
gastrointestinal, BSEP: bile salt exort pump, SULT: sulfotransferase, UGT: UDP-
glucuronosyltransferase. 
 
 
6 CRIZOTINIB AND DASATINIB 
 
For crizotinib and dasatinib, cytotoxicity and ATP depletion were not enhanced under 
galactose conditions compared to glucose conditions suggesting a non-mitochondrial 
mechanism of hepatotoxicity. In addition, CYP-associated metabolites of crizotinib and 
dasatinib were less toxic compared to the parent compounds. Both compounds started to 
induce apoptosis at 10 µM and 20 µM, respectively, which was at lower concentrations than 
other investigated effects like ATP depletion, mitochondrial membrane potential, and ROS 
formation, which started at 20 µM, 50 µM, or 100 µM. Therefore, the induction of apoptosis 
is probably not associated with mitochondrial mechanisms. Crizotinib was not associated with 
inhibition of glycolysis, whereas dasatinib inhibited glycolysis at 50 µM. Typical plasma 
concentrations in patients are 1.9 µM for crizotinib (Kurata et al. 2015) and 0.6 µM for 
dasatinib (Haura et al. 2010). These concentrations are clearly below the concentrations where 
we observed toxicity. This proposes a non-mitochondrial mechanism of hepatotoxicity for 
crizotinib and dasatinib. 
 
Our observations for crizotinib and dasatinib are for the most part consistent with previous 
findings. In isolated rat liver mitochondria, crizotinib induced mitochondrial effects at much 
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higher concentrations than Cmax concentration in patients and dasatinib did not cause 
mitochondrial toxicity (Zhang et al. 2017b). In another study in rat hepatocytes, dasatinib was 
associated with oxidative stress, decreased mitochondrial membrane potential, and induction 
of apoptosis starting at 7.5 µM or 15 µM (Xue et al. 2012) which is again higher than plasma 
concentration in patients. But a study after single oral dose of radio-labeled dasatinib 
administered to rats showed that the liver concentration was eight-times higher than dasatinib 
plasma concentration (He et al. 2008). Considering this, the observed effects may be starting 
at patients' liver concentrations. 
 
 
7 ERLOTINIB AND PAZOPANIB 
 
Erlotinib and pazopanib were the least toxic compounds of the 10 investigated TKIs in this 
study. Neither showed cytotoxicity or ATP depletion and did not disturb the mitochondrial 
membrane potential or mitochondrial oxygen consumption in HepG2 cells up to 20 µM and 
50 µM, respectively. Higher concentrations could not be investigated due to solubility 
problems in the cell culture medium. Erlotinib was slightly cytotoxic and decreased the ATP 
in HepaRG cells and CYP induction decreased the toxicity of erlotinib, implying the 
formation of non-toxic metabolites. Because erlotinib did not affect oxidative metabolism or 
mitochondrial membrane potential, mitochondrial mechanism of hepatotoxicity could be 
excluded. Erlotinib did not impair glycolysis, but induced apoptosis at 20 µM. The induction 
of the apoptotic pathway is probably due to non-mitochondrial pathways. Our results are in 
relative agreement with another study in isolated rat liver mitochondria that showed no 
mitochondrial impairment of erlotinib except inhibition of complex V at 10-fold Cmax 
(Zhang et al. 2017b). 
 
Deng et al. proposed a pathway for erlotinib-induced apoptosis (Fig. 39) (Deng et al. 2007). 
The key step is the induction of BIM, a pro-apoptotic protein, to the intrinsic apoptotic 
pathway. This pathway could be demonstrated in non-small cell lung cancer cells as wells as 
in a model hematopoietic cell line suggesting that this apoptosis-inducing pathway might be a 
general feature to be expected of inhibition of activated EGFR in many different cellular 
contexts. Among all tissues, EGFR is most highly expressed in hepatocytes of adult livers 
indicating the important role in liver repair and regeneration (Komposch and Sibilia 2015). 
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Therefore, it is possible that erlotinib-induced apoptosis in hepatocytes in due to the same 
pathway. Unfortunately, in our study we did not investigate the protein content of members of 
the Bcl2-family like BIM or Bcl-2. We could show an increased release of cytochrome c into 
the cytosol and cleavage of caspase 3. 
 
 
Figure 39: Model of erlotinib-induced apoptosis (Deng et al. 2007). Erlotinib inhibits 
activated EGFR. This result is up-regulation of BIM, a pro-apoptotic molecule. The 
downstream effect of BIM is induction of apoptosis. 
 
Pazopanib had a slightly increased ROS accumulation, but to a much lower extent than all the 
other TKIs. In addition, it induced apoptosis at 20 µM and inhibited glycolysis at 20 µM. The 
induction of apoptosis is probably non-mitochondrial. It has to be considered, that pazopanib 
can reach plasma concentrations up to 100 µM in patients while we could investigate the 
effects only up to 50 µM. Therefore, exposure-dependent toxicity at higher concentration 
cannot be excluded completely. A study described pazopanib-mediated hepatotoxicity in 
patient-specific hepatocyte-like cells (HLCs) derived from induced pluripotent stem cells 
(Choudhury et al. 2017). In this study, pazopanib was more cytotoxic in HLCs derived from 
patients with pazopanib-induced clinically hepatotoxicity compared to HLCs derived from 
patients treated with pazopanib having no hepatic effects. In addition, pazopanib induced 
oxidative stress, depletion of GSH, and caused disruption of iron metabolism. Another study 
in isolated rat liver mitochondria showed impaired oxygen consumption and inhibition of 
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complex I at Cmax concentration (Zhang et al. 2017b). These results were obtained in 
different cell systems and species, perhaps explaining the different findings. 
 
 
8 ARE THE OBSERVED HEPATOTOXICITY EVENTS ON- OR 
OFF-TARGET EFFECTS? 
 
The fact that some approved TKIs show no liver injury (Shah et al. 2013), indicates that the 
TKI-induced hepatotoxicity is unlikely due to overall kinase inhibition. But the question 
arises whether the inhibition of a designated TK leads to hepatotoxicity. Table 4 shows the 
targets of the 10 investigated TKIs. The investigated TKIs inhibit a broad range of kinases 
with VEGFR, PDGFR, c-kit, and BCR-ABL1 as the most common targets. Most case reports 
for hepatotoxicity can be found for regorafenib and sorafenib, the most pronounced 
mitochondrial toxicants and inhibitors of glycolysis in our study. Regorafenib and sorafenib 
both inhibit VEGFR and PDGFR, but this is also the case for pazopanib, which was almost 
not toxic to HepG2 cells. We could therefore postulate that off-target effects unrelated to the 
pharmacological activity leading to hepatotoxicity. 
 
Table 4: Targets of the investigated TKIs. The TKIs are listed according to their 
hepatotoxicity with erlotinib as the least toxic TKI. The main targets are marked in red. 
 VEGFR PDGFR FGFR RAF c-kit BCR-ABL1 Others 
Regorafenib x x x x x   
Sorafenib x x   x   
Ponatinib x  x   x  
Sunitinib x x   x  FLT3, CSF1R 
Imatinib  x   x x  
Lapatinib       ErbB1, HER2, 
EGFR 
Crizotinib       ALK, ROS1 
Dasatinib     x x Src 
Pazopanib x x   x   
Erlotinib       EGFR 
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In addition, there is no evidence that hepatotoxicity is related to a particular chemical class as 
lapatinib is an anilinoquinazoline, pazopanib is an aminopyrimidine, regorafenib is a 
pyridylcarboxamide, and sunitinib is a pyrrolylcarboxamide while all showing hepatotoxicity 
in vitro and in patients (Shah et al. 2013). But it has to be mentioned, that the chemical 
structures of regorafenib and sorafenib (compare Fig. 30 and Fig. 31) are quite similar with 
just a fluoro-group difference and both have a similar pathway of hepatotoxicity. 
Furthermore, patients who develop hepatotoxicity on gefitinib are able to tolerate erlotinib, 
although both have a 4-anilinoquinazoline structure and inhibit both EGFR-mediated 
pathways (Shah et al. 2013). For sunitinib-induced cardiotoxicity, an off-target inhibition of 
AMP-activated protein kinase was postulated (Kerkela et al. 2009). Taking all these points 
together, off-target toxicity of TKIs could be suggested. 
 
 
9 LIVER CONCENTRATIONS 
 
The hepatic exposure of drugs is primarily dependent on the administered dose, but may also 
be affected by interacting drugs. Since all TKIs are mainly metabolized by CYP3A4 (Josephs 
et al. 2013), concomitant treatment with CYP3A4 inhibitors, such as ketoconazole, may 
increase toxicity and the likelihood of developing fatal liver injury. For imatinib, lapatinib, 
and sunitinib, CYP3A4 inducers could also increase the risk for liver toxicity, since the 
metabolites formed may be more toxic than the corresponding parent compounds. Because of 
the involvement in the metabolism of the TKIs, differences in CYP3A4-mediated metabolism 
may have important consequences that influence the development of clinical hepatotoxicity, 
which could arise because of different genetic or environmental factors (Castellino et al. 
2012). 
In addition, as shown by data in mice, the TKI concentrations in liver may be higher than the 
plasma concentrations. The increase in liver to plasma concentration was eight-fold for 
dasatinib, 35-fold for sunitinib, and 10-fold for lapatinib (He et al. 2008; Lau et al. 2015; 
Spector et al. 2015). In our mice study, we could demonstrate a 26-fold increased liver 
concentration compared to plasma concentrations.  
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10 INTRINSIC VS. IDIOSYNCRATIC DILI 
 
The finding of mitochondrial toxicity for regorafenib and sorafenib at in vitro concentrations 
similar or below clinically therapeutic blood concentrations raises the question why 
hepatotoxicity is not more frequently seen in patients treated with these drugs. Thus, the 
infrequent but profound hepatotoxicity seen in patients may reflect individual variations in 
regorafenib and sorafenib pharmacokinetics such that in vivo hepatocyte exposures indeed 
approach the hepatotoxic level observed in the current studies (Weng et al. 2015). In addition, 
the strong regeneration capacity of the liver has to take into consideration. 
 
Considering the low incidence and occurrence at therapeutic dosage, TKI-induced liver injury 
can be regarded as an idiosyncratic (type B) adverse reaction, suggesting that affected patients 
have susceptibility factors (Tujios and Fontana 2011). However, as indicated by our studies 
and as observed in clinical practice, TKI-associated hepatotoxicity seems to be dose-related, 
favoring intrinsic (type A) toxicity as a mechanism. The data of our studies and clinical 
experience suggest that exposure is an important risk factor for TKI-associated toxicity. As 
discussed in the previous chapter, hepatic exposure is primarily dependent on the 
administered dose, but may also be affected by interacting drugs. 
 
In addition to mitochondrial toxicity, patients with preexisting mitochondrial dysfunction 
such as an impaired ETC or an impaired antioxidative system, may also be at increased risk 
for toxicity. 
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In conclusion, our investigations demonstrate that regorafenib and sorafenib were strong 
mitochondrial inhibitors at concentrations that can be reached in plasma and liver of patients. 
The inhibition of the ETC is perhaps the initial event leading to downstream effects such as 
ATP depletion, ROS formation, mitophagy, and apoptosis. Moreover, they also inhibited 
glycolysis, which may further increase their toxic effects. Imatinib, lapatinib, ponatinib, and 
sunitinib were associated with mitochondrial dysfunctions and inhibition of glycolysis at 
concentration that may be reached in liver of affected patients, as liver concentrations could 
be multifold higher than plasma concentrations. In contrast, crizotinib, dasatinib, erlotinib, 
and pazopanib showed neither relevant mitochondrial impairment nor inhibition of glycolysis. 
For these drugs, undefined, non-mitochondrial mechanisms of hepatotoxicity have to be 
postulated. 
As TKIs are used for cancer patients who have exhausted conventional treatment options, the 
possible liver risk should be carefully weighed against its clinical benefits. 
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Our studies demonstrated that inhibition of the electron transport chain and oxidative stress 
are two of the key factors for the toxicity of several TKIs. 
A possibility to investigate whether an impaired antioxidant system is a susceptibility factor 
for TKI-associated hepatotoxicity is by knocking down SOD2 or NRF2 or depleting the GSH 
pool with buthionine-sulfoximine in HepG2 cells. SOD2 is an important enzyme for 
detoxifying ROS and protects cells against cell death. A lack of SOD2 leads to increased 
mitochondrial ROS formation, which leads to activation of apoptosis. NRF2 is a nuclear 
transcription factor which induces the antioxidant system after stimulation by ROS (Ma 
2013). If an impaired antioxidant system would be a susceptibility factor, this should make 
cells more susceptible to TKIs. 
We investigated the effects of sunitinib in vivo in C57BL/6 wild-type mice and could show 
induced hepatocellular injury, which was related to mitochondrial damage and hepatocyte 
apoptosis after treatment with 7.5 mg/kg/day sunitinib for 14 days. It would be interesting to 
do the same experiments in a mouse model with reduced antioxidant capacity to see whether 
this could be a risk factor for hepatotoxicity. Such mouse models could be the SOD2+/- mouse 
model or the NRF2 knock-out mouse model. SOD2+/- mice are more susceptible to 
nimesulide than wild-type mice (Ong et al. 2006). In agreement with the important role of 
NRF2 for the regulation of the antioxidant system, NRF2 knock-out mice have been shown to 
be more susceptible to paracetamol (Enomoto et al. 2001) and to 1-bromopropane (Liu et al. 
2010). Thus, treatment of these mice with sunitinib should increase mitochondrial 
impairment, confirming that oxidative stress is a susceptibility factor in mice treated with 
sunitinib.  
Furthermore, at the moment there is not enough known about the susceptibility factors of 
TKI-induced hepatotoxicity. Genome-wide association studies (GWAS) could be used to 
identify genetic susceptibility factors for TKI-associated hepatotoxicity.  
Moreover, our data show that acute and long-term exposure can affect mitochondria 
differently. At the moment, it is not clear where the differences in the hepatotoxicity-
mechanisms are. We suggest that the actual concentration of TKIs in the mitochondria might 
be lower in HepG2 cells after long-term exposure compared to acutely exposed isolated 
mitochondria. Therefore, it would be useful to investigate the difference of acute and long-
term exposure and the time-dependency of TKI-induced hepatotoxicity in more detail to 
obtain a complete picture of mitochondrial toxicity of TKIs and their susceptibility factors.  
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